Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20020188105 A1
Publication typeApplication
Application numberUS 10/024,809
Publication dateDec 12, 2002
Filing dateDec 19, 2001
Priority dateFeb 20, 1997
Also published asDE69838510D1, DE69838510T2, EP1036183A1, EP1036183B1, US6420524, WO1998037205A1
Publication number024809, 10024809, US 2002/0188105 A1, US 2002/188105 A1, US 20020188105 A1, US 20020188105A1, US 2002188105 A1, US 2002188105A1, US-A1-20020188105, US-A1-2002188105, US2002/0188105A1, US2002/188105A1, US20020188105 A1, US20020188105A1, US2002188105 A1, US2002188105A1
InventorsNancy Craig
Original AssigneeJohns Hopkins University School Of Medicine
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Gain of function mutations in ATP-dependent transposition proteins
US 20020188105 A1
Abstract
The invention is specifically directed to efficient, random, simple insertion of a transposon or derivative transposable element into DNA in vivo or in vitro. The invention is particularly directed to mutations in ATP-utilizing regulatory transposition proteins that permit insertion with less target-site specificity than wild-type. The invention encompasses gain-of-function mutations in TnsC, an ATP-utilizing regulatory transposition protein that activates the bacterial transposon Tn7. Such mutations enable the insertion of a Tn7 transposon or derivative transposable element in a non-specific manner into a given DNA segment. Insertion can be effected in plasmid and cosmid libraries, cDNA libraries, PCR products, bacterial artificial chromosomes, yeast artificial chromosomes, mammalian artificial chromosomes, genomic DNAs, and the like. Such insertion is useful in DNA sequencing methods, for genetic analysis by insertional mutagenesis, and alteration of gene expression by insertion of a given genetic sequence.
Images(27)
Previous page
Next page
Claims(25)
That what is claimed:
1. An isolated ATP-utilizing regulatory protein encoded by a transposon, said protein containing a mutation that allows efficient and simple insertion of and reduced target site specificity on a transposable element derived from said transposon.
2. The protein of claim 1 wherein said protein is TnsC.
3. The protein of claim 2 wherein said mutation is valine at amino acid number 225.
4. A transposon encoding an ATP-utilizing regulatory protein, the protein containing a mutation that allows efficient and simple insertion of and reduced target site specificity on said transposon.
5. The transposon of claim 4, wherein said transposon is Tn7 or a derivative thereof.
6. The transposon of claim 5 wherein said mutation is valine at amino acid number 225.
7. A composition containing an isolated ATP-utilizing regulatory protein encoded by a transposon, said protein containing a mutation that allows efficient and simple insertion of and reduced target site specificity on said transposon and a transposable element derived from said transposon.
8. The composition of claim 7 wherein said protein is TnsC.
9. The composition of claim 8 wherein said mutation is valine at amino acid number 225.
10. A composition containing a transposon encoding an ATP-utilizing regulatory protein, the protein containing a mutation that allows efficient and simple insertion of and reduced target site specificity on said transposon.
11. The composition of claim 10 wherein said transposon is Tn7 or a derivative thereof.
12. The composition of claim 11 wherein said mutation is valine at amino acid number 225.
13. The composition according to claim 7 further containing a transposon or transposable element derived therefrom capable of being activated by said protein.
14. The composition of claim 13 further comprising target DNA into which said transposon or derivative is capable of inserting.
15. The composition of claim 13 in which said transposon or derivative contains at least one primer binding site that is native to said transposon or heterologous.
16. The composition of claim 15 further comprising primers that hybridize to said primer binding site on the transposon or derivative.
17. The composition of claim 13 in which said transposon or derivative contains a heterologous DNA sequence.
18. The composition according to claim 10 further comprising a target sequence into which said transposon is capable of insertion.
19. The composition according to claim 11 which said transposon contains at least one primer binding site that is native to said transposon or heterologous.
20. The composition of claim 19 further comprising primers that hybridize to the primer binding site on said transposon.
21. The composition according to claim 11 in which said transposon contains a heterologous DNA sequence.
22. A composition containing an isolated ATP-utilizing regulatory protein encoded by a transposon, said protein containing a mutation that allows efficient and simple insertion of and reduced target site specificity on a transposable element derived from said transposon, further comprising a transposon or transposable derived therefrom capable of being activated by said protein.
23. The composition of claim 22 wherein said transposon is a Tn7 or a derivative thereof and said protein is TnsC.
24. The composition of claim 23 wherein said mutation is valine at amino acid number 225.
25. A kit containing the composition according to claim 22.
Description
    CROSS-REFERENCE TO RELATED APPLICATIONS
  • [0001]
    This application is a continuation of U.S. application Ser. No. 09/027,169, filed Feb. 20, 1998, which claims priority to provisional application no. 60/037,955 filed on Feb. 20, 1997, the teachings of which are hereby incorporated herein in their entirety by reference.
  • BACKGROUND OF THE INVENTION
  • [0002]
    The invention is specifically directed to efficient, random, simple insertion of a transposon or derivative transposable element into DNA in vivo or in vitro. The invention is particularly directed to mutations in ATP-utilizing regulatory transposition proteins that permit insertion with less target-site specificity than wild-type. The invention encompasses gain-of-function mutations in TnsC, an ATP-utilizing regulatory transposition protein that activates the bacterial transposon Tn7. Such mutations enable the insertion of a Tn7 transposon or derivative transposable element in a non-specific manner into a given DNA segment. Insertion can be effected in plasmid and cosmid libraries, cDNA libraries, PCR products, bacterial artificial chromosomes, yeast artificial chromosomes, mammalian artificial chromosomes, genomic DNAs, and the like. Such insertion is useful in DNA sequencing methods, for genetic analysis by insertional mutagenesis, and alteration of gene expression by insertion of a given genetic sequence.
  • [0003]
    Description of the Background Art
  • [0004]
    Transposable elements are discrete segments of DNA capable of mobilizing nonhomologously from one genetic location to another, that typically carry sequence information important for two main functions that confer the ability to mobilize. They encode the proteins necessary to carry out the catalytic activity associated with transposition, and contain the cis-acting sequences, located at the transposon termini, that act as substrates for these proteins. The same proteins can participate in the selection of the target site for insertion.
  • [0005]
    The selection of a new insertion site is usually not a random process; instead, many transposons show characteristic preferences for certain types of target sites. One broad characteristic that differentiates the wide variety of transposable elements known is the nature of the target site selectivity (1). A component of this selectivity can be the target sequence itself. The bacterial transposon Tn10 preferentially selects a relatively highly conserved 9 bp motif as the predominant site for transposon insertion and less often selects other more distantly related sites in vivo (2). The Tc1 and Tc3 mariner elements of C. elegans insert preferentially at a TA dinucleotide such that each end of the element is flanked by a TA duplication (3) (4) (5). A lower specificity consensus sequence, N-Y-G/C-R-N has been determined from populations of both in vivo and in vitro insertions for the bacteriophage Mu (7). In contrast to these elements, the bacterial transposon Tn5 exhibits markedly lower insertion site specificity, although some isolated “hotspots” have been detected (8).
  • [0006]
    Another selection mechanism relies on structural features or presence of cellular protein complexes at the target sites. The yeast transposon Ty3 preferentially inserts into the promoters of genes transcribed by RNA polymerase III, responding to signals from cellular proteins TFIIIB and TFIIIC (9).
  • [0007]
    Understanding how these factors modulate transposase activity to impose target site preferences will lend insight into the spread of transposons and viruses, and may suggest ways to manipulate those target preferences. The bacterial transposon Tn7 is distinctive in that it uses several element-encoded accessory proteins to evaluate potential target DNAs for positive and negative features, and to select a target site (1). Tn7 encodes five genes whose protein products mediate its transposition (10) (11).
  • [0008]
    Two of the proteins, TnsA and TnsB, constitute the transposase activity, collaborating to execute the catalytic steps of strand breakage and joining (12). The activity of this transposase is modulated by the remaining proteins, TnsC, TnsD, and TnsE, and also by the nature of the target DNA.
  • [0009]
    TnsC, TnsD, and TnsE interact with the target DNA to modulate the activity of the transposase via two distinct pathways. TnsABC+TnsD directs transposition to attTn7, a discrete site on the E. coli chromosome, at a high frequency, and to other loosely related “pseudo att” sites at low frequency (13). The alternative combination TnsABC+E directs transposition to many unrelated non-attTn7 sites in the chromosome at low frequency (13) (10) (11) and preferentially to conjugating plasmids (14). Thus, attTn7 and conjugable plasmids contain positive signals that recruit the transposon to these target DNAs. The alternative target site selection mechanisms enable Tn7 to inspect a variety of potential target sites in the cell and select those most likely to ensure its survival.
  • [0010]
    The Tn7 transposition machinery can also recognize and avoid targets that are unfavorable for insertion. Tn7 transposition occurs only once into a given target molecule; repeated transposition events into the same target are specifically inhibited (15) (16). Therefore, a pre-existing copy of Tn7 in a potential target DNA generates a negative signal which renders that target “immune” to further insertion. The negative target signal affects both TnsD- and TnsE-activated transposition reactions and is dominant to any positive signals present on a potential target molecule (16). Several other transposons, such as Mu and members of the Tn3 family, also display this form of negative target regulation (17) (18) (19) (7).
  • [0011]
    Target selection could be an early or late event in the course of a transposition reaction. For example, a transposon could constitutively excise from its donor position, and the excised transposon could then be captured at different frequencies by different types of target molecules. Tn10 appears to follow this course of events in vitro, excising from its donor position before any interactions with target DNA occur (20) (21). Alternatively, the process of transposon excision could itself be dependent on the identification of a favorable target site. Tn7 transposition shows an early dependence on target DNA signals in vitro: neither transposition intermediates nor insertion products are seen in the absence of an attTn7 target (22). Thus, the nature of the target DNA appears to regulate the initiation of Tn7 transposition in vitro.
  • [0012]
    An important question is how positive and negative target signals are communicated to the Tn7 transposase. Reconstitution of the TnsABC+TnsD reaction in vitro has provided a useful tool for detailed dissection of Tn7 transposition (22) (23). This reaction has been instrumental in delineating the role of each of the individual proteins play in target site selection. Dissection of the TnsABC+D reaction in vitro has implicated TnsC as a pivotal connector between the TnsAB transposase and the target DNA. TnsC is an ATP-dependent DNA-binding protein with no known sequence specificity (24). However, TnsC can respond to signals from attTn7 via an interaction with the site-specific DNA-binding protein TnsD. In a standard in vitro transposition reaction TnsD is required for transposition to the attTn7 site on a target DNA molecule. This site-specific insertion process is tightly regulated by TnsC, but does not occur in the absence of TnsD. Additional evidence for a TnsC-TnsD interaction comes from DNA protection and band shift analysis with attTn7 DNA (23). Direct interaction between TnsC and the TnsAB transposase has also recently been observed (25) (26).
  • [0013]
    Therefore, TnsC may serve as a “connector” or “matchmaker” between the transposase and the TnsD+attTn7 target complex (23) (27). This connection is not constitutive, but instead appears to be regulated by the ATP state of TnsC. Only the ATP-bound form of TnsC is competent to interact with target DNAs and activate the TnsA+B transposase; the ADP-bound form of TnsC has neither of these activities and cannot participate in Tn7 transposition (24) (23). TnsC hydrolyzes ATP at a modest rate (25), and therefore can switch from an active to an inactive state. The modulation of the ATP state of TnsC may be a central mechanism for regulating Tn7 transposition.
  • [0014]
    The possibility that TnsC regulates the connection between the TnsA+B transposase and the target site prompted the inventor to predict that TnsC mutants can be isolated that would constitutively activate Tn7 transposition.
  • [0015]
    TnsC therefore became an excellent candidate for mutagenesis, to search for a gain of function protein capable of circumventing the requirement for targeting proteins. The inventor therefore identified gain-of-function TnsC mutants which can activate the TnsA+B transposase in the absence of TnsD or TnsE. They have characterized the ability of these mutants to promote insertions into various targets, and to respond to regulatory signals on those targets.
  • [0016]
    One class of TnsC mutants activates transposition in a way that is still sensitive to target signals, whereas a second class of TnsC mutants activates transposition in a way that appears to bypass target signals. As had been observed in vitro, the critical communication between the transposon and the target DNA appears to be an early event in the Tn7 reaction pathway in vivo, preceding the double-strand breaks at the transposon ends that initiate transposition.
  • [0017]
    A particular mutant isolated from the random mutagenesis is TnsCA225V, a mutant capable of an impressive activation of Tn7 transposition in the absence of TnsD (25). The single amino acid substitution made to generate TnsCA225V has altered the protein such that it no longer requires an interaction with the target-associated TnsD, enabling it to activate transposition to a variety of target molecules very efficiently (25) (26). The inventor concluded that TnsCA225V could promote transposition to target DNAs with low specificity based on results where transposition driven by the TnsABCA225V machinery was directed to either F plasmids containing an attTn7 site, F plasmids lacking an attTn7 site, or the E. coli chromosome with no apparent preference.
  • [0018]
    DNA Sequencing
  • [0019]
    Sequencing DNA fragments cloned into vectors requires provision of priming sites at distributed locations within the fragment of interest, if the fragment is larger than the sequence run length (amount of sequence that can be determined from a single sequencing reaction). At present there are three commonly used methods of providing these priming sites:
  • [0020]
    A) Design of a new primer from sequence determined in a previous run from vector-encoded primer or other previously determined primer (prime and run, primer walking)
  • [0021]
    B) Random fragmentation and reckoning of smaller pieces, followed by determination of the sequence of the smaller pieces from vector-encoded (universal) priming sites, followed by sequence assembly by overlap of sequence (random shotgun sequencing).
  • [0022]
    C) Deletion of variable amounts of the fragment of interest from an end adjacent to the vector, to bring undetermined fragment sequence close enough to the vector-encoded (universal) primer to allow sequence determination.
  • [0023]
    All of these methods have disadvantages.
  • [0024]
    Method A is time-consuming and expensive because of the delay involved in design of new primers and their cost. Moreover, if the fragment contains DNA repeats longer than the sequence run, it may be impossible to design a unique new primer; sequence runs made with primers within the repeat sequence will display two or more sequences that cannot be disentangled.
  • [0025]
    Method B requires recloning; random fragmentation is difficult to achieve because fragments that are efficiently clonable (restriction enzyme digestion) do not have ends randomly distributed (Adams, M. D., Fields, C. and Ventor, J. C. editors Automated DNA Sequencing and Analysis Academic Press 1994; Chapter 6, Bodenteich, K. et al.), and fragmentation methods that provide randomly distributed ends (shearing, sonication) do not provide DNA ends that are efficiently clonable (with 5′ phosphate and 3′ OH moieties). Sequence assembly of is also difficult or impossible when two or more repetitive sequences longer than the sequence run are present in the starting fragment.
  • [0026]
    Method C depends on providing randomly distributed end points for enzymatically-determined deletions. There are many methods for making such deletions (especially those involving exonuclease digestions, typically Exonuclease III), none of which provide entirely random endpoints and which depend on the presence of unique suitable restriction enzyme sites at one or both ends of the cloned fragment. However, because the deletion series in principle allows construction of a map (of nested remaining fragment lengths in deletion derivatives) that is independent of the sequence itself, this method can allow repetitive sequence longer than the sequence run to be located within the fragment at appropriate locations.
  • [0027]
    A method for introduction of universal priming sites at randomly distributed locations within a fragment of interest is therefore a useful advance in sequencing technology.
  • [0028]
    Transposition and the Sequencing Problem.
  • [0029]
    Previous efforts have been made to provide distributed priming sites by means of transposable elements. These methods have fallen short of this goal in three ways: first, the transposable elements have not provided a sufficiently random distribution of priming sites; second, the transposition method (carrying out transposition in vivo, followed by recovery of the targeted DNA and repurification) has been time-consuming and laborious; third, the Systems have been prone to produce undesired products. These undesired products include but are not limited to: a) cointegrates (replicon fusions) between the donor of the transposon and the target plasmid; b) insertions in which the two ends of the transposon act at different positions (leading to deletion of the intervening target); c) insertions of multiple copies of the transposon into the target, so that priming from one end of the transposon yields two superimposed sequences. The method has been laborious in two ways: the majority of insertions have been into chromosomal DNA of the host, and even for those insertions into the plasmid the recovery method has entailed loss of independence of insertions. in vitro methods of insertion have suffered from both the non-random location of insertion sites and the undesired products, and also from poor efficiency, so that it has been impractical to obtain large numbers of insertions into the target of interest without excessive labor.
  • [0030]
    Increasing interest in large scale sequencing projects and a concomitant search for highly efficient in vitro mutagenesis methods has promoted the adaptation of several in vitro transposon systems as tools to study genomes. An in vivo reaction for the bacterial transposon Tn3 has been used to efficiently sequence plasmid inserts of variable lengths; however, only approximately 37% of the nucleotides were found to be capable of serving as sites for insertion (Davies, 1995 #419). A similar, more random system has been developed for yeast retrotransposon Ty1, employing synthetic transposons with U3 ends as substrates and Ty1 virus-like particles supplying transposition functions (28) to sequence plasmids with yeast and human DNA inserts. A disadvantage to this method is the requirement for the cumbersome preparation of VLPs. In vitro transposition with an MLV integrase system has been utilized as a tool to dissect some of the mysteries of chromatin packaging (29) (30) (31) and as a tool for functional genetic footprinting (32). However, the MLV insertions do not appear to be completely random. An object of the invention therefore is to provide a transposon and transposition reaction with more random target site specificity. Therefore, the inventor examined the target site selectivity of the TnsCA225V machinery in vitro and explored the viability of this reaction as an effective tool for random insertional mutagenesis.
  • BRIEF SUMMARY OF THE INVENTION
  • [0031]
    Accordingly, a general object of the invention is to provide a transposable system that achieves efficient, simple, non-specific or random insertion into any given DNA segment.
  • [0032]
    A further object of the invention is to provide a transposable system that achieves efficient random insertional mutagenesis via simple insertion.
  • [0033]
    Therefore, a specific object of the invention is to provide a transposable system that achieves efficient target site specificity that is reduced from wild-type and preferably random, via simple insertion.
  • [0034]
    A more particular object of the invention is to provide a transposon containing a mutation in a transposon-derived protein that allows efficient, simple insertion and target site selectivity that is reduced from the wild-type, and preferably random.
  • [0035]
    A more particular object of the invention is to provide a transposable system with a mutation in a transposon-derived ATP-utilizing regulatory protein. The mutation allows the efficient, simple, non-specific or random insertion of the transposable element into a DNA segment or at least provides reduced target site specificity from the wild-type.
  • [0036]
    A preferred object of the invention is to provide a Tn7 transposable system that achieves simple, efficient, non-specific or random insertion into a given DNA segment, or at least reduced target site specificity compared to the wild-type Tn7.
  • [0037]
    A preferred object of the invention is to provide a mutation in the Tn7 transposon that confers efficient, simple, non-specific insertion into a given DNA segment, or at least reduced target site specificity compared to the wild-type Tn7.
  • [0038]
    A preferred object of the invention is to provide a Tn7 transposable system with a mutation in the TnsC protein encoded in the Tn7 transposon, which mutation allows efficient, simple insertion with reduced target site specificity compared to the wild-type, and preferably allows non-specific insertion into a DNA segment.
  • [0039]
    Objects of the invention include methods for using the above compositions.
  • [0040]
    Accordingly, a general object of the invention is to provide a method for efficient, simple, random insertion of a transposable element into a given DNA segment.
  • [0041]
    A further object of the invention is to provide a method for efficient, simple, random insertional mutagenesis by a transposable element.
  • [0042]
    A specific object of the invention is to provide a method for efficient, simple, random transposition of a transposable element into a DNA segment, or in which the specificity of transposition is reduced compared to wild-type.
  • [0043]
    A more particular object of the invention is to provide a method for efficient, simple, random transposition of a transposable element into a DNA segment in which the specificity of transposition is reduced compared to the wild-type by using a transposable system containing a mutation that confers efficient, simple insertion with reduced target site specificity compared to the wild-type, and preferably random insertion.
  • [0044]
    A more particular object of the invention is to provide a method for efficient, simple, random transposition of a transposable element into a DNA segment or in which the specificity of transposition is reduced compared to wild-type, by using a transposable system with a mutation in an ATP-utilizing regulatory protein, the mutation allowing the efficient, simple, non-specific insertion of the transposable element into a DNA segment or at least providing for reduced target site specificity compared to the wild-type.
  • [0045]
    A preferred object of the invention is to provide a method for efficient, simple transposition of a transposable element into a DNA segment in which the specificity of transposition is reduced compared to wild-type, or is preferably random, by providing a Tn7 transposable system that is capable of non-specific insertion into a DNA segment, or at least reduced target site specificity compared to the wild-type Tn7.
  • [0046]
    A further object of the invention is to provide a method for efficient, simple transposition of a transposable element transposon into a DNA segment in which specificity of transposition is reduced compared to wild-type or is preferably random by providing a Tn7 mutation that confers the efficiency, ability to make a simple insertion, and the randomness or reduced specificity.
  • [0047]
    A further object of the invention is to provide a method for efficient, simple, random transposition of a transposable element into a DNA segment, or in which the specificity of transposition is reduced compared to the wild-type, by providing a mutation in the TnsC protein encoded in the Tn7 transposon, the mutation allowing a reduction in target site specificity compared to the wild-type and preferably allowing non-specific or random insertion of the Tn7 transposable element into a DNA segment.
  • [0048]
    A further object of the invention is to provide a method for DNA sequencing using a transposable system to introduce priming sites at randomly-distributed locations within a fragment of interest where the fragment is larger than the sequence run length.
  • [0049]
    A preferred object of the invention is to provide a method for DNA sequencing using a transposable system with a mutation that allows efficient and simple insertion and target site selectivity that is reduced from the wild-type and preferably random.
  • [0050]
    A preferred object of the invention is to provide a mutation in an ATP-utilizing regulatory protein. The mutation allows the efficient, simple, non-specific insertion of the transposon into a DNA segment or at least provides reduced target site specificity over wild-type.
  • [0051]
    A highly preferred object of the invention is to provide a method for DNA sequencing using a Tn7 transposable system that allows efficient, simple, non-specific insertion into a DNA segment or at least reduced target site specificity compared to the wild-type Tn7.
  • [0052]
    A highly preferred object of the invention is to provide a method for DNA sequencing using a Tn7 transposable system with a mutation in the TnsC protein, the mutation allowing efficient, simple insertion and a reduction in target site specificity compared to the wild-type and preferably allowing non-specific or random insertion of the Tn7 transposable element into the DNA segment.
  • [0053]
    A further object of the invention is to provide methods as described above that can be applied to any given DNA segment. These include, but are not limited to, plasmids, cellular genomes, including prokaryotic and eukaryotic, bacterial artificial chromosomes, yeast artificial chromosomes, and mammalian artificial chromosomes, and subsegments of any of these.
  • [0054]
    An object of the invention is to provide these methods in vitro or in vivo.
  • [0055]
    A further object of the invention is to provide kits for carrying out the above-described methods using the above-described transposons or parts thereof.
  • [0056]
    The inventor has accordingly developed a transposable system and methods that improve on in vitro and in vivo transmission methods previously described in that the methods are efficient for transposition, provide relatively random insertion, and almost all products recovered are simple insertions at a single site which thus provide useful information.
  • [0057]
    In a general embodiment of the invention, the invention is directed to a transposable system that achieves simple, efficient, random insertion into a given DNA segment.
  • [0058]
    In a further embodiment of the invention, the invention is directed to a transposable system that is capable of efficient random insertional mutagenesis, preferably by means of a simple insertion.
  • [0059]
    In a specific embodiment of the invention, the invention is directed to a transposable system with target site specificity that is reduced from the wild-type and preferably random, which allows simple and efficient insertion.
  • [0060]
    In a further specific embodiment of the invention, the invention is directed to a transposable system containing a mutation that allows target site specificity that is reduced from the wild-type and is preferably random.
  • [0061]
    In a preferred embodiment of the invention, the invention is directed to a transposable system with a mutation in an ATP-utilizing regulatory protein, the mutation allowing the efficient, simple, non-specific insertion of the transposon into a DNA segment or at least providing reduced target site specificity from the wild-type.
  • [0062]
    In a highly preferred embodiment of the invention, the invention is directed to a Tn7 transposable system that achieves efficient, simple, non-specific insertion into a given DNA segment, or at least reduced target site specificity compared to the wild-type Tn7.
  • [0063]
    In a highly preferred embodiment of the invention, the invention is directed to a mutation in a Tn7 transposon that confers the capability of efficient, simple, non-specific insertion into a DNA segment, or at least reduced target site specificity compared to the wild-type Tn7.
  • [0064]
    In a highly preferred embodiment of the invention, the invention is directed to a mutation in the TnsC protein encoded in the Tn7 transposon, the mutation allowing simple, efficient insertion and a reduction in target site specificity compared to the wild-type and preferably allowing non-specific or random insertion of the Tn7 transposition into a DNA segment.
  • [0065]
    In a specific disclosed embodiment of the invention, the invention is directed to a Tn7 mutant designated TnsCA225V, which is a mutant having an alanine to valine substitution at amino acid number 225 in the TnsC gene.
  • [0066]
    The invention also embodies methods for using all of the above compositions. Methods are directed to transposition or insertion of the transposable elements described above.
  • [0067]
    Accordingly, in one embodiment, the invention provides generally for efficient, simple, random insertion of a transposon into a given DNA segment, or at least insertion with reduced specificity compared to the wild-type.
  • [0068]
    In a further embodiment of the invention, the invention is directed to methods for insertional mutagenesis using a transposable system that is capable of efficient, simple, random insertion or at least insertion with reduced specificity compared to wild-type.
  • [0069]
    In a further embodiment of the invention, the invention is directed to methods for insertion of a transposable element into a DNA segment in which target site specificity is reduced from wild-type and is preferably random, where insertion is efficient and simple.
  • [0070]
    In a further embodiment of the invention, the invention is directed to methods for insertion of a transposable element into a DNA segment, by providing a transposable element containing a mutation that allows efficient and simple insertion and target site specificity that is reduced from the wild-type and is preferably random.
  • [0071]
    In a preferred embodiment of the invention, the invention is directed to methods for inserting a transposable element into a DNA segment by providing a transposable system with a mutation in an ATP-utilizing regulatory protein, the mutation allowing simple, efficient, and non-specific insertion of the transposon into a DNA segment, or at least providing reduced target site specificity from the wild-type.
  • [0072]
    In a highly preferred embodiment of the invention, the invention is directed to methods for inserting a transposable element into a DNA segment by providing a Tn7 transposable system allowing efficient, simple, non-specific insertion into a given DNA segment or at least reduced target site specificity compared to the wild-type Tn7.
  • [0073]
    In a highly preferred embodiment of the invention, the invention is directed to a Tn7 transposable system with a mutation that allows simple, efficient, and non-specific insertion of a transposable element into a DNA segment or at least provides reduced target site specificity from the wild-type Tn7.
  • [0074]
    In a highly preferred embodiment of the invention, the invention is directed to methods for inserting a transposable element into a DNA segment by providing a Tn7 transposable system with a mutation in the TnsC protein, the mutation allowing efficient and simple insertion and a reduction in target site specificity compared to the wild-type and preferably allowing non-specific or random insertion of the Tn7 transposition into a DNA segment.
  • [0075]
    In a specific disclosed embodiment of the invention, the invention is directed to methods for inserting a transposable element into a DNA segment, by providing the Tn7 mutant TnsCA225V.
  • [0076]
    The invention also provides kits for performing the above-described methods and the methods further described herein. In a preferred embodiment, a kit is supplied whose components comprise a mutant ATP-utilizing regulatory protein derived from a transposon, the mutation allowing efficient, simple, non-specific insertion of the transposon into a given DNA segment. The kit also provides a transposable element which can be found as part of a larger DNA segment; for example, a donor plasmid. The kit can further comprise a buffer compatible with insertion of the transposable element. The kit can further comprise a control target sequence, such as a control target plasmid, for determining that all of the ingredients are functioning properly. For DNA sequencing, the kit can further comprise sequencing extension primers with homology to one or more sites in the transposable element. Primers can have homology to sequences outside the transposable element (i.e. in a target vehicle).
  • [0077]
    In the kits, the mutant protein may be added as a purified protein product, may be encoded in the transposable element and produced therefrom, or encoded on vectors separate from the transposable segment, to be produced in vivo.
  • [0078]
    It is to be understood that the invention encompasses transposable systems with varying degrees of reduction of target site specificity from the wild-type which are useful for the purposes of the invention described herein.
  • BRIEF DESCRIPTION OF THE FIGURES
  • [0079]
    [0079]FIG. 1. Papillation phenotypes of the TnsC gain-of-function mutants. Cells were patched on MacConkey lactose plates and photographed after three days' incubation at 30 C. TnsA+B was present in each strain; the TnsC species present is indicated below each patch.
  • [0080]
    [0080]FIG. 2. Amino acid changes in the TnsC mutants. The TnsC protein sequence (SEQ ID NOS.1 and 2) is cartooned, with the residues altered in the Class I mutants indicated above the protein and the Class II mutants below the protein. Hatched boxes represent Walker A and Walker B motifs.
  • [0081]
    [0081]FIG. 3. TnsC mutants promote transposition to the chromosome. Frequencies of R transposition of miniTn7-KmR from a λ phage to the chromosome were measured by the λ hop assay. TnsA+B was present in each strain; the TnsC species present is indicated below each column.
  • [0082]
    [0082]FIG. 4. TnsC mutants promote transposition to conjugable plasmids. Frequencies of transposition of miniTn7-KmR from the chromosome to the conjugable target plasmid pOX-G were measured by the mating-out assay. TnsA+B was present in each strain; the TnsC species present is indicated below each column.
  • [0083]
    [0083]FIG. 5. The substrates, intermediates and products of Tn7 transposition. One substrate is a donor plasmid containing a miniTn7 element which contains the essential cis-acting sequences at each end for transposition. The other substrate is a target plasmid. Transposition initiates with a double strand break at either end of the element, followed by a second break at the other end to generate an excised linear transposon. This excised transposon is then joined to the target DNA to form a simple insertion.
  • [0084]
    [0084]FIG. 6. Analysis of Tn7 transposition reactions on a agarose gel. The donor plasmid, a pBR derivative, contained a miniTn7 element containing a kanamycin gene and the target plasmid contained an attTn7 site. Recombination reactions were carried out as described, the DNAs isolated from the reaction mixture by phenol extraction, digested with a restriction enzyme that cuts once in the donor backbones, displayed by electrophoresis on an agarose gel, transferred to a membrane by electrotransfer and hybridized with a probe specific for the miniTn7 element. Lane 1: TnsA+B; Lane 2: TnsA+B+Cwt; Lane 3: TnsA+B+CE233K; Lane 4: TnsA+B+CS401YΔ402, Lane 5: Tns(A+B)+CA225V.
  • [0085]
    [0085]FIG. 7. Tn7 insertion mediated by TnsA+B+CA225V occurs at many different sites in a target DNA. In vitro transposition reactions using TnsA+B+CA225V were carried out and the DNAs isolated by phenol extraction and ethanol precipitation. A PCR reaction using the transposition products as a template was then carried out in which one primer (NLC 209) (SEQ ID NO:8) complementary to a sequence on the target DNA and another primer NLC 95 (SEQ ID NO:7) complementary to the left end of Tn7. The length of the PCR products will vary depending on the position of the Tn7 insertion, for example, insertions being closer to the target primer will be short (insert 1) and those more distant will be longer (insert 2). The products of the in vitro reaction were then displayed on a denaturing acrylamide gel by electrophoresis, transferred from the gel to membranes and analyzed by hybridization to a radioactively labeled probe that hybridizes to Tn7 sequences on one end of the transposon.
  • [0086]
    [0086]FIG. 8. Analysis of distribution of insertions in different regions of the plasmid. Tn7 displays little target site selectivity at many regions of a target. In vitro transposition reactions were carried out and the products used as a template for PCR reactions as described above except for the target primer. In these experiments, one primer in the end of Tn7 (NLC 95) (SEQ ID NO:7) was used and in separate reactions primers from several different positions in the target DNA were used.
  • [0087]
    FIGS. 9A-C. Structure of Tn7 donor plasmids. A. A plasmid contains a miniTn7 element in which the essential cis-acting sequences at the element termini flank a selectable marker. The translocation of the element can be readily followed by hybridization to a miniTn specific probe. Many different kinds of information could be inside the ends as a selectable (or identifable marker, for example, an antibiotic resistance gene. If the products of transformation are to be recovered in vivo, it is convenient to remove unreacted donor DNA by digestion with a restriction enzyme that is selective for the donor backbone; alternatively a conditional replicon can be used. B. Sequence of Donor plasmid pEM delta R.adj to 1 (SEQ ID NO:3). Plasmid carries a 1625 bp mini-Tn7 element: 199 bp of Tn7R and 166 bp of Tn7L flank a Kan gene with SalI sites at the junctions. The backbone is pTRC99 (Pharmacia); mini-Tn7 plus flanking host DNA was cloned into the SmaI site. C. A commonly used derivative is pEM-Δ, (SEQ ID NO:4) a pBR plasmid containing a kanamycin mTn7 element.
  • [0088]
    FIGS. 10A-B. Tn7 target plasmids. A. Sequence of Target plasmid pER 183 (SEQ ID NO:5). This 8.9 kb pACYC184 derivative carries chloramphenicol resistance, a p15A origin of replication, and inserts carrying mcrB, mcrC, hsdS, and a segment of phage fl. A large target was used to detect preference of moderate complexity (up to four bp preferences should be detectable). In addition, different segments of the plasmid vary in G+C content from 35% to 68%, so that any preference the transposition system might display for a particular G+C content might be revealed. B. The major targets used in this work are pRM2 (SEQ ID NO:6), a 3190 bp pBR derivative containing at attTn7 segment and pER183 (SEQ ID NO:5), a pACYC derivative containing several E. coli genes.
  • [0089]
    [0089]FIG. 11. Diagram of sequencing runs used to ascertain the positions of 63 insertions of mini-Tn7 into pER183 (SEQ ID NO:5). Numbers at the top refer to coordinates on the sequence of pER183 (SEQ ID NO:5) displayed in FIG. 11B. Arrows indicate the direction of primer extension; arrow stems cover the sequence obtained from the run. Arbitrary numbers attached to the arrows assigned by the sequence assembly program AUTOASSEMBLE.
  • [0090]
    [0090]FIG. 12. Graph of the observed distribution of insertions in 100-bp intervals of pER183 (SEQ ID NO:5) and the distribution expected if the distribution were random. On the abcissa is the number of insertions per interval; on the ordinate is the number of intervals that exhibit that number of insertions. Crosses show the expected values for a random (Poisson) distribution of insertions along the sequence; diamonds show the observed values.
  • [0091]
    [0091]FIG. 13. The base composition of the 5 bp sequences duplicated by the process of Tn7 insertion for the 63 sites examined. On the abcissa, sequence positions are numbered relative to the right end of Tn7 (Tn7R) such that position 1 is immediately adjacent, position 5 is 5 bp away (see diagram below the graph). On the ordinate is the number of instances of a particular base at that position. All bases are well represented at all sites.
  • [0092]
    [0092]FIG. 14. Effect of four methods of stopping the transposition reaction in preparation for introduction into cells. Results for four replicates (abcissa) of each of four stop methods (z axis), reported as number of transformants per {fraction (1/50)}th of the total reaction (ordinate). Treatments were: no treatment; heat treatment at 65 C. for 20 min; heat treatment at 75 C. for 10 min; and phenol extraction followed by ethanol precipitation. Heat treatment at 75 C. but not 65 C. allows effective recovery.
  • [0093]
    [0093]FIG. 15. A second experiment displaying the effect of three methods of stopping the transposition reaction in preparation for introduction into cells. Results are shown for two replicates of each of three stop methods (abcissa) for four doses of two different aliquots of TnsB (z axis), reported as number of transformants per {fraction (1/25)}th reaction. Treatments were: heat treatment at 75 C. for 10 min; ethanol precipitation alone; or heat treatment at 65 C. for min. On the z axis, two aliquots (1- or 2-) of TnsB were used, in four different doses, 1 μl 1.5 μl 2 μl or 3 μl. The row labeled 1-2, for example, employed aliquot 1 and used 2 μl of it. Heat treatment at 75 C. but not 65 C. allows effective recovery. This experiment also illustrates the dose-response to TnsB.
  • [0094]
    [0094]FIG. 16. Effect of two methods of storing proteins on the efficiency of the transposition reaction. Abcissa displays the storage conditions tested: “individually”, TnsA, TnsB and TnsC proteins stored individually in separate tubes at −70 C.; “as a mixture (A2a)”, TnsA, TnsB and TnsC proteins stored together as a mixture at −70 C. Ordinate displays the number of transformants per {fraction (1/50)}th of the total reaction. Each treatment was tested in quadruplicate.
  • [0095]
    [0095]FIG. 17. Effect of three methods of storing proteins on the efficiency of the transposition reaction. Abcissa displays the storage conditions tested: “individually”, TnsA, TnsB and TnsC proteins stored individually in separate tubes at −70 C.; “as a mixture, −70 (A2a)”, TnsA, TnsB, and TnsC proteins stored together as a mixture at −70 C. “as a mixture, −20 (A2b)”, TnsA, TnsB and TnsC proteins stored together as a mixture at −20 C. Ordinate displays the number of transformants per {fraction (1/50)}th of the total reaction. Each treatment was tested in quadruplicate.
  • [0096]
    FIGS. 18A-18B. 18A. nucleotide sequence of TnsC (SEQ ID NO:1). 18B. Amino acid sequence of TnsC (SEQ ID NOS:1 and 2).
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0097]
    In the art, the term “transposon” encompasses a segment flanked by particular cis-acting sites that are required for mobilization to occur, together with the genes that specify the proteins that act on those cis-acting sites to mobilize the segment defined by them, whether or not the protein-encoding genes lie between the sites mentioned. For example, according to the present invention, a Tn7 transposon can correspond to the wild type transposon except that the transposon encodes a mutant TnsC. This transposon thus provides the protein products required for mobilization. However, an entire transposon is not necessary to practice the invention. Thus, the term “transposon derivative”, “transposable element”, or “insertable element” as used herein can also refer to DNA minimally comprising the cis-acting sites at which the trans-acting proteins act to mobilize the segment defined by the sites. It is also understood that the sites may contain intervening DNA.
  • [0098]
    The phrase “transposable system” as used herein encompasses a transposon containing a mutation in a native ATP-utilizing regulatory protein which, when expressed from the transposon, allows for the non-specific target site selectivity or reduced target site selectivity disclosed herein. The phrase also encompasses modifications in which the relevant proteins are not encoded on the transposable element but nevertheless, acts upon it to achieve the objects of the invention. Thus, the system encompasses compositions in which the mutant protein is added to a transposable element that is derived from a transposon but where the element contains less than the full complement of genes. The only limitation on this element is that it contain the cis-acting sequences upon which the mutant protein acts that allows integration of the element into a target DNA. Thus, the system comprises DNA with cis-acting sites (which may contain heterologous DNA sequences) and the trans-acting proteins that employ those sites to mobilize the segment defined by the sites, regardless of how they are organized in DNA. Accordingly, the proteins may be provided in separate plasmids or in purified form.
  • [0099]
    The term “transposon-derived” as used herein to refer to the mutant protein, refers to a derivative of a protein normally found on the transposon. However, this need not be the naturally occurring protein but can be the protein produced by recombinant or chemical synthetic methods known to those in the art.
  • [0100]
    The term “transposable element” encompasses both transposons and derivatives thereof. The only limitation on the derivative is that it is capable of integrating into DNA, containing cis-acting sequences that interact with transacting proteins to effect integration of the element.
  • [0101]
    The invention provides a transposable system that allows simple integration of a transposable element into a given DNA target efficiently and with a relatively low degree of specificity, preferably random specificity. By “relatively” is intended the degree of specificity compared to the wild-type.
  • [0102]
    The efficiency of integration can vary depending upon the particular use for which insertion is desired. The mutations described herein increase the efficiency of integration compared to the wild-type frequency. The invention encompasses an efficiency of one simple integration event per every 5-10 kilobases. Preferred levels of integration allow multiple simple insertions in different positions in every gene.
  • [0103]
    Integration is also effected by the degree of specificity that the mutation confers or allows. Thus, specificity relates to the relationship of a target DNA sequence and the transposable system.
  • [0104]
    A preferred degree of specificity results in an average insertion in every gene. A practical lower limit would be, on average, one insertion per twenty genes.
  • [0105]
    For sequencing, greater than or equal to 90% of the insertions screened are at different locations (i.e. 10 insertions hit at least 9 different sites) so that almost every template examined gives new information. This is true in DNAs of a variety of different base compositions since possible target DNAs may vary between 20% and 80% G+C. Another way to describe the possible randomness of the system is to say that of 63 insertions, 62 insertion sites were found (around 98% of insertions are at different locations).
  • [0106]
    For mutagenesis, non-commercial systems have been widely used that yield as little as 10% of insertions at different sites (i.e. 9 of 10 insertions are at the same site). The present invention improves on this level of randomness.
  • [0107]
    Furthermore, the types of insertions that are relevant to the discussion of frequency are simple insertions.
  • [0108]
    The invention provides a transposable system with a mutation that provides for efficient, simple insertion and reduced or random target site specificity.
  • [0109]
    The term “simple insertion” refers to a single copy integration event of the element introduced into the target by double-strand breakage and rejoining.
  • [0110]
    Although simple insertions (only one copy of the integrant) are preferred, there may be certain embodiments in which more than one copy does not interfere with the purpose of the application, for example some applications of in vitro mutagenesis, or is actually desirable (for example, for multiple copies of a heterologous DNA sequence are to be inserted). Accordingly, the invention is not limited to the case in which the transposable system provides for simple insertion only.
  • [0111]
    In a preferred embodiment of the invention the mutation is in a transposon-derived ATP-utilizing regulatory protein. One can recognize such a protein by its similarity to the TnsC protein of Tn7, that is by its sequence homology, its possession of a protein sequence motif element similar to an ATP binding site motif in other ATP-dependent proteins, or by reconstitution of an in vitro transposition system and demonstration of a requirement for nucleotides in that in vitro transposition system.
  • [0112]
    In a highly preferred embodiment, the mutation is in the TnsC gene (SEQ ID NO:1) encoding the TnsC protein (SEQ ID NOS:1 and 2) of Tn7. This mutation provides a Tn7 transposon that is capable of relatively non-specific insertion into a given DNA segment.
  • [0113]
    Thus, the invention is directed to insertion of the Tn7 transposable element but is not limited to this transposable element. Accordingly, the invention can be practiced with transposable elements related to Tn7 in that transposition occurs by means of an ATP-mediated process. Thus, mutations in the ATP-utilizing proteins in such transposons is contemplated in this disclosure. Accordingly, transposons with ATP-utilizing regulatory proteins in addition to Tn7 are encompassed in the invention. Examples of such transposons are Tn5090/Tn420; the transposon-encoded transposition proteins are TniA, TniB, and TniQ. The TniB would be the ATP-utilizing protein.
  • [0114]
    Another class of transposon is encompassed by the invention in which it is possible to increase the frequency by altering the ATP-utilizing proteins examples are Tn552 and IS21.
  • [0115]
    The invention provides for the insertion of the transposable elements described herein into any DNA segment of any organism. Moreover, the invention also provides for the insertion into any synthetic DNA segment.
  • [0116]
    Insertion of the transposable element can be in vivo. In this case, the transposable element is introduced into a desired host cell, where it inserts directly into DNA in that cell. The only limitation is that the transposable element be capable of insertion in the specific host cell DNA. Thus, as long as the proteins required for transposition can be expressed in a desired cell, this cell can provide a host for insertion of the transposable element into any DNA found in that host cell.
  • [0117]
    Insertion can be for the purpose of gene inactivation. Gene inactivation is useful for genetic analysis (e.g. gene function).
  • [0118]
    Genetic analysis includes:
  • [0119]
    assessment of the phenotype of a null allele (not expressing functional protein due to interruption of the gene by the transposable segment); assessment of the consequences of insertion of particular active DNA structures or sequences for genetic properties of chromosomes or their parts, such as but not limited to accessibility to Dnase I or to footprinting reagents, or expression or silencing of nearby transcribable genes, or for activity of genetic or epigenetic processes such as, but not limited to homologous recombination, chemical mutagenesis, oxidative DNA damages, DNA methylation, insertion of proviruses or retroposons; assessment of protein domain structure via creation of multiple interruption points within a gene for a multidomain protein, wherein a gene product missing one or more domains of the multidomain protein might exhibit partial activity or activities, including antigenic activities or immunodominant epitopes [randomness is paramount here, many insertion positions are needed if borders are to be defined accurately]; assessment of expression pattern via creation of transcriptional fusions of a promoter in the target to a reporter (e.g. beta galactosidase or green flourescent protein or chloramphenicol transacetylase or luciferase) within the transposable segment; assessment of expression pattern via creation of translational fusions of a portion of a gene product encoded by a target to a gene product or an antigenic peptide encoded by the transposable segment (e.g. beta galactosidase or an epitope tag or an affinity tag); assessment of operon structure, in which interruption of transcription by insertion upstream of a gene results in altered expression of a gene without disrupting the coding sequence of that gene; gratuitous expression of a gene, in which transcription from a promoter within the transposable segment results in expression of a gene downstream of the position of insertion of the transposable segment, with or without regulation of transcription of the promoter within the transposable segment; gratuitous expression of a protein fusion, in which transcription from a promoter within the transposable segment results in translation of a protein beginning within the transposable segment and proceeding toward the outside of the transposon, then continuing into the gene within which the transposable segment is inserted, resulting in a fusion of the transposon-encoded protein with the target protein; assessment of the consequences of introducing into the host cell any transcript or gene product entirely encoded within the transposable segment, especially where it is desirable to assess position-effects (the consequences not only of expression but of expression in different positions within the genome).
  • [0120]
    Insertion can also be for the purpose of introducing heterologous DNA sequences into the DNA of a host cell. The DNA in the host cell in which the insertion occurs can be the host genomic DNA or extrachromosomal elements. This includes both naturally-occurring elements and elements introduced exogenously.
  • [0121]
    Heterologous genes that can be introduced via the insertion include reporter genes. DNA sequences can also be introduced that provide physical markers in a chromosome. Insertion can also be used as a simple way to recover the host DNA that is flanking the inserted element. Genomic DNA is cut with restriction enzymes and the insertion plus the flanking DNA is then cloned.
  • [0122]
    Another utility or another application of the invention is to analyze the interaction of various non-transposition proteins with a DNA sequence, for example, DNase footprinting of repressors bound to DNA. A further use is to study the structure of genomic chromatin i.e., the state at which DNA is actually found in the cell.
  • [0123]
    A further advantage in using Tn7 and similar transposons is that of double end or “concerted” joining. Accordingly, Tn7 inserts in a “cut and paste” manner with both ends of the transposon being joined to the target DNA.
  • [0124]
    Insertion can also be in vitro. In vitro insertion provides an advantage over insertion in vivo. Using in vitro insertion, the transposable element can be placed in any DNA target and that target then introduced into a host cell where it can integrate or replicate. Accordingly, this greatly expands the host cell range.
  • [0125]
    Targets for insertion, accordingly, include DNA fragments, plasmids and other extrachromosomal elements capable of replication in prokaryotic and/or eukaryotic host cells. Given the array of plasmids available, potentially any cell can be used as a host for an insertion target containing a transposable element that was introduced into the target in vitro. The target can be based on a bacterial plasmid, bacteriophage, plant virus, retrovirus, DNA virus, autonomously replicating extra chromosomal DNA element, linear plasmid, mitochondrial or other organelle DNA, chromosomal DNA, and the like.
  • [0126]
    When introduced into the host cell, the target can be maintained as an autonomously replicating sequence or extrachromosomal element or can be integrated into host DNA. When integrated, integration can occur by homologous recombination or by means of specific integration sequences such as those derived from retroviruses, DNA viruses, and the like.
  • [0127]
    It may be, but is not necessarily, desirable to obtain replication of the target in the host cell. A specific application in which this is desirable is the case in which a transposable element is used as a component for introducing primer binding sites for DNA sequencing.
  • [0128]
    Accordingly, in a highly preferred embodiment of the invention, a transposable element is introduced into a target containing a DNA segment for which a sequence is desired. This target is then introduced into a host cell where it is allowed to replicate, thus producing sufficient copies to allow DNA sequencing using a primer specifically recognizing a sequence in the target.
  • [0129]
    In one embodiment of this method, the primers recognize one or both ends of the transposable element such that sequencing can proceed bidirectionally from the transposable element insertion site into the surrounding DNA. The target may be composed entirely of DNA segments for which the sequence is required or may simply contain subsequences for which a sequence is required. In this aspect the only limitation on the target is that it is able to replicate in the host cell (and therefore contains sequences that allow this to occur).
  • [0130]
    It is also highly desirable that the target have a selection marker in order to eliminate the background in host cells containing the target without the insertion of the transposon.
  • [0131]
    An alternative way to eliminate this background, however, is to provide a method for disabling a target that has not received an insertion so that it is unable to replicate in the host cell and is thus diluted out during host cell culture. Accordingly, the transposable element itself could contain an origin of replication for the host cell. Thus targets not receiving an insertion would be unable to replicate. An insertion could also result in the formation of functional replication sequences. The target could also contain a heterologous conditional origin, such as the R6K origin, that cannot replicate without the pir protein. The person of ordinary skill in these arts would be aware of the various methods for constructing targets with the (in)ability to replicate in a specific host cell.
  • [0132]
    It is also possible, however, to use the transposable elements described herein for DNA sequencing without the in vitro insertion described above. Insertion could be directly accomplished in host cell DNA and then the DNA containing the insertion removed from the host. This DNA segment could then be replicated although it does not necessarily have to be if the host has produced sufficient copies for sequencing. Accordingly, sufficient numbers of the segment with the insertion sequence could then be sequenced as above.
  • [0133]
    An example of the case in which the DNA segment receiving an in vivo insertion would not need to be further replicated in another host is, for example, a case in which the insertion occurs in a sequence capable of being amplified directly in the host cell. This could be a plasmid containing an amplifiable marker, such as the dhfr gene, the cell being grown in a selective medium containing methotrexate. The person of ordinary skill in the art would know the various methods for amplifying DNA segments using selectable markers. The selectable marker could be introduced on the transposon but would not necessarily need to be.
  • [0134]
    In a further DNA sequencing protocol, the primers that are used facilitate DNA segment amplification by the PCR reaction. For example, a primer can be used that recognizes an end of the transposable element with the second primer being found in the target DNA sequence. The primer could be based on random sequences or on known sequences deliberately placed in the target vehicle. Thus the target vehicle could contain a characterized plasmid (as an example) in which the sequences are known. In this instance, primers can be designed to hybridize to any area within the plasmid, the segment to be sequenced being between the transposon and the second primer site in the target vehicle.
  • [0135]
    In accordance with the above-described embodiment, the invention is also directed to kits for performing transposable element insertion in vitro. As described, such insertions can be used to provide priming sites for DNA sequence determination or to provide mutations suitable for genetic analysis or both.
  • [0136]
    Essential components in the kit are gene products allowing transposition that are normally encoded on the transposable element or their functional equivalents. A further component is a transposable element donor vehicle. This nucleic acid vehicle provides the transposable element to be inserted into a given specific target. The transposable element donor is preferably DNA but could encompass RNA, being operable via a cDNA copy. Preferred DNA vehicles include, but are not limited to, bacterial plasmids. Other vehicles include any DNA that can be isolated in super coiled form or placed into a super coiled configuration by the use of topoisomerases, for example, bacteriophaged DNA, autonomously replicating molecules from eukaryotes or archae, or synthetic DNA that can be ligated to form a topologically closed circle.
  • [0137]
    Optional components of the kit include one or more of the following: (1) buffer constituents, (2) control target plasmid, (3) sequencing primers. The buffer can include any buffer suitable for allowing the transposition activity to occur in vitro. A preferred embodiment is HEPES buffer. A specific disclosed embodiment is included in the exemplary material herein.
  • [0138]
    Preferred donor plasmids do not need to be destroyed before introducing transposition products into commonly used bacterial and preferably E. coli strains. These vectors do not replicate without regulatory genes not provided by the host cell which allow a functional replication origin. An example is the pir gene which is present only in specially constructed strains, having been derived from the plasmid R6K. In this way, artifactual background consisting of cells transformed with both the donor DNA and the target DNA without any transposition having occurred is eliminated. As discussed herein, there are other ways to do this such as restriction digestion of the donor DNA but not of the target or transposable segment or deletion and titration of the transposition reaction so that there are more cells than DNA molecules in the transformation step. However, these are not preferred.
  • [0139]
    The control target plasmid does not contain the transposable element and does contain transposable element integration site. The purpose is to assure that the reaction is not inhibited by a contaminant in non-kit ingredients (introduced by the kit user); i.e. it ensures that all components allow optimal insertion.
  • [0140]
    Sequencing primers include, but are not limited to primers that have homology with both ends of the transposable element and, as such, allow sequencing to proceed bidirectionally from the ends of the transposable element. However, primers could be made to any area within the transposable element or within the target vehicle itself as long as extension is allowed into the DNA segment to be sequenced. Kits designed for allowing sequencing by the PCR reaction may also include a second primer that allows the amplification of the sequence between the first and second primers.
  • [0141]
    The control target plasmid preferably contains a selectable marker for recovery of the desired DNA segment from a specific host cell. It is understood that, when using the kit, the target DNA does not carry the same selectable marker as the control target nucleic acid.
  • [0142]
    A fourth optional component of a kit is target DNA itself. Target DNA that might be desirable would include but is not limited to purified chromosomal DNA, total cDNA, cDNA fractionated according to tissue or expression state (e.g. after heat shock or after cytokine treatment other other treatment) or expression time (after any such treatment) or developmental stage, or plasmid, cosmid, BAC, YAC or phage library of any of the foregoing DNA samples, especially such target DNA from important study organisms such as Homo sapiens, Mus domesticus, Mus spretus, Canis domesticus, Bos, Caenorhabditis elegans, Plasmodium falciparum, Plasmodium vivax, Onchocerca volvulus, Brugia malayi, Dirofilaria immitis, Leishmania, Zea maize, Arabidopsis thaliana, Glycine max, Drosophila melanogaster, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Neurospora, Escherichia coli, Salmonella typhimurium, Bacillus subtilis, Neisseria gonorrhoeae, Staphylococcus aureus, Streptococcus pneumonia, Mycobacterium tuberculosis, Aquifex, Thermus aquaticus, Pyrococcus furiosus, Thermus littoralis, Methanobacterium thermoautotrophicum, Sulfolobus caldoaceticus, and others.
  • [0143]
    Other suitable selectable markers include chloramphenicol resistance, tetracycline resistance, spectinomycin resistance, streptomycin resistance, erythromycin resistance, rifampicin resistance, bleomycin resistance, thermally adapted kanamycin resistance, gentamycin resistance, hygromycin resistance, trimethoprim resistance, dihydrofolate reductase (DHFR), GPT; the URA3, HIS4, LEU2, and TRP1 genes of S. cerevisiae.
  • [0144]
    There may be certain instances in which it is desired to introduce primer binding sites other than those naturally found in the transposable element or in the insertion vehicle. In this case, the transposable element can be used as a vehicle for introducing any desired primer or primers. An example of when the use of exogenous primers may be desirable is the case in which the transposable element ends form a secondary structure that interferes with sequencing, or cases in which there is a similarity of sequence between the two ends of the transposable element, and cases in which the only practical binding sites in the transposable element are so far internal that they undesirably curtail the amount of nucleotides that can be sequenced from that site.
  • [0145]
    The invention also generally encompasses compositions containing an ATP-dependent DNA binding protein encoded by a transposon, the protein containing a mutation conferring reduced target site specificity, preferably random target site insertion.
  • [0146]
    The protein is isolated from a biological preparation produced in vivo or in vitro. Thus, the protein is purified or substantially purified from cellular components with which it is found in vivo. When produced in vitro, the protein may also be purified or substantially purified from the other components used to produce it.
  • [0147]
    In preferred embodiments the protein is the TnsC protein (SEQ ID NOS:1 and 2).
  • [0148]
    In a specific disclosed embodiment, the protein contains a valine at amino acid number 225.
  • [0149]
    The invention is also directed to compositions containing the protein described herein and the transposable element substrate on which the protein acts to cause insertion.
  • [0150]
    Compositions can also include target DNA into which the transposable element is capable of being inserted.
  • [0151]
    The mutant proteins of the present invention include the naturally occurring proteins encoded by a transposon as well as any substantially homologous and/or functionally equivalent variants thereof. By “variant” protein is intended a protein derived from the native protein by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Methods for such manipulations are generally known in the art.
  • [0152]
    For example, amino acid sequence variants of the polypeptide can be prepared by mutations in the cloned DNA sequence encoding the native protein of interest. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, (37) (38) (39) (40); U.S. Pat. No. 4,873,192; and the references cited therein; herein incorporated by reference. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of Dayhoff et al. (1978) (41) in Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be preferred.
  • [0153]
    In constructing variants of the protein of interest, modifications to the nucleotide sequences encoding the variants will be made such that variants continue to possess the desired activity. Obviously, any mutations made in the DNA encoding the variant protein must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. See EP Patent Application Publication No. 75,444.
  • [0154]
    Thus nucleotide sequences of the invention and the proteins encoded thereby include the naturally occurring forms as well as variants thereof. The variant proteins will be substantially homologous and functionally equivalent to the native protein. A variant of a native protein can be “substantially homologous” to the native protein when at least about 80%, more preferably at least about 90%, and most preferably at least about 95% of its amino acid sequence is identical to the amino acid sequence of the native protein. However, substantial homology includes high homology in the catalytic or other conserved functional regions with possible low homology outside these. By “functionally equivalent” is intended that the sequence of the variant defines a chain that produces a protein having substantially the same biological effect as the native protein of interest. Thus, for purposes of the present invention, a functionally equivalent variant will confer the phenotype of activating transposition with reduced target site specificity, preferably random. Such functionally equivalent variants that comprise substantial sequence variations are also encompassed by the invention.
  • [0155]
    The invention also encompasses compositions containing a transposable element containing DNA sequence encoding an ATP-utilizing regulatory protein, the protein containing a mutation that confers reduced target site specificity and preferably random insertion.
  • [0156]
    In preferred embodiments of the invention, the transposable element is a Tn7 transposable element.
  • [0157]
    In specific disclosed embodiments, the mutation is valine as amino acid number 225 in the TnsC protein.
  • [0158]
    The invention also encompasses compositions containing the above-described transposable element and a given DNA segment intended to be the target for insertion of the transposable element.
  • [0159]
    The invention, accordingly, is directed to DNA into which has been inserted the transposable element containing the mutation described herein that confers simple, efficient insertion with reduced target site specificity or random target site insertion. The DNA in this composition, in one embodiment, is capable of being introduced into a cell in which it can exist as an extrachromosomal element or as an integration element into cellular DNA.
  • [0160]
    The invention is also directed to DNA segments encoding the mutant proteins disclosed herein, vectors containing these segments and host cells containing the vectors. The vectors containing the DNA segments may be used to propagate (i.e. amplify) the segment in an appropriate host cell and/or to allow expression from the segment (i.e. an expression vector). The person of ordinary skill in the art would be aware of the various vectors available for propagation and expression of a cloned DNA sequence. In a preferred embodiment, a DNA segment encoding mutant TnsC protein is contained in a plasmid vector that allows expression of the protein and subsequent isolation and purification of the protein produced by the recombinant vector. Accordingly, the proteins disclosed herein can be purified following expression from the native transposon, obtained by chemical synthesis, or obtained by recombinant methods.
  • [0161]
    Relevant compositions, accordingly, include expression vectors for the mutant protein alone or in combination with expression vectors for the other proteins necessary for insertion of a transposable element. Such compositions may further comprise the transposable element to be acted upon by the proteins. Such mixtures are useful for achieving in vivo insertion, among other things.
  • [0162]
    The invention further encompasses kits containing the above-described compositions.
  • [0163]
    Tn7 can be obtained as strain ATCC 29181; a K-12 derivative carrying the resistance transfer factor R483; originally identified as carrying a transposon in Barth et al. J. Bacteriol. 125:800-810 (1976). The sequence of Tn7 is Genbank entry ISTN7TNS, Assession no. X17693; reported in Flores et al. Nucleic Acids Res. 18:901-11 (1990).
  • [0164]
    Having now generally described this invention, the same will be further described by reference to certain specific examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.
  • Experimental EXAMPLE 1
  • [0165]
    Materials and Methods
  • [0166]
    Media, Chemicals, and Enzymes:
  • [0167]
    LB broth and agar were prepared as described (42). Trimethoprim selection was on Isosensitest agar (Oxoid). Lac phenotypes were evaluated on MacConkey lactose agar (Difco). Antibiotic concentrations used were 100 μg/ml carbenicillin (Cb), 30 μg/ml chloramphenicol (Cm), 7.5 μg/ml gentamycin (Gn), 50 μg/ml kanamycin (Km), 10 μg/ml nalidixic acid (Nal), 20 μg/ml tetracycline (Tet) and 100 μg/ml trimethoprim (Tp). Hydroxylamine was purchased from Sigma. DNA modifying enzymes were purchased from commercial sources and used as recommended by the manufacturer.
  • [0168]
    Bacterial Strains, Phages and Plasmids:
  • [0169]
    BR293 is E. coli F A(lac-pro) thi rpsL Δ(gal-λG)+lacZ pL cI+434 pRS7 (43) (44). BR293 is identical to NK8027 (45), and was provided by Nancy Kleckner. NLC51 is E. coli F araD139 Δ(argF-lac) U169 rpsL150 relA1 flbB5301 deoC1 ptsF25 rbsR ValR recA56 (46). CW51 is E. coli F ara arg Δlac-proXIII recA56 NalR RifR (11). λKK1 is lambda 780 hisG9424::Tn10 del16 del17::attTn7::miniTn7-KmR (47). Tns transposition proteins were provided by pCW15 (tnsABC), pCW23 (tnsD), pCW30 (tnsE), or pCW4 (tnsABCDE) (11). Target plasmids were derivatives of pOX-G, a conjugable derivative of the F plasmid that carries GnR (48). pOX-attTn7 carries a (−342 to +165) attTn7 sequence (16). The immune plasmid pOX-attTn7 EP-1::miniTn7-CmR was made by transposing miniTn7-CmR (47) onto pOX-attTn7 using TnsABC+E to direct the insertion into a non-attTn7 position. Construction of the immune target plasmid pOX-G: :miniTn7-dhfr is described below. The transposon donor plasmid for the papillation assay was pOX-G::miniTn7lac, containing promoterless lacZY between the transposon ends (50). The high copy transposon donor for mating-out assays was pEMΔ, containing miniTn7-KmR (23).
  • [0170]
    Manipulation and Characterization of DNA:
  • [0171]
    Phage and plasmid isolation, transformation, and standard cloning techniques were performed as described in (40). Conjugation and P1 transduction were performed as described in (42). DNA sequencing was done on an automated ABI sequencer. Two plasmids were constructed in this work: (1) pOX-G::miniTn7-dhfr. MiniTn7-dhfr was constructed by replacing the KmR cassette in pLA1 (16) with a dhfr cassette from pSD511 (28), which had been amplified by PCR to add flanking SalI sites. The PCR fragment was ligated into the TA vector (Invitrogen), the dhfr cassette was then removed by SalI digestion and inserted into the SalI site of pLA1, replacing the KmR gene. The resulting plasmid was transformed into NLC51+pCW4+pOX-G, and grown for several days to allow transposition to occur. pOX-G plasmids which had received a miniTn7-dhfr insertion were identified by mating into CW51 and selecting for TpR.
  • [0172]
    Mutagenesis of tnsC:
  • [0173]
    The TnsABC plasmid pCW15 was exposed to 1M hydroxylamine hydrochloride in 0.45 M NaOH (final pH approximately 7.0) at 37 C. for 20 hours (ROSE et al. 1990). The DNA was recovered by multiple ethanol precipitations, and PvuII-SphI fragments containing mutagenized tnsC were subcloned into untreated pCW15, replacing the wild-type TnsC (SEQ ID NO.1). These plasmids were then introduced into CW51+pOX-G::miniTn7lac by electroporation, and transformants were selected on MacConkey lactose plates containing Cm. The plates were incubated at 30 C. for 3-4 days, and screened for the emergence of Lac+ papillae, indicating transposition of miniTn7lac.
  • [0174]
    λ Hop Transposition Assay:
  • [0175]
    Tn7 transposition was evaluated in NLC51 strains into which tns functions were introduced by transformation, and pOX-G was introduced by conjugation (for FIG. 5). The protocol of (47) was followed: Cells were grown in LB and 0.2% maltose at 37 C. to an OD600 of 0.4-0.6 and then concentrated to 1.6109 cells/ml by centrifugation and resuspension in 10 mM MgSO4. 0.1 ml cells were combined with 0.1 ml λKK1 containing miniTn7-KmR at a multiplicity of infection of 0.1 phage per cell. The infection proceeded for 15 min at 37 C., and was terminated by the addition of 10 mM sodium citrate in 0.8 ml LB. Cells were allowed to recover with aeration for 60 minutes at 37 C., and then spread on plates containing Km and citrate. Transposition frequency is expressed as the number of KmR colonies/pfu of λKK1.
  • [0176]
    Mating-out Transposition Assay:
  • [0177]
    Tn7 transposition was evaluated in the derivatives of BR293 used to monitor SOS induction (Table 3), or in NLC5 1 strains into which tns functions were introduced by transformation, and pOX-G or pOX-G::miniTn7-dhfr were introduced by conjugation. MiniTn7-KmR was present in the NLC51 strains either in the chromosomal attTn7 site (FIG. 4 and Table 1) or the high copy plasmid pEMΔ (Table 2) (SEQ ID NO:4). The protocol was adapted from (11): The donor strains described above and the recipient strain CW51 were grown at 37 to an OD600 of 0.4-0.6 with gentle aeration. Donors and recipients were mixed at a ratio of 1:5, and growth was continued for another hour. Mating was disrupted by vigorous vortexing, and the cells were diluted and plated. The total number of exconjugants was determined by selection on GnNal plates. Tn7-containing exconjugants were selected on TpNalplates, and miniTn7-KmR exconjugants were selected on KmNal plates. Transposition frequencies are expressed as the number of TpR- or KmR-exconjugants/total number of exconjugants.
  • [0178]
    Results
  • [0179]
    Isolation of the TnsC gain-of-function Mutants:
  • [0180]
    To focus on the relationship of TnsC and the target DNA, the inventor isolated gain-of-function TnsC mutants that activated the TnsA+B transposase in the absence of TnsD or TnsE. Since overexpression of wild-type TnsC does not relieve the requirement for TnsD or TnsE (11), these gain-of-function mutations were predicted to affect the biochemical properties of TnsC, rather than its expression or stability.
  • [0181]
    A visual assay for Tn7 transposition (50) (51) was used to identify mutants. This assay uses a miniTn7lac element which carries promoterless lacZY genes between the cis-acting sequences at the transposon ends. The miniTn7lac element is located in a transciptionally silent position on a donor plasmid; cells containing this plasmid are phenotypically Lac. When Tns functions are provided in trans, miniTn7lac can transpose to new sites in the E. coli chromosome. Some of those transposition events place the element downstream from active promoters, resulting in increased lacZ expression. This is observed on MacConkey lactose color indicator plates as the emergence of red (Lac+) papillae in an otherwise white (Lac) colony. Therefore, the number of papillae reflects the amount of transposition which occurred during the growth of that colony.
  • [0182]
    Cells containing miniTn7lac and various Tns functions were patched on color indicator plates (FIG. 1). Virtually no Lac+papillae were seen in cells containing only TnsABCwt. Cells containing TnsABCwt+E produced many Lac+ papillae. Southern blotting demonstrated that TnsABCwt+E papillae result from translocations of miniTn7lac to a variety of chromosomal locations rather than from intramolecular rearrangements of the donor plasmid (50). Most TnsABCwt+D events are silent because there is no appropriately oriented promoter adjacent to attTn7 (50) (52).
  • [0183]
    This visual assay was used to screen for TnsC mutants that had acquired the ability to activate Tn7 transposition in the absence of TnsD or TnsE. Randomly mutagenized tnsC was cloned into a plasmid containing tnsAB. These tns genes were introduced into cells containing miniTn7lac. Six gain-of-function TnsC mutants were identified (FIG. 1).
  • [0184]
    Transposition activated by these TnsC mutants still required the TnsA+B transposase and intact transposon ends. The papillation phenotypes of the TnsC mutants varied considerably, suggesting that different mutants were activating different amounts of miniTn7lac transposition. Several TnsC mutants promoted more transposition than TnsABCwt+E. TnsABCS401YΔ402 achieved the highest level of transposition.
  • [0185]
    The amino acid changes responsible for the mutant phenotypes were determined by DNA subcloning and sequencing. tnsC encodes a protein of 555 amino acids, with Walker A and B motifs in the amino-terminal half of the protein (53). Walker A and B motifs have been implicated by structural and mutational analyses to be directly involved in nucleotide binding and/or hydrolysis in a variety of ATPases and GTPases (37) (55).
  • [0186]
    The tnsC mutations primarily result in single amino acid substitutions whose locations are scattered across the TnsC protein sequence (FIG. 2). TnsC mutants segregate into two phenotypic classes. Transposition reactions activated by Class I mutants are sensitive to immune targets and the target selection factors TnsD and TnsE. Transposition reactions activated by the Class II mutants are impaired in their responses to these signals. The residues affected in two of the mutants (TnsCA225V and TnsCE233K) lie in or very close to the Walker B motif.
  • [0187]
    TnsC Mutants Promote Intermolecular Transposition:
  • [0188]
    The papillation assay is a powerful screen for transposition activity, but it does not necessarily report intermolecular transposition events. Internal rearrangements of the miniTn7lac donor plasmid, which fortuitously place the miniTn7lac element downstream from a promoter, would also produce Lac+ papillae. Therefore, the inventor investigated whether the TnsC mutants facilitate the TnsA+B transposase to do intramolecular recombination, or whether the mutants promote intermolecular transposition.
  • [0189]
    The λ hop assay measures the translocation of a miniTn7-KmR element from a replication- and integration-defective λ phage to the bacterial chromosome during a transient infection. The miniTn7-KmR element carries a kanamycin resistance cassette with a constitutive promoter. Therefore, the λ hop assay reports the total number of transposition events occurring into the chromosome. TnsABCwt had no detectable transposition activity in the λ hop assay. TnsABCwt+E generated 2.210−7 KmR colonies/pfu (FIG. 3). Transposition promoted by TnsABCwt+D generated 1.810−4 KmR colonies/pfu. All of the TnsC mutants could promote the translocation of miniTn7-KmR. TnsABCA225V and TnsABCS404YΔ402 promoted 8- and 50-fold more transposition than TnsABCwt+E. Other TnsC mutants promoted transposition, although not at such levels.
  • [0190]
    The mating-out assay was used to explore the ability of the TnsC mutants to promote translocations into a different type of target molecule. This assay measures the frequency of transposition of miniTn7-KmR from the chromosome to pOX-G, a conjugable derivative of the E. coli F factor. The TnsABCwt+E machinery preferentially selects conjugable plasmids as targets for transposition, whereas the TnsABCwt+D machinery does not recognize pOX-G unless it contains attTn7 sequences (ROGERS et al. 1986, WADDELL and CRAIG 1988, WOLKOW et al. 1996). The TnsC mutants could promote transposition to pOX-G (FIG. 4). Thus, the results demonstrate that the gain-of-function TnsC mutants can promote intermolecular transposition.
  • [0191]
    Effects of the Target Selection Factors TnsD and TnsE:
  • [0192]
    Frequencies of transposition of miniTn7-KmR from a lambda phage to the chromosome and/or pOX-G were measured in strains containing TnsA+B and the TnsC mutants, either alone or in combination with TnsD or TnsE. The preferred target for TnsE reactions, pOX-G, was introduced by conjugation into strains containing TnsC mutants or the TnsC mutants+TnsE. The distribution of miniTn7-KmR insertions between the chromosome and pOX-G was determined by mating the pOX-G plasmids from the KmR products of a lambda hop assasy into the Kms strain CW51, and testing whether Km resistance was plasmid linked. No transposition was detected in strains containing TnsABCwt alone or TnsABCE233K+TnsD.
  • [0193]
    Response to the Target Selectors TnsD and TnsE:
  • [0194]
    TnsD and TnsE are required to activate the TnsABCwt machinery and to direct transposition into particular target DNAs mutant (10) (11) (13) (14). The TnsABCmutant machineries, by definition, do not require the inputs of TnsD or TnsE. However, the inventor investigated whether TnsD or TnsE could influence the frequencies or distribution of transposition events promoted by the TnsC mutants.
  • [0195]
    The λ hop assay was used to evaluate the effects of TnsD and an available attTn7 site on transposition promoted by the TnsC mutants. All of the mutant reactions were responsive to TnsD+attTn7, but those responses varied widely. Reactions activated by TnsABCA225V and TnsABCE273K were strongly stimulated by TnsD+attTn7, promoting 500- and 5000-fold more transposition, respectively, in the presence of TnsD+attTn7 than with TnsABCA225V or TnsABCE273K alone. The remaining mutant reactions were less profoundly influenced by TnsD: TnsABCS401F reactions showed a moderate (50-fold) stimulation. Reactions activated by TnsCE233K, TnsCS401YΔ402 and TnsCA282T were somewhat inhibited in the presence of TnsD.
  • [0196]
    The effects of TnsE was also studied by the λ hop assay. In the absence of TnsE, the vast majority of the TnsABCmutant transposition events were targeted to the chromosome. In the presence of TnsE, preferential insertion into pOX-G was observed with some of the TnsC mutants.
  • [0197]
    These differential responses suggest that the six TnsC mutants are not activating Tn7 transposition through a single mechanism. Instead, the mutants can be segregated into two classes, based on their ability to respond to TnsD and TnsE. Transposition activated by the Class I mutants—TnsCA225V and TnsCE273K—can by stimulated by TnsD and targeted to pOX-G by TnsE. Transposition activated by the Class II mutants—TnsCE233K, TnsCA282T, TnsCS401YΔ402 and TnsCS401F—is not responsive to the positive effects of TnsD or TnsE or both. By these criteria, TnsCS401F is proposed to be a member of Class II: although TnsCS401F-activated reactions are somewhat stimulated by TnsD, the distribution of insertions in TnsCS401F-activated reactions is not affected by TnsE. The grouping of the TnsC mutants into these two classes is supported by the differential responses of the TnsABCmutant reactions to immune targets, as described below.
  • [0198]
    Discussion
  • [0199]
    Proteins Involved in Target Evaluation:
  • [0200]
    How is an appropriate target for Tn7 transposition identified? The inventor has hypothesized that TnsC may serve as a “connector” or “matchmaker”, linking the transposase and the target DNA in a manner regulated by the ATP state of TnsC (23) (27). TnsC has the biochemical properties necessary for that connection: it can directly interact with target DNA (24) and with the TnsA+B transposase (A. STELLWAGEN and N. L. CRAIG, unpublished results). However, wild-type TnsC (SEQ ID NO:1) is not sufficient to activate transposition. Instead, Tn7 transposition is dependent on TnsD or TnsE to activate the TnsABCwt machinery and select a target site. TnsD is an attTn7 binding protein (23) which recruits TnsC to this target. The resulting TnsC-TnsD-attTn7 complex can then attract the transposase in vitro (23). The mechanism by which TnsE activates transposition is not yet known. TnsE might be preferentially localized to conjugating plasmids and subsequently recruit TnsC to those molecules, or TnsE might modify TnsC so that TnsC's binding activity is now directed to those targets. Alternatively, TnsE might modify the transposase directly, without proceeding through TnsC. The results suggest that TnsD and TnsE provide alternative inputs into TnsC, which in turn recruits the TnsA+B transposase to the target DNA.
  • [0201]
    The successful isolation of TnsC gain-of-function mutants reveals that the TnsABC machinery is capable of engaging target DNA and promoting insertions without TnsD or TnsE. However, the mutant reactions have not mimicked the abilities of TnsD or TnsE to direct transposition into particular targets: transposition activated by the TnsC mutants does not show the preferential insertion into conjugable plasmids seen with TnsE-activated reactions, nor the attTn7 specificity of TnsD-activated reactions. Therefore, TnsD and TnsE are essential to recognize these positive target signals.
  • [0202]
    TnsC appears to receive a variety of inputs—from TnsD, TnsE and from immune targets—which control its activity. The activity of TnsC can also be influenced by mutation. Six gain-of-function TnsC point mutants have been described in this work, which segregate into two classes. The fact that different classes of TnsC mutants with different transposition activities were recovered is consistent with the hypothesis that there are multiple routes to activating TnsC. The Class I mutants, TnsCA225V and TnsCE273K, enable the TnsABC machinery to execute transposition without sacrificing its ability to respond to both positive and negative target signals. Both are substantial gain-of-function mutants, with TnsABCA225V promoting eight-fold more transposition to the chromosomes than TnsABCwt+E (FIG. 3). Transposition activated by these Class I mutants can be profoundly stimulated by TnsD+attTn7, or directed to conjugable plasmids by TnsE, as well as being able to discriminate between immune and non-immune targets. Thus, the gain-of-function phenotypes seen with the Class I mutants have been achieved while preserving the ability of these TnsCs to transduce information between the target DNA and the transposase.
  • [0203]
    The TnsC mutants which fall into the second class behave much more like constitutively activated versions of TnsC. Some of these mutants also promote considerable amounts of transposition: TnsABCS401YΔ402 results in 50-fold more transposition to the chromosomes than TnsABCwt+E (FIG. 3). However, the nature of the transposition reactions promoted by the Class II TnsC mutants is quite different than those seen with the Class I mutants. Immune and non-immune targets are used essentially equivalently in reactions with the Class II mutants, and TnsD and TnsE are not able to profoundly influence the frequency or distribution of these transposition events. A similar loss of responsiveness to target signals is seen when Tn7 transposition is activated by nonhydrolyzable ATP analogs in vitro. Transposition can still occur when TnsC's ATPase activity is blocked with AMP-PNP, but those transposition events no longer require TnsD and are no longer targeted to attTn7 (BAINTON et al. 1993). Instead, any DNA molecule, including immune targets, can serve as a target for Tn7 insertion. Thus, TnsABC transposition can be constitutively activated by AMP-PNP or by the Class II TnsC mutants. It is noteworthy that the amino acid affected in TnsCE233K lies in one of TnsC's ATP motifs.
  • [0204]
    Comparison to Other Elements:
  • [0205]
    The use of an ATP-dependent protein such as TnsC to regulate target site selection is not unique to Tn7. Bacteriophage Mu transposition is also profoundly influenced by its ATP-utilizing protein MuB. MuB is an ATP-dependent DNA binding protein (57) (MAXWELL et al. 1987) which is required for efficient transposition in vivo (58) (59). In vitro, the MuA transposase preferentially directs insertions into targets that are bound by MuB (60) (61) (19). Although there is no particular sequence specificity to MuB binding, its distribution on DNA is not random: MuB binding to target molecules that already contain Mu sequences is specifically destabilized through an ATP-dependent mechanism (19). Therefore Mu, like Tn7, recognizes and avoids immune targets; moreover, MuB and TnsCA225V appear to play functionally similar roles in regulating transposition.
  • [0206]
    Mu and Tn7 belong to a family of transposons which encode proteins with ATP binding/hydrolysis motifs; other members include IS21 (35) (62), Tn552 (36), Tn5053 (33), and Tn5090 (34). Therefore, the strategy of using an ATP binding protein to regulate target site selection may extend to the entire family. Tn5053 is particularly interesting, since it encodes three proteins which are required for its transposition: a presumptive transposase containing a D, D(35)E motif characteristic of transposases and integrases, a potential regulatory protein containing Walker A and B motifs, and a third protein of unknown function (33). Tn5053 shows some degree of target site specificity, inserting predominantly into the par locus of the conjugable plasmid RP4. It is tantalizing to speculate that the third protein of Tn5053 is a target selector, like TnsD or TnsE, directing insertions into the par locus.
  • [0207]
    The inventor's work has illustrated the role of target DNA in controlling Tn7 transposition in vivo, and has strongly implicated TnsC as a central player in this regulation. Single amino acid changes in TnsC can disrupt the communication between the transposon and the target site, reducing the stringency of Tn7 s target site selectivity. TnsD promotes Tn7 insertion at high frequency into attTn7, a safe haven in the bacterial chromosome, whereas TnsE allows Tn7 access to conjugable plasmids, and thus a means to spread through bacterial populations. Avoidance of immune targets also promotes the spread of the element, rather than local hopping, and prevents one Tn7 element from inserting into another. TnsC may integrate all of these target signals, and communicate that information to the transposase.
    TABLE 1
    TnsCA225V promotes intermolecular transposition
    Tns functions Transposition frequency
    TnsABCwt <10−7
    TnsABCA225V 8.8 (8.1) 10−6
    TnsABCwtDE 5.5 (1.1) 10−4
  • [0208]
    Frequencies of transposition of miniTn7-KmR from a high copy plasmid to pOX-G were determined using the mating-out assay, and are expressed as the number of KmR exconjugants/total exconjugants. Each value is the average of three independent measurements.
  • EXAMPLE 2
  • [0209]
    Materials and Methods
  • [0210]
    Media, Chemicals, and Enzymes
  • [0211]
    Luria broth (LB) and agar were prepared as described by (42). Carbenicillin and kanamycin selections were carried out at a concentration of 100 μg/ml. DNA modifying and restriction enzymes were purchased from commercial sources and used according to manufacturer's instructions. Taq polymerase was purchased from Boehringer Mannheim Biochemicals.
  • [0212]
    Bacterial Strains and Plasmids
  • [0213]
    Tn7 donor plasmids contain a miniTn7 element in which the minimal end sequences of Tn7 (Tn7L 1-166 and Tn7R 1-199) flank a selectable marker. A pBR plasmid containing a mTn7-kanamycin element with NotI and SpeI sites at the ends of the kanamycin cassette has been shown to be an effective donor. When transposition products are to be recovered by transformation, it is useful to prevent transformation of unreacted donor. One strategy is to cut the donor backbone with a restriction enzyme that does not cut within the Tn7 element or within the target DNA. Another strategy is to use donor plasmids that will not replicate with the products recovered. One strategy is to make the replication of the donor depend on a protein that is not present in the transformation strain. For example, the mTn7 element can be placed on a plasmid which does not itself encode an initiator protein for replication. A particular example is to make the donor backbone an R6K plasmid that does not encode the replicator protein pir. The R6Kpir-miniTn7 plasmid can then be grown in a strain which contains pir (supplied for example by a heterologous plasmid) and the transposition mixture transformed into a strain lacking pir. With selection for the marker on the mTn7, only insertions into the target DNA will be recovered. Subcloning Efficiency DH5alpha competent cells were purchased from GIBCO BRL and used according to the manufacturer's instructions.
  • [0214]
    The target plasmid pRM2 (SEQ ID NO:6) contains bases -342 to +165 of attTn7 cloned into pUC18 [47]. The donor plasmid pEMA (SEQ ID NO:4) carries a miniTn7 element comprised of the 166 terminal bases of the left end of Tn7 and 199 bases of the right end flanking a gene conferring resistance to kanamycin [23].
  • [0215]
    Tns Proteins
  • [0216]
    The purification of TnsA and TnsB-His are described in (63). TnsA was stored in 25 mM Hepes (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 5% glycerol at −80 C. TnsB was TnsB-His, a derivative containing a C-terminal polyhistidine tag, and was stored in 25 mM Hepes (pH 8.0), 500 mM KCl, 2 mM DTT, 1 mg/ml BSA, 25% glycerol at −80 C. The purification of TnsC and TnsCA225V is a modified procedure from (24) which is described in (25) (26). Both proteins were stored in 25 mM Hepes (pH 8.0), 1M NaCl, 2.5 mM DTT, 1 mM ATP, 10 mM MgCl2, 0.1 mM EDTA, 10 mM CHAPS, 10% glycerol at −80 C. TnsD was TnsD-His (P. Sharpe and N. Craig, in preparation), a derivative containing a C-terminal polyhistidine tag, and was purified by Ni+2 chromatography before being stored in 50 mM Tris (pH 7.5), 2 mM DTT, 500 mM KCl, 1 mM EDTA and 25% glycerol at −80 C.
  • [0217]
    Transposition Reactions in vitro
  • [0218]
    Transposition reactions are adapted from the standard in vitro reaction described in (23). Reaction mixtures, 100 μl in volume, contained (final concentration) 0.25 nM pEMΔ donor, 1.9 nM pRM2 target, 26 mM Hepes, 4.2 mM Tris (pH 7.6), 50 μg/ml BSA, 100 μg/ml yeast tRNA, 2 mM ATP (pH 7.0), 2.1 mM DTT, 0.05 mM EDTA, 0.2 mM MgCl2, 0.2 mM CHAPS, 28 mM NaCl, 21 mM KCl, 1.35% glycerol, 60 ng TnsA, 25 ng TnsB, either 100 ng TnsCwt, or 100 ng TnsCA225V, and 40 ng TnsD, unless otherwise indicated, in a 30 minute preincubation at 30 C. (TnsA=19 nM, TnsB=3.1 nM, TnsC=16 nM, TnsD=6.5 nM). Magnesium acetate was added to a final concentration of 15 mM and the reactions were allowed to proceed for an additional 60 minutes at 30 C. Products were extracted with a 1:1 mixture of phenol/chloroform, ethanol-precipitated, and resuspended in water in preparation for subsequent analyses.
  • [0219]
    PCR Primers and Amplification
  • [0220]
    Oligonucleotides used for the various PCR amplifications to analyze the products of transposition are:
  • [0221]
    NLC95 (SEQ ID NO.7): (5′)-ATAATCCTTAAAAACTCCATTTCCACCCCT-(3′)
  • [0222]
    NLC209 (SEQ ID NO.8): (5′)-GTGATTGCACCGATCTTCTACACCGTTCC -(3′)
  • [0223]
    NLC429 (SEQ ID NO.9): (5′)-TTTCACCGTCATCACCGAAACGCGCGAGAC-(3′)
  • [0224]
    NLC430 (SEQ ID NO.10): (5′)-AATGACTTGGTTGAGTACTCACCAGTCACA-(3′)
  • [0225]
    NLC431 (SEQ ID NO.11): (5′)-ATGAACGAAATAGACAGATCGCTGAGATAG-(3′)
  • [0226]
    NLC432 (SEQ ID NO.12): (5′)-CAAGACGATAGTTACCGGATAAGGCGCAGC-(3′)
  • [0227]
    Two percent of the 100 μl transposition reaction was used as the template in a given PCR amplification. 100 pg of plasmid pMCB20 was used when amplifying a marker product for size comparison on the high resolution denaturing gels. 30 temperature cycles of 94 C. for 1.0 minute, 55 C. for 1.5 minutes, and 72 C. for 1.5 minutes were run for all amplifications, followed by a single 5 minute incubation at 72 C. The buffer composition and quantity of Taq polymerase recommended by the manufacturer (Boehringer Mannheim Biochemicals) were used for all reactions. PCR products were ethanol-precipitated, resuspended in water, and loaded on a high resolution denaturing gel.
  • [0228]
    Probe Labeling
  • [0229]
    Oligonucleotide probes were 5′ end-labeled with [gamma-32P] ATP substrate and bacteriophage T4 polynucleotide kinase for 45 minutes at 37 C. Labeled probes were separated from unincorporated label by size exclusion through a G50 Nick Spin Column (Pharmacia).
  • [0230]
    High Resolution Denaturing Gels
  • [0231]
    The resuspended PCR products were electrophoresed on either a 5% or 6% polyacrylamide denaturing gel and electrotransferred to Gene Screen Plus membrane (du Pont). The resulting blots were visualized by hybridization with an appropriate oligonucleotide probe at 50 C. and exposed overnight to phosphorimager screens (Molecular Dynamics), which were scanned the following day.
  • [0232]
    Results
  • [0233]
    TnsCA225V Supports Efficient Transposition in vitro
  • [0234]
    A diagram of Tn7 transposition is shown in FIG. 5. Tn7 mobilizes via a cut-and-paste mechanism, whereby both ends of the element are first excised from the donor backbone by double-strand breaks, and join to the target DNA most likely via transesterification reactions to form simple insertions with short gaps at either end. Other possible intermediates of a transposition reaction are double-strand breaks (DSBs), where one end of the transposon has been excised but the other end remains attached to the donor backbone, excised linear transposons (ELTs), where both ends have been excised from the donor and neither end has joined to the target, and double-strand break, single-end joins (DSB-SEJs), where one transposon end has been broken in the donor and joined to the target molecule.
  • [0235]
    The Tn7 transposition reaction has been reconstituted in vitro, in which purified Tns proteins promote the transposition of a mini Tn7 element from a donor plasmid into an attTn7-containing target plasmid (Bainton 1993). TnsABCwt+D supports this reaction with great efficiency. In the absence of TnsD, TnsABCwt does not generate a detectable level of insertion products (FIG. 6, lane 2) although double-strand break intermediates are seen upon prolonged incubation. By contrast, reactions containing TnsABCA225V show a dramatic accumulation of simple insertions, at efficiencies that approach TnsABCwt+D reactions (FIG. 6, lane 5). Neither the TnsABCA225V nor the TnsABCwt+D reactions generate visible levels of DSB-SEJ products, indicating that the vast majority of Tn7 transposition events result in the complete (i.e., two-ended) insertion of the transposon into the target DNA, rather than a single-ended insertion event.
  • [0236]
    TnsABC+D transposition is not only efficient, it is also very target site-specific. TnsABC+D insertions occur almost exclusively into the attTn7 site present on the target plasmid (Bainton, et al., 1993, data not shown). By contrast, the TnsABCA225V insertions are not limited to the attTn7 site. Alternative restriction analysis of the TnsABCA225V reaction yields a smear of products on an agarose gel (data not shown), suggestive of a population of insertions located at many different positions in the target plasmid. To investigate the distribution of these insertions, we subjected the TnsABCA225V reaction products to high-resolution analysis, as described below.
  • [0237]
    Distribution of TnsABCA225V-Mediated Insertions is Highly Nonspecific
  • [0238]
    A PCR-based approach has been used to analyze insertional mutations in SV40 and yeast TRP1ARS1 minichromosomes [30, 31], and perform functional analyses of insertional mutations in yeast chromosome V and the E. coli supF gene [Smith, 1996 #427] and [32], respectively.
  • [0239]
    PCR was utilized to survey the distribution of TnsABCA225V insertions previously seen on the agarose gel at higher resolution. The diagram in FIG. 7 illustrates the PCR strategy used to amplify the population of insertion products present in a TnsABCA225V reaction, with two representative insertions being shown as examples. One PCR primer (NLC95) (SEQ ID NO:7) hybridizes within the cis-acting end sequence of the inserted element and the other (NLC209) (SEQ ID NO:8) hybridizes to an arbitrary position in the target molecule. Thus, the length of the PCR product reflects the positions of the insertions into the target molecule.
  • [0240]
    Amplification of a pool of insertions generated a smear of reaction products when displayed on an agarose gel, as expected (data not shown). The PCR products were run on a 6% polyacrylamide denaturing gel to achieve single nucleotide resolution and visualized by Southern blotting and hybridization with a Tn7-specific probe (FIG. 7). The striking result is that the distribution of products is remarkably nonspecific. Insertions have occurred at nearly every base within the highly resolved lower portion of the gel. PCR products of more than roughly 200 bp in length are resolved poorly. Some areas of dense signal are seen in this region, potentially indicating preferential points of insertion. However, compression of bands could also account for the apparently singular products; analysis of these insertion products with other primer pairs supports this latter possibility (see below).
  • [0241]
    This confirms the inventor's hypothesis that the TnsABCA225V machinery is capable of directing Tn7 transposition into the target plasmid with high efficiency and low specificity.
  • [0242]
    Surveillance of the Entire Target Plasmid
  • [0243]
    In the experiments above, the focus was on a relatively short region of the target plasmid pRM2 (SEQ ID NO:6). It was demonstrated that TnsABCA225V can direct insertions into virtually every base pair of this region. To be certain that the phenomenon is not specific to the region of the plasmid, a family of primers was synthesized, each of which paired with a Tn7 end-specific primer to allow amplification of all regions of pRM2 (SEQ ID NO:6). These primers are spaced at approximately 500 bp intervals around the target plasmid and will amplify insertions in predominantly one orientation. FIG. 8 diagrams the amplicons for each primer pair and shows a denaturing gel Southern blot of the resulting PCR products. The results indicate that the CA225V-mediated insertions do occur into positions all around the target plasmid. As was seen for the original amplicon analyzed, there is considerable variability in the strength of the signal for individual points of insertion, but insertions do occur at some level at every position. Thus, the TnsABCA225V machinery does not appear to have a specificity for any particular region of this target plasmid.
  • [0244]
    In another approach to investigating the possible sequence specificity of TnsABCA225V target site selection, 67 independent insertions into a 12 kb plasmid were collected and analyzed. TnsABCA225V transposition reactions using a target plasmid containing several E. coli genes were transformed into E. coli to select kanamycin-resistant colonies. The target plasmids were then recovered and sequenced to determine the position of each insertion. 62 out of the 63 insertions were located in different positions on the target plasmid. A comparison of the sequences of these insertions supported our previous observations that there is very little sequence specificity governing the selection of TnsABCA225V target sites. Attempts to derive a consensus sequence for the 5 bp target site duplication sequence revealed a faint preference for NYNRN (SEQ ID NO:14), but the bias is not very compelling.
  • [0245]
    Exploiting the TnsABCA225V Machinery for in vitro Mutagenesis
  • [0246]
    The high efficiency and low target specificity of the TnsABCA225V transposition reaction makes this a useful system for mutagenizing a variety of DNA targets. Insertional mutagenesis could be performed on cosmid libraries, cDNA libraries, PCR products, BACs, YACs, and genomic DNAs, among others. The inventor has mutagenized pUC-based plasmids, cosmids, BACs ranging in size from 5 to 120 Kb (data not shown), and H. influenzae genomic DNA (Gwinn et al., 1997). In fact, the inventor has not encountered DNA that cannot serve as a target for TnsABCA225V transposition.
  • [0247]
    Once DNA targets have been successfully mutagenized in vitro, the simple insertions will be recovered. For a simple insertion product to become a stable replicon, the 5′ nonhomologous overhangs trailing off both ends of the inserted transposon must be removed, the gaps filled in, and the strands ligated. A simple method to perform such processing functions is to transform the pool of transposition products into a host and rely on the host's repair machinery, selecting for a transposon-borne marker. In E. coli, the 5′ single-stranded overhangs and gaps on either end of the transposon after a simple insertion are readily repaired by the host (see below). The donor plasmid for other hosts could be customized in a number of ways to best facilitate the recovery of the desired insertional mutants.
  • [0248]
    The inventor recovered simple insertions into pRM2 in E. coli, since Tn7 insertions can be easily repaired in this host.
  • [0249]
    Simply transforming transposition reactions into host cells as a method to recover simple insertion isolates presents a background contributed by donor molecules that have not undergone transposition and thus continue to carry the selectable marker on a stable replicon. In order to eliminate the background false positives that can complicate a screen for insertional mutants, the ability of the unreacted donor to transform cells can be reduced. Two methods have been provided: 1) destruction of the donor plasmid's ability to replicate by restriction digestion prior to the transposition reaction, and 2) use of a conditional replicon origin in the donor backbone which renders the donor incapable of replication in the cells being ultimately transformed with the transposition pool.
  • [0250]
    For the first method, 5 identical TnsABCA225V reactions were carried out on linearized pMCB31 donor DNA paired with cosmid clone ES#3 target DNA, an approximately 50 kb replicon which contains an insert of genomic DNA from E. tarda. Linearizing the plasmid will prevent the donor plasmid from replicating once transformed into the host. The products were pooled for the extraction and precipitation steps, and then a portion of the resultant sample was transformed into BRL Subcloning Efficiency DH5-alpha competent cells. Assuming a 10% loss in the recovery of the DNA after the transposition reaction, the efficiency of transformation relative to μg of input donor DNA was approximately 3.8104 colonies/μg/ml of cells. One-tenth of a microgram of donor DNA is typically used in a reaction, so by extension, if all of the product DNA from a single transposition reaction is transformed, 3800 colonies could be isolated, an efficient mutagenesis. The DH5alpha cells are advertised to have a transformation efficiency of equal to or greater than 1107 colonies/μg supercoiled pUC19/ml of cells. Simply using higher efficiency cells or electroporation cells should yield considerably higher numbers of isolates from a single transposition reaction, and probably aid in picking up rarer events.
  • [0251]
    Another method employs a heterologous origin of replication on the donor plasmid, for example, R6K. Replicons relying on this origin must be maintained in a host carrying a resident copy of the pir gene, which codes for the π protein, a necessary component for initiation of replication at R6Kgamma origins. Thus, it is simple to eliminate false positives stemming from unreacted donor molecules simply by transforming the transposition products into pir cells, and relying on the competent origin of replication in the target molecule for recovery of simple insertion isolates. Transposition reactions employing this donor were prepared for transformation as described above.
  • [0252]
    It is conceivable that the larger plasmid (˜50 kb) would be more difficult to transform after receiving an insertion because it would be a large open circular molecule approximately 10 times the size of the pRM2 (3.2 Kb) open circle with an insertion. To gain insight into the possibility of target size limitations using the transformation method of simple insertion recovery, transpositions of the miniTn7 element from pMCB40 into the two target plasmids were directly compared. The transformation efficiencies of the two reactions were very similar. The different targets were included at comparable concentrations in the transposition reactions, but were not equimolor. The results suggest that ES#3 simple insertions can transform the cells at nearly the same efficiency as the smaller pRM2 simple insertions. It is difficult to test reaction conditions under which the cosmid target is available at the same molarity as the pRM2 target because elevated levels of total DNA in the reactions can compromise the reproducibility with which DNA is recovered after transposition.
  • [0253]
    The high transformation efficiencies demonstrate the utility of this reaction for a mutagenesis in which the simple insertion products can be stably replicated in an E. coli host. This same type of protocol could be used in other bacterial species and strains with development of the appropriate DNA substrates.
  • [0254]
    Discussion
  • [0255]
    TnsCA225V Circumvents the Requirement for a Targeting Protein.
  • [0256]
    Tn7 demonstrates considerable diversity when it comes to target site selection. It has a sophisticated system for choosing either a highly conserved “safe haven” in the E. coli chromosome (attTn7) or somewhat random sites throughout a cell's genome or resident conjugable plasmid, mediating these different selections via alternative targeting proteins encoded by the element. In this way, Tn7 is significantly different than all other well-characterized transposable elements, whose target site selections are mediated predominantly by either the transposase alone (e.g., IS10/Tn10) or in conjunction with one other accessory protein (bacteriophage Mu). IS10/Tn10 selects a target site via a direct interaction of the Tn10 transposase with the target DNA. It has been demonstrated that particular mutations in the Tn10 transposase are capable of altering target recognition features while leaving other functions of the transposase unaffected (65). The bacteriophage Mu, however, encodes a transposase, MuA, and an ATP-dependent activator of MuA, MuB. MuB functions as an accessory protein that, when complexed with target DNA, attracts the MuA transposase to the site of insertion. It is likely that having more proteins involved has allowed Tn7 to be more adaptive to environmental changes when choosing its new sites of residence, and ensured its survival by enabling it to employ a more tailored approach to disseminating itself amongst various cell populations.
  • [0257]
    This example has focused on the role of TnsC in the selection of a target site. As discussed, TnsC has been implicated as the major communicator between the TnsAB transposase bound to donor DNA, and the TnsD or TnsE targeting proteins, complexed with target DNA. Experiments have shown that TnsC does have the capacity to bind DNA nonspecifically in the absence of TnsD and TnsE (ref) but attempts to isolate simple insertions in vivo and in vitro in the absence of the targeting proteins proved unsuccessful with wild-type TnsC (23). Isolation of the TnsCA225V mutant, however, has permitted the inventor to circumvent this requirement and isolate simple insertions from reactions lacking TnsD and TnsE. Not only does the mutant facilitate the recovery of simple insertions, it does so very efficiently.
  • [0258]
    Ability of TnsCA225V to Insert Nonspecifically
  • [0259]
    It is clear that TnsCA225V has a considerable gain of function over wildtype TnsC, as evidenced by the increased yield of simple insertions in a standard in vitro reaction (25) (26) (this example). A more detailed evaluation was necessary to determine the actual sites of insertion because restriction digests of the product pools indicated that there is extensive variability in site selection relative to TnsD-mediated insertions, which are targeted almost exclusively to the attachment site. PCR amplification of pools of transposition products followed by high resolution denaturing gel analysis of several independent reactions has revealed that the insertions into the pRM2 target plasmid are detectable at every base visible within the well-resolved portions of the gels. Although the target site selection is not completely random (there are differences in band intensities), one possibility is that the nonspecific DNA binding activity of TnsC has been enhanced in the TnsCA225V mutant, giving the protein the capacity to direct the TnsAB transposase to the wide variety of insertion sites observed.
  • [0260]
    It is possible that the TnsCA225V mutation has altered TnsC in such a way that it simulates a TnsC-TnsE complex, capable of insertions at more random sites. Perhaps the role of TnsE is to strengthen TnsC's nonspecific interaction with the target DNA, thereby promoting insertions into sites where TnsC and TnsE happen to complex. The ability of TnsE to preferentially direct transposition to conjugating plasmids (14) holds true when TnsCA225V is substituted for wild-type TnsC (SEQ ID NOS:1 and 2) (25) (26). This suggests that this mutation in TnsC does not compensate for all specific activities of a targeting protein. The TnsABCA225V reaction is also sensitive to the presence of the target site specific protein TnsD, as evidenced by a detectable increase in the frequency of insertions when TnsD is present.
  • [0261]
    These observations may explain why Tn7 has chosen to preserve a more complicated target site selection mechanism. In a cell containing only wildtype proteins, an extra layer of regulation can be exercised when two proteins complex to direct insertions, and the result may be less deleterious to cell populations than the somewhat rampant levels of insertions observed in reactions with the TnsCA225V in the absence of targeting proteins. Occurrence of a mutation like TnsCA225V in nature would decrease the specificity and increase the frequency of insertions, the consequence of which could quite possibly be more insertions into essential genes.
  • [0262]
    It is conceivable that TnsC has always played the primary role in directing the TnsAB transposase to insert, and the targeting proteins are more accessory. The inventor has envisioned TnsD binding DNA near the attachment site, and TnsC acting as an activation bridge to the transposase, but an alternative view is that the ability of TnsC to bind DNA plays a more central role in directing the donor complex to an insertion site, and TnsD has the role of “steering” a TnsAB+TnsC complex to a particular point of insertion. The A225V point mutation could confer the ability for TnsC to “steer” the donor complex to insert without the aid of a target-binding protein.
  • [0263]
    There is No Apparent Sequence Preference at the Point of Insertion
  • [0264]
    Two main approaches have been taken herein to analyze the TnsCA225V-mediated insertions at nucleotide resolution. The first involves scanning along a short segment of DNA using PCR and high resolution denaturing gel analysis, quantitating specific signals at each base in a processive manner, and attempting to flush out a sequence motif common to those with the highest signals or lowest signals. The second method focuses on the recovery of the more frequent insertions only, those that can be recovered by simply transforming the transposition products, and relying on the host to conduct a successful repair of the replicons. These two methods provide different views of a common process. Since recovery of specific insertions is reliant of the process of transformation, rare insertion events that can be visualized by the PCR/denaturing gel method will most likely be severely underrepresented in a population of recovered transformants, if we assume that a higher concentration of a specific template will give rise to a diagnostic PCR product of higher intensity. This should bias the representative data accumulated from transposition product transformations to overlap with the subset of PCR products analyzed by denaturing gel analysis with the highest band intensities. In this way, both types of data are valid for attempting to determine a preferred insertion site.
  • [0265]
    The inventor's search for a common insertion site motif failed to uncover any preferred single nucleotides or groups of nucleotides that showed a higher incidence amongst the most intense signals on a denaturing gel or amongst the insertions isolated by transformation. Similarly, there were no apparent motifs common amongst the least preferred sites analyzed in the denaturing gel analysis. The lack of a sequence preference for insertions with this reaction is a very desirable result if it is to be employed as a highly nonspecific method for mutagenizing DNAs.
  • [0266]
    TnsCA225V: A Tool for in vitro Mutagenesis
  • [0267]
    The impressive efficiency and low specificity of the TnsABCA225V in vitro reaction makes the reaction an excellent tool for in vitro mutagenesis. The high efficiency of the reaction (i.e., the high percentage conversion of donor substrate to double-ended simple insertions) is critical when considering how the recombinant DNAs will be recovered. The observation that the majority of the molecules resulting from a reaction that contain a junction between the donor DNA and the target DNA are double-ended simple insertions provides an advantage over alternative transposon-based insertional mutagenesis systems because large portions of the junctions seen in these reactions can be single-end joins (Rowland, S. J. et al. EMBO J. 14:196-205 (1995)). This study has demonstrated that standard commercially available E. coli competent cells are capable of repairing the characteristic gapped molecules formed as a result of a Tn7 simple insertion, provided the target DNA contains an origin capable of replicating in E. coli. Thousands of isolates can be recovered from a single transposition reaction starting with sub-microgram quantities of donor and target DNA. High efficiency cells should yield even greater numbers of isolates. Tn7 insertional mutants could be recovered from many different organisms as long as the target DNA carries information required to replicate in its respective host, the gaps can be repaired by the host, and DNAs can be reintroduced into the host with reasonable efficiency.
  • [0268]
    Cosmid clones have been successfully mutagenized and recovered by the method just described. Pilot reactions were done using purified cosmid clones. But it would be very simple to mutagenize an entire cosmid library and select for mutants by the same process. Replicons as large as 125 kb (a BAC, data not shown) have been successfully targeted and recovered. An earlier study of the inventor demonstrated that the ability of transposition machinery to recognize whether or not a potential target molecule already contains an insertion breaks down as the distance between two insertion sites increases (52). It has been shown that the degree to which a target molecule is “immune” to a second insertion has an inverse relationship to the length of separation of the sites of insertion. TnsCA225V has demonstrated a sensitivity to immunity signals. To date, the inventor has seen very few examples of double insertions into plasmids in the 40-50 kb range, suggesting that this tool will be highly effective for mutagenizing cosmids or plasmids in the 1-50 kb range.
  • EXAMPLE 3
  • [0269]
    A Kit for Making Transposon Insertions
  • [0270]
    The kit provides transposon insertions into DNA in vitro. These insertions can be used to provide priming sites for DNA sequence determination, or to provide mutations suitable for genetic analysis, or both.
  • [0271]
    Section A: Reaction Constituents
  • [0272]
    A1) PROTEINS
  • [0273]
    TnsA 30 μg/ml in 10% glycerol
  • [0274]
    TnsB 20 μg/ml in 25% glycerol
  • [0275]
    TnsC127 100 μg/ml in 10% glycerol
  • [0276]
    Proteins were kept at −70 C.
    A2) BUFFER CONSTITUENTS
    HEPES 0.25 M pH 8.1
    Tris[C1] 0.25 M pH 7.6 [can be omitted]
    BSA   10 mg/ml
    tRNA   50 μg/ml [can be omitted]
    DTT   1 M
    ATP  100 mM
    MgAcetate  375 mM
    A3) TRANSPOSON DONOR  100 μg/ml
    PLASMID
  • [0277]
    The essential features of the plasmid are described above as containing the R6K conditional replicon.
  • [0278]
    A4) CONTROL TARGET PLASMID
  • [0279]
    pLITMUS28 400 μg/ml
  • [0280]
    This plasmid contains both pUc and Mi3 origins, a lacZ′ MCS and amp. See the Figure legend for FIG. 10B.
  • [0281]
    (New England BioLabs, 32 Tozer Road, Beverly, Mass., 01915)
    A5) SEQUENCING PRIMERS
    NLC94 (SEQ ID NO: 13) 3 pmol/μl
    NLC95 (SEQ ID NO: 7) 3 pmol/μl
  • [0282]
    Section B: (Can be Supplied by User)
  • [0283]
    B1) FOR THE REACTION in vitro
  • [0284]
    water; Millicue or equivalent recommended
  • [0285]
    Target DNA not carrying Kanamycin resistance (0.4-0.5 μg per reaction)
  • [0286]
    Water bath or heat block, 30 C.
  • [0287]
    1.5 ml microtubes or other vessel; one per reaction.
  • [0288]
    B2) FOR STOPPING THE REACTION
  • [0289]
    when using chemically competent cells
  • [0290]
    Water bath or heat block, 75 C. Note: not 65 C.
  • [0291]
    when using electocompetent cells
  • [0292]
    Distilled phenol equilibrated with TE or Tris pH 8.0
  • [0293]
    Chloroform equilibrated with TE or Tris pH 8.0
  • [0294]
    EtOH for precipitation
  • [0295]
    NaAcetate 3 M
  • [0296]
    Water or 1 mM Tris pH 8 or TE
  • [0297]
    B3) FOR RECOVERING INSERTIONS:
  • [0298]
    B3a) Transformable Cells:
  • [0299]
    Any standard E. coli strain can be used; we have used ER1821, ER2502 and MC1061 (New England BioLabs, 32 Tozer Road, Beverly, Mass., 01915).
  • [0300]
    Any kanamycin-sensitive organism in which npt can be expressed can also be used with the KanR donor, including but not limited to, Salmonella, other enteric organisms, Haemophilus, Rhizobium, and Bacillus. With a suitably altered selectable marker on the transposon donor plasmid, any prokaryotic or eukaryotic organism into which exogenous DNA can be introduced, may be used to recover insertions.
  • [0301]
    In this example,
  • [0302]
    B3ai) Chemically competent ER1821 New England BioLabs, 32 Tozer Road, Beverly, Mass., 01915 (2107transformants/μg of LITMUS or similar plasmid) was used. A sample protocol for preparing these is provided below, section D1
  • [0303]
    In example 2 we show the use of
  • [0304]
    B3aii) Electrocompetent MC1061 (ATCC#53338)
  • [0305]
    (7109 transformants/μg of pLITMUS-28 or similar plasmid). A sample protocol for preparing these is provided below, section D2
  • [0306]
    Commercially available competent or electrocompetent cells may also be used. The method of determining competence of these preparations is provided below, section D3.
  • [0307]
    B3b) Outgrowth media:
  • [0308]
    Rich Broth (D4a below) or mSOC (D4d) without drug, or equivalent.
  • [0309]
    0.4 ml per reaction; we recommend three reactions as a standard pilot experiment (see Section C below).
  • [0310]
    B3c) Selective media:
  • [0311]
    Rich Agar with drug (D4b), or equivalent
  • [0312]
    at least 1 plate per reaction; the standard pilot experiment described in section C require 6 plates, three with two drugs and three with one drug.
  • [0313]
    Kanamycin is REQUIRED to select for the transposon of the present example
  • [0314]
    Ampicillin is used for the RECOMMENDED positive control. Carbenicillin can be substituted
  • [0315]
    For the example of Section C, below, RB Kan Amp (3 plates) and RB Amp only (3 plates) are used. If the target plasmid carries some other drug resistance, the experimental reaction in the pilot experiment should be plated on Kanamycin plus that drug.
  • [0316]
    B4) FOR DNA PREPARATION FOR SEQUENCING (see example 2):
  • [0317]
    Any standard procedure that ordinarily gives sequencing grade DNA. We have tested Qiagen spin columns and gravity flow plasmid preparations.
  • [0318]
    Section C. Tn7 in vitro Transposition Reaction Protocol
  • [0319]
    C1. REACTION VOLUME=100 μl
  • [0320]
    C2. RECOMMENDED PILOT EXPERIMENT 3 samples to be carried through.
    Tube 1 Experimental (Target DNA, protein and donor plasmid added)
    Tube 2 Reaction positive control (pLITMUS28, protein and donor
    plasmid added)
    Tube 3 Reaction negative control (Target DNA added, no protein,
    donor added)
    Tube 2 is also used as a transformation positive control
  • [0321]
    In this example, all tubes have pLITMUS28 as target (tubes 1 and 2 are duplicates). Tube 2 need not necessarily be included in every experiment.
  • [0322]
    C3. MAKE UP a mix using reagents of Section A:
  • [0323]
    per reaction:
     10 μl Hepes (250 mM pH 8.1)
      1 μl Tris (250 mM pH 7.6)
    0.5 μl BSA (10 mg/ml)
    2.1 μl tRNA (50 μg/ml)
    0.2 μl DTT (1 M)
      2 μl ATP (100 mM)
  • [0324]
    C4. DISPENSE mix of step 3 to each tube (89.7 μl)-(volume of target DNA)/reaction; in this example, this is 88.7 μl.
  • [0325]
    C5. ADD target DNA of section B (0.4 μg) to tubes 1-3. In this example, this is pLITMUS28, 1 μl. This works well for plasmid targets. For cosmids, 0.5 μg worked well when the cosmid was around 10 times the size of the donor (5.2 kb) i.e. a molar ratio of around 2:1 (donor to target). Increasing the ratio to 4:1 decreased the efficiency slightly.
    C6. ADD to each tube
    Tube 1 Tube 2 Tube 3
    TnsA 1.3 μl 1.3 μl (40 ng) 0
    TnsB   3 μl   3 μl (20 ng) 0
    TnsC127   1 μl   1 μl (100 ng) 0
    dH2O   0   0 5.3 μl
  • [0326]
    C7. ADD 1 μl donor DNA (0.1 g pMCB40). Mix well by pipetting up and down a few times.
    Tube 1 Tube 2 Tube 3
    Donor pMCB40 1 μl 1 μl 1 μl
  • [0327]
    C8. INCUBATE 10 minutes at 30 C. (assembly reaction)
  • [0328]
    C9. ADD 4 μl MgAc (375 mM) to each tube. Mix well by pipetting up and down a few times
    Tube 1 Tube 2 Tube 3
    MgAc 4 μl 4 μl 4 μl
  • [0329]
    C10. INCUBATE 1 hour 30 C. (transposition reaction)
  • [0330]
    C11. HEAT INACTIVATE 75 C. 10 minutes. Note: 65 C. is not adequate.
  • [0331]
    C12. TRANSFORM using chemically competent cells (see procedure of section D1):
  • [0332]
    a. Add 10 μl of the reaction mix to 100 μl competent cells thawed on ice.
  • [0333]
    b. Incubate 1 h on ice.
  • [0334]
    c. Heat at 37 C. for 45 sec.
  • [0335]
    d. Chill on ice 2 min.
  • [0336]
    e. Dilute the transformation mix into 0.4 ml RB (total volume 0.5 ml).
  • [0337]
    f. incubate 40 min at 37 C.
  • [0338]
    g. plate 100 μl tubes 1-3 on Kanamycin-containing selective media.
  • [0339]
    h. plate dilutions of tube 2 on medium selective for the target plasmid only: dilute 100 fold (10 μl/1 ml) and 1000-fold (1 μl/1 ml) and plate 100 μl of undiluted and of each dilution (3 plates)
  • [0340]
    In this example, selective medium was RB Kan (20 μg/ml) Amp (100 μg/ml) (tubes 1-3) and RB Amp (100 μg/ml, tube 2). Competent cells were ER1821, chemically competent (Section D1).
  • [0341]
    C13. Transformation result:
  • [0342]
    On Kan Amp:
  • [0343]
    Tube 1 285 colonies
  • [0344]
    Tube 2 600 colonies
  • [0345]
    Tube 3 0 colonies
  • [0346]
    On Amp only:
  • [0347]
    Tube 2 confluent (undiluted)
  • [0348]
    Section D: Recipes and Auxiliary Procedures
  • [0349]
    D1) Chemically competent cells (E. coli):
  • [0350]
    a. Inoculate a single colony from an RB agar plate (see D4b) into 2 ml of RB (D4a) in a plating tube. Shake overnight at 37 C.
  • [0351]
    b. Subculture the overnight 1:100 in 1 Volume Unit of RB+20 mM MgSO4 (typically 250 ml). Grow to OD590=0.4-0.6 or Klett=60 (˜2-3 h).
  • [0352]
    c. Centrifuge 5,000 rpm 5 min at 4 C.
  • [0353]
    d. Gently resuspend pellet in {fraction (1/2.5)} Volume Unit ice cold TFBI (see below, D4f). Keep all steps on ice and chill all pipets, tubes, flasks, etc. from this point on.
  • [0354]
    e. Incubate on ice for 5 min.
  • [0355]
    f. Centrifuge 5,000 rpm 5 min 4 C.
  • [0356]
    g. Gently resuspend pellet in {fraction (1/25)} original volume cold TFB2 (D4g). For 250 ml of original subculture, use 10 ml TFB2.
  • [0357]
    h. Incubate on ice 15-60 min. before aliquoting 100 μl/tube for storage at −70 C. Quick-freeze the tubes.
  • [0358]
    i. To transform, thaw an aliquot on ice; add DNA; incubate 1 h on ice; heat shock 45 seconds at 37 C.; incubate on ice 2 min; dilute 5-fold into RB with no drug (for phenotypic expression); grow with vigorous aeration at 37 C. for 20 min.; plate on selective medium.
  • [0359]
    This procedure works with most strains and should routinely give >107 cfu/μg of pLITMUS28 (using 0.1 ng/transformation). Frozen cells last at least a year.
  • [0360]
    D2) Electrocompetent cells (E. coli)
  • [0361]
    D2a. Rationale and Comments
  • [0362]
    This procedure prepares cells for use in gene transfer employing an electroporator device such as that supplied by BioRad. DNA is introduced into cells by means of an electric field.
  • [0363]
    Successful electroporation requires a low electrolyte concentration, to avoid arcing (and cell killing) in the device. Cells are grown to midexponential phase, washed extensively in distilled water and sterile 10% glycerol, concentrated 500-fold in glycerol, aliquoted and stored at −70 C.
  • [0364]
    Any strain can be used for this purpose, although some strains are said to give larger numbers of transformants. Resuspended cells should be well-dispersed for best results. Some strains resuspend more evenly in the low electrolyte solutions; some lyse under these conditions with rough treatment.
  • [0365]
    The electroporation procedure itself involves transfer of the thawed cells to an electroporation cuvette (which has leads that contact the device appropriately), addition of DNA, imposition of the electric field, recovery from this treatment (by incubation in broth), and plating selectively.
  • [0366]
    Efficiency of transformation with this method is 100-500 fold greater than with standard transformation. It is therefore especially suitable when low transformation efficiency is expected or large numbers of transformants are desired. The method is said to be especially suitable for introduction of large DNA molecules.
  • [0367]
    D2b. Preparation of Electrocompetent E. coli Cells (from BioRad Recommended Procedure)
  • [0368]
    i. Materials for 2 ml of electrocompetent cells (20 aliquots, 100 μl):
    overnight culture of desired strain 1 ml
    (in Rich Broth (D4a) or Luria Broth (D4c))
    Luria Broth (D4c) 1 L
    dH2O, sterile, 4 C. or 0 C. 1.5 L
    10% (w/v) glycerol, sterile (D4h) 22 ml
    1 L sidearm flasks 2
    250 ml centrifuge bottles 6
    50 ml Oak Ridge centrifuge tubes 2
    1.5 ml microtubes, polypropylene 20
    Pipet tips (sterile) for P200 or equivalent 20
    Sterile glass or plastic pipets, 25 ml 3
    Klett-Summerson colorimeter
    High speed centrifuge (e.g. Beckman J21)
    Micropipetter, e.g. Gilson Pipetman P200
    Water bath rack that can be used to immerse tubes in liquid
    nitrogen.
    Liquid nitrogen bath for quick freezing
  • [0369]
    ii. Procedure for making electrocompetent cells
  • [0370]
    Be sure the sterile dH2O and 10% glycerol is cold.
  • [0371]
    If necessary, distribute the Luria Broth to sidearm flasks, 500 ml/flask
  • [0372]
    Inoculate each flask with 0.5 ml of the overnight culture
  • [0373]
    Incubate with shaking until Klett=90 (5108 cfu/ml). Quick conversion if Klett is not available: 1 OD=150 Klett Units; 109 cells/1.1 OD)
  • [0374]
    Chill on ice with swirling, until cold. It is very important to keep everything cold from this point on.
  • [0375]
    Transfer to centrifuge bottles, 167 ml/bottle or as desired.
  • [0376]
    Centrifuge 4,000 rpm 15 min 5 C. in JA14 rotor in Beckman. Decant supernatant.
  • [0377]
    Resuspend gently in equal volume (1 L total) cold sterile distilled water. Keep in an ice bath while resuspending. Repeated pipetting will help; chill pipets for this use.
  • [0378]
    MC1061 cells (ER1709) can be kept on ice at this stage for at least an hour
  • [0379]
    Centrifuge 4,000 rpm 15 min 5 C. in JA14 rotor in Beckman; decant supernatant.
  • [0380]
    Resuspend gently in volume cold sterile distilled water (0.5 L total). Keep in an ice bath while resuspending. Cells can now be combined into three bottles if desired.
  • [0381]
    Centrifuge 4,000 rpm 15 min 5 C. in JA14 rotor in Beckman. Decant supernatant.
  • [0382]
    Resuspend in {fraction (1/50)}th volume cold sterile 10% glycerol (20 ml total). Keep cold while resuspending.
  • [0383]
    Transfer entire amount to a 50 ml Oak Ridge tube (35 ml capacity).
  • [0384]
    Centrifuge 4,000 rpm 15 min 5 C. in JA17 rotor in Beckman, with balance tube. Decant supernatant
  • [0385]
    Resuspend in {fraction (1/500)}th volume (2 ml total) cold 10% glycerol. Keep cold.
  • [0386]
    Distribute 100 μl/tube to microtubes in ice water bath rack; immerse rack in liquid N2; transfer to box; store at −70 C.
  • [0387]
    D2c. Procedure for Electroporation of Poratable E. coli Cells (from BioRad Recommended Procedure)
    D2ci. Materials (per electroporation reaction)
    Electrocompetent cells 100 μl
    18 150 mm culture tubes 1
    Electroporation cuvettes (BioRad cat# 1652086 or equivalent) 1
    mSOC (see D4d) 1 ml
    Pasteur pipets, sterile 1
  • [0388]
    DNA to be transformed; in low ionic strength medium, e.g. dH2O or TE (see D4i).
  • [0389]
    Electroporator (BioRad Gene Pulser or equivalent)
  • [0390]
    Ice bath trays for cuvettes and outgrowth tubes
  • [0391]
    Rollordrum in 37 C. incubator or other means of incubating culture tubes
  • [0392]
    Selective agar plates and plating materials
  • [0393]
    37 C. or suitable temperature incubator
  • [0394]
    D2cii. Procedure
  • [0395]
    Be sure all materials are set up ready to go before getting cells out of the freezer. The DNA must be added and the electorporation done as soon as the cells are thawed; cells will lyse after a short time, resulting in arcing as the medium becomes more conductive.
  • [0396]
    Chill cuvettes and hold on ice (>5 min). Transformation efficiency declines at least 100-fold if cuvettes are at room temperature
  • [0397]
    Set BioRad Gene Pulser to 25 F. capacitance, 2.5 kV, and the pulse controller to 200 Ω (maximum voltage)
  • [0398]
    Thaw electrocompetent cells at room temperature and transfer to ice.
  • [0399]
    In a cuvette mix 40 μl cells with 0.4 μg-0.3 μg DNA. Shake the suspension to the bottom of the cuvette, rap on table to shake loose air bubbles.
  • [0400]
    Place the cuvette in the holder
  • [0401]
    Apply one pulse by pushing both red buttons until a beep is heard. This will result in a pulse of 125 kV/cm with a time constant of 4-5 sec.
  • [0402]
    Immediately add 1 ml mSOC to the cuvette and gently but quickly resuspend the cells.
  • [0403]
    A P1000 with sterile blue tips or sterile pasteur pipets can be used for this. A 1 min delay in adding the medium results in 3 fold decrease in transformation efficiency.
  • [0404]
    Transfer cells to culture tube.
  • [0405]
    Incubate 37 C. 1 hour
  • [0406]
    Plate on selective media.
  • [0407]
    D3) Standardization of Transformation or Electroporation
  • [0408]
    D3a. Rationale and Comments
  • [0409]
    To ensure that gene transfer is successful, we recommend that the cells prepared above (D1 or D2) or purchased commercially be transformed with a standard DNA dilution series before experimental use. Below is an example of such a standardization for electrocompetent cells (D2). Chemically competent cells will yield 100-500 fold fewer transformants, so dilutions given below should be appropriately adjusted.
  • [0410]
    D3b. Materials for a Standardization Experiment
  • [0411]
    Dilutions of standard DNA, usually a high-copy small plasmid (e.g. LITMUS28), in TE:
    A  1 ng/μl
    B  10 pg/μl
    C  1 pg/μl
    D 100 fg/μl
    Selective agar plates; RB 1.5% Amp 100 μg/ml for pLITMUS28 12
    Dilution medium, usually 0.85% saline 7 ml
    Dilution tubes, usually 13 100 mm 7
    Sterile plastic or glass pipets, 0.1 ml 10
    Sterile plastic or glass pipets, 0.2 ml 1
    Sterile plastic or glass pipets, 1 ml 1
    Micropipetters, e.g. P200 and P20 or P10, for DNA transfer
    and dilution
  • [0412]
    series
  • [0413]
    Pipet tips for P200 and P20 or P10
  • [0414]
    Spreader
  • [0415]
    Ethanol or isopropanol for flaming the spreader
  • [0416]
    37 C. incubator
  • [0417]
    D3c. Procedure for Standardization Experiment
  • [0418]
    D3ci. Set up dilution tubes below and label plates beforehand or while cultures are growing out.
  • [0419]
    D3cii. Carry out electroporation as above (D2) with DNA dilutions A-D D3ciii. Place cultures on ice to prevent further growth while making dilutions and plating as below.
  • [0420]
    D3civ. Dilute in saline:
    Sample A 10−1 , 10−2 , 10−3 , 10−4
    Sample B 10−1, 10−2
    Sample C 10−1
    Sample D no dilutions
  • [0421]
    This can be carried out as:
  • [0422]
    10−1 dilution: 100 μl sample+900 μl saline
  • [0423]
    10−2 dilution: 10 μl sample+1 ml saline
  • [0424]
    10−3 dilution: 10 μl 10−1 dilution+1 ml saline
  • [0425]
    10−4 dilution: 10 μl 10−2 dilution+1 ml saline.
  • [0426]
    D3cv. Plate on selective media by spreading; flame the spreader after each plate:
    Dilutions: undiluted 10−1 10−2 10−3 10−4
    Samples:
    A 0.1 ml 0.1 ml 0.1 ml 0.1 ml
    B 0.1 ml 0.1 ml 0.1 ml
    C 0.1 ml 0.1 ml
    D 0.1 ml
    0.2 ml
    0.5 ml
  • [0427]
    D3vi. Example of result:
    DNA Dilution/vol Transformants
    Sample added plated Colonies per ml per μg
    A 1 ng 1/0.1 Confluent
    2/0.1 very numerous
    3/0.1 ˜1000 
    4/0.1  71 7 106   7 109 
    B 10 pg  0/0.1 very numerous
    1/0.1 405
    2/0.1  49 4 104   4 109 
    C 1 pg 0/0.1 very numerous
    1/0.1 106 1 104 1.1 1010
    D 100 fg  0/0.1 ˜500 
    0/0.2 173
    0/0.5  75 8 102   8 109 
    Average transformants/μg 7.6 109
    D4) Recipes
    Bacteriological
    D4a) RB, per liter
    Tryptone (Difco) 10 g 
    Yeast Extract (Difco) 5 g
    NaCl 5 g
    NaOH (1 N)  2 ml
    Autoclave
    D4b) RB Agar with drug, per liter
    Tryptone (Difco) 10 g 
    Yeast Extract (Difco) 5 g
    NaCl (Baker) 5 g
    NaOH (1 N)  2 ml
    Agar (Difco) 15 g 
    Autoclave
    Drugs: add after autoclaving and cooling to 55 C., per liter:
    Kanamycin (REQUIRED)  20 mg
    Other drugs that MAY be added, per liter;
    choice depends on target plasmid:
    Ampicillin or carbenicillin  100 mg 
    Chloramphenicol  15 mg
    Tetracycline  15 mg
    Others drugs not tested but presumably usable in an
    appropriate host strain:
    Spectinomycin
    Streptomycin
    Gentamycin
    Erythromycin
    Rifampicin (recessive marker)
    Bleomycin
    Other antibacterial small molecules
    D4c) Luria Broth, per liter
    Tryptone 10 g 
    Yeast extract 5 g
    NaCl 10 g 
    MgCl2 6H2O 1 g
    glucose 1 g
    Aliquot and autoclave. For preparing electrocompetent
    cells (C2) it is convenient to aliquot 500 ml/flask in
    1 L sidearm flasks before autoclaving.
    D4d) mSOC, per liter
    (modified from BioRad recipe)
    Luria Broth   1 L 
    MgSO4, 1 M sterile  10 ml
    40% glucose, sterile 6.5 ml 
    Add MgSO4 and glucose sterilely to sterile Luria Broth
    D4e) 0.85% saline, per liter
    NaCl 8.5 g 
    Distribute in suitable aliquots, autoclave.
    Buffers and storage media
    D4f). TFBI
     30 mM KOAc (potassium acetate)
    100 mM RbCl
     10 mM CaCl2
     50 mM MnCl2
     15% glycerol
    Adjust to pH 5.8 with acetic acid and filter to sterilize.
    It is convenient to make this as:
      5 g RbCl (Alfa)
    12.3 ml KOAc 1 M
     4.1 ml CaCl2 1 M
    20.5 ml MnCl2 1 M
    (this is pink)
    61.5 g glycerol; pH to 5.8 with ≦ 8 ml HOAc 0.1 M
    make up to 410 ml; distribute in 100 ml sterile aliquots;
    and use 1 aliquot/250 ml culture.
    D4g). TFBII
    10 mM MOPS
    75 mM CaCl2
    10 mM RbCl
    15% glycerol
    Adjust pH to 6.5 with KOM and filter to sterilize
    Make up as
     1.5 ml MOPS 1 M pH 6.5 (this is yellow)
    11.25 ml CaCl2 1 M
     1.5 ml RbCl 1 M
     22.5 g glycerol
    pH with 1 N KOH; make to 150 ml, filter;
    use 10 ml per original 250 ml culture.
    D4h) 10% glycerol, per liter
    Glycerol 100 g 
    dH2O  1 L 
    Aliquot and autoclave
    D4i) TE, per liter
    1 M Tris pH 8.0 10 ml
    0.5 M EDTA pH 8.0  2 ml
  • EXAMPLE 4 Random Insertion of Primers for Sequencing
  • [0428]
    Section A: Components used for Transposition Reaction
  • [0429]
    A1) PROTEINS
    A1) PROTEINS
    TnsA 40 μg/mL in 10% glycerol
    TnsB 20 μg/mL in 50% glycerol
    TnsC127 100 μg/mL in 50% glycerol
    Stored at −70 C.
    A2) BUFFER CONSTITUENTS
    HEPES 0.25 M pH 8.1
    Tris[Cl] 0.25 M pH 7.6 [can be omitted]
    BSA 10 mg/ml
    tRNA 50 μg/ml
    DTT 1 M
    ATP pH7 100 mM
    MgAcetate 375 mM
    TnsD storage buffer TnsD is stored in the following buffer: 3.3 μl
    500 mM KCl, 50 mM Tris-HCl (pH 8.0),
    1 mM EDTA, 2 mM DTT and 25% glycerol
    A3) TRANSPOSON DONOR PLASMID
    pEM delta R.adj to 1 50 μg/ml
    (Sequence appears in FIG. 9B and SEQ ID NO:3))
    A4) TARGET PLASMID
    1) pER183 mini-cleared lysate 200 μg/ml
    2) pER183 CsCl preparation 400 μg/ml
    3) pRM2 400 μg/ml
    (Sequence of pER183 appears in FIG. 10A and SEQ ID NO:5)
  • [0430]
    Section B: Components Used for Processing Reaction
  • [0431]
    Phenol/chloroform equilibrated with TE
  • [0432]
    Phenol equilibrated with Tris pH 8.0
  • [0433]
    NaAcetate 3 M
  • [0434]
    Ethanol (EtOH)
  • [0435]
    BstEII New England BioLabs, 32 Tozer Road, Beverly, Mass., 01915
  • [0436]
    DNA Polymerase I Holoenzyme New England BioLabs, 32 Tozer Road, Beverly, Mass., 01915
  • [0437]
    T4 DNA Ligase New England BioLabs, 32 Tozer Road, Beverly, Mass., 01915
  • [0438]
    10 Fi/L buffer (section 13)
  • [0439]
    10 Buffer 3 (NEB#007-3) New England BioLabs, 32 Tozer Road, Beverly, Mass., 01915
  • [0440]
    tRNA 1 mg/ml
  • [0441]
    DNA buffer (section I2)
  • [0442]
    TE (section 14)
  • [0443]
    Section C: Components Used for Recovery of Insertions
  • [0444]
    MC1061 electrocompetent cells (made and used as in Example 3, D2 and D3) Selective media (made and used as in Example 3, D3 and D4)
  • [0445]
    Section D: Components Used for Sequence Determination
    D1) SEQUENCING PRIMERS
    NLC94                3.2 pmol/μl.
    Sequence of this primer (SEQ ID NO:13):
    5′AAAGTCCAGTATGCTTTTTCACAGCATAAC
    NLC95                3.2 pmol/μl
    Sequence of this primer (SEQ ID NO:7)
    5′ATAATCCTTAAAAACTCCATTTCCACCCCT
    D2) QIAPREP SPIN MINIPREP KIT (Qiagen Cat #27106)
    D3) ABI Sequencer (info) and reagents
    Section E: in vitro transposition protocol
    E1) MAKEUP Mix:
    208.2 μl dH2O
    30 μl Hepes (25O mM pH 8.1)
    3 μl Tris (250 mM pH 7.6)
    1.5 μl BSA (10 mg/ml)
    6.3 μl tRNA (50 μg/ml)
    0.6 μl DTT (1M)
    6 μl ATP (100 mM)
    E2) DISPENSE 85.2 μl to three tubes
    E3) ADD target DNA of A4, 2 μl
    E4) ADD to each tube
    Tube 1 Tube 2 Tube 3
    TnsA 1.3 μl 1.3 μl 1.3 μl
    TnsB 1 μl 1 μl 1 μl
    TnsC127 1 μl 1 μl 1 μl
    D buffer 3.3 3.3 3.3 μl
    Donor 2 2 2 μl
    E5) INCUBATE 30 minutes at 30 C. (assembly reaction)
    E6) ADD 4 μl MgAc (375mM) to each tube.
    E7) INCUBATE 1 hour at 30 C. (insertion)
  • [0446]
    Section F: Reaction Processing
  • [0447]
    In this example, the transposon donor was capable of replicating in the host used for recovery of insertions. Transformation of the reaction mixture on plates selecting for the transposon and the target markers might well result in many colonies with two different plasmids, rather than with a single plasmid containing both markers. For this reason, we digested the reaction with a restriction endonuclease cleaving in the donor replicon but not within the transposon or in the target DNA. In addition, we examined the consequences of repairing the strands not ligated by the transposition reaction, using DNA polymerase I holoenzyme and ligase.
  • [0448]
    Per reaction (100 μl):
  • [0449]
    PC extract:
  • [0450]
    Add 100 μl phenol/chloroform, vortex
  • [0451]
    Centrifuge 5′ in microfuge
  • [0452]
    Backextract
  • [0453]
    Remove organic phase to a new tube with 100 μl TE; vortex
  • [0454]
    Centrifuge 5′ in microfuge
  • [0455]
    Combine aqueous phases (185 μl total)
  • [0456]
    EtOH precipitate
  • [0457]
    20 μl 3M NaAc
  • [0458]
    500 μl EtOH
  • [0459]
    chill on dry ice
  • [0460]
    Centrifuge 5 min in microfuge
  • [0461]
    Drain supernatant, air dry
  • [0462]
    Resuspend in 100 μl DNA buffer
    Divide each reaction for further treatment (all volumes are μl)
    Repair
    Digestion Diget
    Treatment: A B
    1) Repair/ligation
    DNA 40 40
    10X Fi/L 5
    dH2O 2
    Pol I (10,000 μ/ml) 2
    a) Incubate 15 min room temperature
    Ligase (400,000 u/ml) 1
    b) Incubate 4 h 16 C.
    2) Digestion
    1 M NaCl 6.0
    10 X buffer 3 6.0
    BstEII (10,000 u/ml) 1 1
    Incubate 60 C. 1 h
    3) Protein removal, buffer exchange 1
    Phenol, equilibrated 50 50
    a) Mix, centrifuge 5′ in microfuge
    b) Back extract organic phase with DNA buffer
    c) Combine aqueous phase
    Total volume, step 3c 100 100
    3 M NaAc 10 10
    tRNA 1 mg/ml 1 1
    EtOH 120 120
    a) Incubate 5 min room temperature
    b) Centrifuge, discard supernatant
    c) Wash twice with cold 70% EtOH (100 μl)
    DNA buffer 50 50
    d) Resuspend
    Final volume, step 3d 50 50
    4) Buffer exchange 2
    Re-precipitation
    DNA from step 3d 35 35
    3 M NaAc 5 5
    EtOH 137.5 137.5
    a) Incubate −70 C. overnight
    b) Centrifuge, discard supernatant
    c) wash twice 200 μl 70% EtOH
    TE 50 50
    d) Resuspend
  • [0463]
    Section G: Recovery of Insertions
  • [0464]
    Electroporated 10 μl of samples into MC1061 following procedure of Example 3, section D3
    TABLE 2
    Sample codes, treatments, and target concentrations
    corrected for losses during manipulation
    Target Target [Target DNA]
    Name Treatment Selection (fmol/μl)
    1A pER183 Fi/L, Dig Cam 0.015
    1B pER183 Digested Cam 0.05
    2A pER183 Fi/L, Dig Cam 0.98
    2B pER183 Digested Cam 0.42
    3A pRM2 Fi/L, Dig Amp 0.66
    3B pRM2 Digested Amp 0.56
  • [0465]
    [0465]
    TABLE 3
    Colony forming units per ml on appropriate selective plates
    Sample 1A 1B 2A 2B 3A 3B
    Donor
    (or recomb)
    Kan Only 130 1.8 105 5 103   7 103 3.7 104 4 104
    Recipient
    Cam only 1 104   8 105 4 104   6 106
    Amp only   3 107 4 107
    Colonies/fmol 6 104 1.6 106 4 103 1.4 106 4.5 106 7 106
    Recombinant
    Kan Cam  16 2.7 103 880   1 104
    Kan Amp 1.1 105 4 104
    Recomb/recip  1 10−3   3 10−3  2 10−2  1 10−3   4 10−3  1 10−3
  • [0466]
    75 recombinant colonies were chosen, 31 from samples 2A, 44 from samples 2B, for further characterization
  • [0467]
    H. Determination of Sequence Location.
  • [0468]
    1. Procedure Summary
  • [0469]
    75 recombinant colonies were picked into 0.5 ml RB in racked array for storage. Subcultures of these storage cultures were grown with selection (RB Cam Kan), and minipreps made according to the directions of the manufacturer for large plasmids of low copy number.
  • [0470]
    DNA concentration of the plasmid preps was determined by comparison with a dilution series of linearized pLITMUS28 on agarose gels. Plasmid preps were linearized for this purpose with an enzyme that cleaves once in the target plasmid and not in the transposon (SacII).
  • [0471]
    Primers NLC94 (SEQ ID NO:13) and NLC95 (SEQ ID NO:7) were used for sequence determination, using flourescently-labeled dideoxynucleotide sequencing reagents from Applied Biosystems.
  • [0472]
    Sequences were run on an ABI sequencer, and sequence acquisition, editing and assembly was carried out with the supplied programs (SEQED, FACTURA and AUTOASSEMBLE).
  • [0473]
    Output is FIG. 11
  • [0474]
    2. Results
  • [0475]
    a. Table 4: Summary result of 75 recombinants (CamR KanR colonies), potential Tn7 insertions into pER183.
    Total DNA preps 75
    DNA concentration too low to attempt sequence: 7
    Transformant contained two plasmids, not sequenced: 1
    Total not sequenced 8
    DNA preps sequence attempted 67
    Sequence unreadable (miscellaneous reasons) 2
    Sequence unreadable because 2 insertions in one plasmid 1
    Total sequence unreadable 3
    DNA preps sequence obtained 64
    Sequence rejected (cross contamination of adjacent wells) 1
    Total insertions rejected 1
    Independent insertions for which location was obtained 63
    Number of insertion locations 62
    Number inserted clockwise 33
    Number inserted counterclockwise 30
    Aberrant insertions
    Number of insertion plasmids with structural aberrations 1
    This was a deletion far from the insertion
    Number of structural aberrations associated with insertion site 0
    Number of insertions with disagreement in 5 bp duplication 2
  • [0476]
    These were:
  • [0477]
    G→A transition mutation in one copy with respect to target plasmid sequence
  • [0478]
    G→T transversion mutation in one copy with respect to target plasmid sequence.
  • [0479]
    b. Analysis of the distribution of insertions among sequences and intervals. For the purpose of obtaining maximum sequence from an unknown target, it is desirable that the insertions be distributed as randomly as possible with respect to regions of sequence and with respect to specific sequences. The summary of Table 4 already suggests a very random process, since 63 independent insertions hit 62 different locations, i.e. no hotspots for insertion were identified. For comparison, relaxed-specificity derivative of Tn10 (ATS2, examined with in vivo insertions into the lac operon) hit 23 sites with 50 insertions.
  • [0480]
    Primary data for further analysis below is found in Table 5, which gives the location of al the insertions, their orientation with respect to the target plasmid, and the sequence immediately adjacent to the insertion (the five bp sequence duplicated by the insertion mechanism) in a uniform frame of reference.
    TABLE 5
    Insertion locations and associated 5 bp duplication
    Sequence at
    Directions position orientation
    Sequence Insert relative to Tn7R (Tn7 R
    Isolate obtained Location name 1 2 3 4 5 clockwise = +)
    1 1 6464 A5 A G C T C
    2 2 8428 A6 C T G G T
    3 1 8349 A7 C C T G A +
    4 2 5515 A8 T A A C T +
    5 2 7822 A9 C C C G C +
    6 2 365 A10 T C A A C +
    7 2 5695 A11 T C A C G
    9 2 2500 B1 G G A T G +
    10 1 8286 B2 C T T C C +
    11 1 2764 B3 C T T T A +
    12 2 6953 B4 C G A G G +
    13 2 3414 B5 C T T T G +
    14 1 3139 B6 T C G T T
    15 1 3208 B7 G C A C T
    16 2 4208 B8 A G A G C
    17 2 3671 B9 G T T T A +
    18 2 5563 B10 C C A A C
    19 1 3539 B11 G C T T C +
    20 2 3803 B12 A T T C C
    21 2 8474 C1 C C G C C +
    22 2 5661 C2 A T G A T +
    23 2 7693 C3 C G C G T
    24 2 3205 C4 T C T T C
    25 2 1650 C5 C C T A T
    26 2 8020 C6 G C C G G
    27 2 2566 C7 A T T T T +
    29 2 2275 C9 G C C C A +
    30 1 6368 C10 G C T A T
    32 2 2629 C12 T A T A C +
    33 2 5988 D1 G G C G A +
    34 2 3499 D2 A T G T A
    35 2 3933 D3 T T G A T
    36 2 6077 D4 G T T G T +
    37 2 6756 D5 T T G A G
    38 2 5563 D6 G T T G G +
    38 2 8224 D7 G G A G G
    40 2 3123 D8 C A A A T
    41 1 2746 D9 A A A A C
    42 1 1646 D10 C G A G A +
    43 1 5678 D11 A T G T G +
    44 2 7406 D12 T G C A T +
    45 2 1744 E1 G C C A T
    46 2 3584 E2 T A G G T +
    47 2 2112 E3 C C T A C +
    48 2 4205 E4 G C A G C
    49 1 2708 E5 G C G G T +
    50 2 7828 E6 A C A G A +
    52 2 3873 E8 A G T C T
    53 2 3591 E9 C A T G C
    56 2 5550 E12 A T C G C
    57 2 2702 F1 T T C A C +
    61 2 4490 F5 G T T A A
    62 2 5811 F6 A C G C G +
    63 2 2024 F7 A C T G T
    64 2 1479 F8 A T C G T
    66 2 5675 F10 T T T A T +
    67 2 5208 F11 A T A A A +
    68 2 6020 F12 G G T A A +
    69 2 6264 G1 G A G T A +
    70 2 3881 G2 A T T T G
    72 2 2891 G4 A T T C G
    74 2 1681 G6 A C T C T
    76 2 5315 G7 A A T A C +
  • [0481]
    Table 5 Legend:
  • [0482]
    Isolate: Number of the colony
  • [0483]
    Directions sequenced: 1=only one direction from the insertion; 2=both directions
  • [0484]
    Position: coordinate on pER183 (SEQ ID NO:5) top strand of the first base of the 5 bp duplication
  • [0485]
    Insert name: accession number in notebook
  • [0486]
    Sequence at position #: position 1 is the base immediately adjacent to Tn7R top strand (i.e. it can be either the top or the bottom strand of pER183 (SEQ ID NO:5)); position #2 is the next but one to Tn7R; and so forth.
  • [0487]
    Orientation: of the insertion relative to the top strand of pER183 (SEQ ID NO:5). +, Tn7R is to the right of Tn7L when displayed on the top strand of pER183 (SEQ ID NO:5). −, Tn7R is to the left of Tn7L.
  • [0488]
    1. Distribution of insertions fits the Poisson distribution
  • [0489]
    1. These insertions are randomly distributed as judged by the fit of the interval distribution to the distribution predicted by a Poisson process.
  • [0490]
    The Poisson distribution gives the probability of observing exactly Xi events (insertions) in a unit (interval) when the average number of events per unit is μ (from Zar, J. H. Biostatistical Analysis Prentice-Hall, Englewood Cliffs, N.J. 1974 p.301). P ( X 1 ) = μ Xi - μ X i ! eq 1
  • [0491]
    Where
  • [0492]
    Xi=exactly Xi insertions per interval
  • [0493]
    μ=average number of insertions per interval
  • [0494]
    Let
  • [0495]
    Xi=number of insertions in a 100 bp interval
  • [0496]
    fi=Observed number of 100 bp intervals with Xi insertions/interval
  • [0497]
    n=number of 100 bp intervals in the set (=73)
  • [0498]
    μ=ΣfiXi/Σfi=63/73
  • [0499]
    P(xi)=probability of finding Xi insertions in a 100 bp interval (from the Poisson distribution,. eq 1)
  • [0500]
    Fi=P(xi)n=expected number of intervals with i insertions.
  • [0501]
    From the data in Table 5 and eq 1 we can construct the following comparison of expected and observed data:
    TABLE 6
    Observed and expected distribution of insertions
    in 100 bp intervals
    Expected
    Observed Probability of number of
    Insertions intervals with X1 insertions per intervals with
    per interval X1 insertions interval X1 insertions
    Xi fi P(Xi) Fi
    0 34 0.42189 30.80
    1 24 0.35410 26.58
    2 9 0.15711 11.47
    3 3 0.04520 3.299
    4 3 0.00975 0.712
  • [0502]
    These distributions are illustrated in FIG. 12, where fi=observed distribution, Fi=expected distribution. The fit looks good to the eye.
  • [0503]
    b. Statistical test of fit between observed and expected distributions
  • [0504]
    To test whether the observed and expected distribution are statistically indistinguishable, we used a Chi-square test for goodness of fit (from Zar, J. H. Biostatistical Analysis Prentice-Hall, Englewood Cliffs, N.J. 1974 p. 303). For this purpose we pool the tail of the distribution so that no expected number is less than 4. Rewriting Table 6, we obtain
    TABLE 7
    Chi-square test of goodness of fit to a random distribution
    Expected number
    Insertions per Observed intervals of intervals with X1 (fiFi)2
    Interval with X1 insertions insertions Fi
    Xi Fi Fi Chi-square
    0 34 30.80 0.3329
    1 24 26.58 0.2504
    2 9 11.47 0.5315
    ≧3    6 4.1541 0.8209
    Sum 1.944
  • [0505]
    The null hypothesis is that the observed distribution was drawn from a Poisson distributed population. For two degrees of freedom this sum of chi-square values gives a probability that this is the case of 0.25<p<0.5. The null hypothesis is not rejected.
  • [0506]
    In sum, the eye (part a, FIG. 12) and a statistical test (Table 7 and following) agree that the distribution of insertions in intervals along the DNA is random.
  • [0507]
    ii. Analysis of the base composition of insertion sites.
  • [0508]
    Site Preference of TnsABC127 for Insertion of miniTn7 into pER183
  • [0509]
    Certain bases are preferred at some positions in the five-base insertion site duplication, as shown in a histogram of base incidence versus position in the site (FIG. 13), taken from the data in Table 5. In collating the data for this histogram, the five duplicated bases were assigned position numbers relative to Tn7R; position one is the base immediately adjacent to Tn7R when the sequence is displayed with Tn7R on the right and Tn7L on the left. The orientation of the transposon relative to the target sequence during target choice is thus controlled for: the target is displayed in the same way relative to the transposon for all insertion sites.
  • [0510]
    A model for a preferred site was formulated: NYTRN. The elements of this site were tested for statistical significance individually and collectively by chi-square analysis (Table 8). The null hypothesis was that sites were drawn randomly from the universe of sequence defined by the sequence of pER183 (SEQ ID NO.5) after deleting sequence subject to selection (bp 1-250 and 2481-2509, CamR; and 581-1400, replication origin). Expected frequencies of the four bases, of purines and pyrimidines, and of trinucleotides were derived from frequencies obtained for pER183 (SEQ ID NO:5)-condensed by the GCG program COMPOSITION.
    TABLE 8
    Chi-square tests (tests that differ from
    random expectation (p<0.05) in bold)
    Base Expected Observed Chisquare probability
    Four bases individually, all sites
    collectively (315 bp experimental, 7410 bp control)
    A 78.4 73 .372
    C 74.3 77 .981
    G 76.2 72 .232
    T 85.7 93 .622
    2.21 0.5<p<0.75
    Four bases individually, each position
    individually (63 bp experimental, 7810 bp control)
    Position 1
    A 15.7 19 0.694
    C 14.9 15 0.00066
    G 15.2 17 0.213
    T 17.1 12 1.52
    2.43 0.25<p<0.5
    Position 2
    A 15.7 8 3.8
    C 14.9 22 3.38
    G 15.2 11 1.16
    T 17.1 22 1.4
    9.74 0.01<p<0.025
    Position 3
    A 15.7 15 0.031
    C 14.9 11 1.02
    G 15.2 12 0.674
    T 17.1 25 3.65
    5.37 0.1<p<0.25
    Position 4
    A 15.7 19 0.693
    C 14.9 11 1.02
    G 15.2 20 1.52
    T 17.1 13 0.983
    4.21 0.1<p<0.25
    Position 5
    A 15.7 12 0.872
    C 14.9 18 0.645
    G 15.2 12 0.674
    T 17.1 21 0.889
    3.08 0.25<p<0.5
    Purines and Pyrimidines, each position
    individually (63 bp experimental,
    7410 bp control)
    Position 1
    R 30.9 36 0.842
    Y 32.1 27 0.810
    1.65 0.1<p<0.25
    Position 2
    R 30.9 19 4.58
    Y 32.1 44 4.41
    8.99 0.001<p<0.005
    Position 3
    R 30.9 27 0.49
    Y 32.1 36 0.422
    0.914 0.25<p<0.5
    Position 4
    R 30.9 39 2.12
    Y 32.1 24 2.04
    4.17 0.025<p<0.05
    Position 5
    R 30.9 24 1.54
    Y 32.1 39 1.48
    3.10 0.05<p<0.1
    T or not-T, position 3
    T 17.16 25 3.58
    not-T 45.84 38 1.34
    4.92 0.025<p<0.05
    Triplets, positions 234 (63 experimental triplets,
    7408 control triplets to
    determine expectation)
    Triplet Expected Observed Chisquare probability
    All triplets
    YNR 15.96 25 7.54
    RNY 15.97 5 5.12
    RNR 14.98 14 0.064
    YNY 16.07 19 0.534
    13.25 0.001<p<0.005
    Specific triplets, positions 234
    YNR 16 25 5.06
    Not YNR 47 38 1.7
    6.78 0.005<p<0.01
    RNY 16 5 7.56
    Not RNY 47 59 3.06
    10.62 0.001<p<0.005
    YTR 3.93 10 9.38
    not YTR 59.07 53 0.623
    10.0 0.001<p<0.005
    Pairing between position 2 and 4 (GNC, CNG, ANT, TNA)
    Paired 16.95 16 0.053
    Not paired 46.05 47 0.0196
    0.073 0.75<p<0.9
  • [0511]
    Preference for this site was statistically significant (p<0.005), and preference for each of its parts was also significant (p<0.05). However, the preference is not particularly strong, in that representation of the site was only 2.5-fold more frequent in insertion sites than expected from the composition of the plasmid; and 53 out of 63 sites do not fit the consensus. Each preferred position contributes independently to the overall preference, since multiplying together the overrepresentation of each position yields the overrrepresentation of the site as a whole (Table 9).
    TABLE 9
    overrepresentation of preferred bases in Tn7 insertion sites
    Fold overrepresentation
    Position preference expected observed (Obs/Exp)
    2 Y 32.1 44 1.37
    3 T 17.6 25 1.42
    4 R 30.9 39 1.26
    product ((O/E)2 (O/E)3 (O/E)4) 2.46
    triplet YTR 3.93 10 2.54
  • [0512]
    We conclude that insertion mediated by TnsABC127 is extremely random, with only a slight preference for sites of the form NYTRN (SEQ ID NO:15).
  • [0513]
    I. Recipes.
    1. 100 X DNA buffer per liter
    Tris Base  121.1 g
    Dissolve in 700 ml
    4 M HCl  ˜90 ml
    Bring pH to 7.4
    Na2EDTA  37.2
    NaCl  29.22 g
    Make up to ˜950 ml
    adjust pH
    Make up to 1 L
    Aliquot, autoclave
    2. 1 X DNA buffer
    100 x DNA buffer   1 ml
    dH2O, sterile  100 ml
    3. 10 X Fi/L (Fill-in, ligation) buffer
    10 X ligase buffer 1500 μl
    New England BioLabs, 32 Tozer Road, Beverly, Massachusetts, 01915
    100 mM dATP   3.75 μl
    New England BioLabs, 32 Tozer Road, Beverly, Massachusetts, 01915
    100 mM dCTP   3.75 μl
    New England BioLabs, 32 Tozer Road, Beverly, Massachusetts, 01915
    100 mM dGTP   3.75 μl
    New England BioLabs, 32 Tozer Road, Beverly, Massachusetts, 01915
    100 mM dTTP   3.75 μl
    New England BioLabs, 32 Tozer Road, Beverly, Massachusetts, 01915
    4. TE
    1 M Tris pH 8.0   1 ml
    0.5 M EDTA pH 8.0   0.2 ml
    dH2O to 100 ml
  • [0514]
    Filter sterilise
  • EXAMPLE 5
  • [0515]
    A Convenient Method for Stopping a Transposon Insertion Reaction
  • [0516]
    In order to use DNA molecules with transposon insertions, they must be recovered in vivo. It is most convenient to be able to do this without the labor and losses associated with extraction with organic solvents and alcohol precipitation. Prior art has suggested, however, that transposition reaction products formed during in vitro insertion experiments are DNA: protein complexes that are extremely stable; evidence suggests that a chaperone-like activity is required for disruption of these products. Accordingly, organic extraction was deemed required for satisfactory disruption of the complexes.
  • [0517]
    This example demonstrates that heat inactivation at 75 C. is adequate for disrupting these complexes or at least for putting them into a form that can be introduced into the cell by chemical transformation.
  • [0518]
    Section A. MATERIALS
  • [0519]
    A1) PROTEINS
  • [0520]
    TnsA 30 μg/ml in 10% glycerol
  • [0521]
    TnsB 20 μg/ml in 25% glycerol
  • [0522]
    TnsC127 100 μg/ml in 10% glycerol
  • [0523]
    Keep stored at −70 C. Sufficient protein for 10 reactions is provided. At the time of use, keep frozen on dry ice until ready to add to the reaction, and keep on dry ice until returned to the freezer.
    A2) BUFFER CONSTITUENTS
    HEPES 0.25 M pH 8.1
    Tris [Cl] 0.25 M pH 7.6
    BSA  10 mg/ml
    tRNA  50 μg/ml
    DTT  1 M
    ATP 100 mM
    Mg Acetate 375 mM
    A3) TRANSPOSON DONOR PLASMID
    100 μg/ml
    This is as described for Example 3.
    A4) TARGET PLASMID
    pLITMUS28 400 μg/ml
    A5) OTHER
    Millicue water
    Heat block, 30 C.
    1.5 ml microtubes.
  • [0524]
    A6) FOR STOPPING THE REACTION
  • [0525]
    when using chemically competent cells
  • [0526]
    Water bath or heat block, 75 C.
  • [0527]
    Water bath or heat block, 65 C.
  • [0528]
    Distilled phenol equilibrated with TE
  • [0529]
    Chloroform equilibrated with TE
  • [0530]
    EtOH for precipitation
  • [0531]
    NaCl 3 M
  • [0532]
    Water or 1 mM Tris pH 8
  • [0533]
    CHEMICALLY COMPETENT TRANSFORMABLE CELLS:
  • [0534]
    In this example, we show the use of
  • [0535]
    Chemically competent ER 1821 (2107 transformants/μg of LITMUS
  • [0536]
    Chemically competent ER2502 (6106 transformants/μg of LITMUS
  • [0537]
    prepared as in Example 3
  • [0538]
    A8) MEDIA
  • [0539]
    Rich Broth and Rich Agar (Kan, Amp) prepared as in Example 3.
  • [0540]
    Section B. Tn7 in vitro Transposition Reaction Protocol
  • [0541]
    1. Experiment 1. Four Stop Treatments
  • [0542]
    Reactions were carried out as in Example 3, using quadruplicate samples for each of four treatments. At step 12, one of these treatments was substituted. For transformation, ER2502 was used.
  • [0543]
    Treatment 1: No treatment.
  • [0544]
    Treatment 2: Heat treatment at 65 C. for 20 min
  • [0545]
    Treatment 3: Heat treatment at 75 C. for 10 min.
  • [0546]
    Treatment 4: Phenol extraction once, chloroform extraction once, ethanol precipitation once, resuspension in original volume of TE.
  • [0547]
    The results of this experiment are given in Table 9 below and illustrated in FIG. 14
    Table 10
    Transformants obtained per 1/50th volume of transposition reaction
    Replicate
    #1 #2 #3 #4
    nothing 1 0 0 0
    65 C 20′ 1 0 0 0
    75 C 10′ 32 24 22 10
    phenol + pptn 30 23 20 17
  • [0548]
    2. Experiment 2. Three Stop Treatments
  • [0549]
    Reactions were carried out as in Example 3, using duplicate samples for each of three stop treatments, for two aliquots of TnsB, and for three volumes of TnsB. At step 12, one of the stop treatments was substituted. For transformation, ER1821 was used.
  • [0550]
    Treatment 1: Heat treatment at 75 C. for 10 min.
  • [0551]
    Treatment 2: Ethanol precipitation only, resuspension in original volume of TE
  • [0552]
    Treatment 3: Heat treatment at 65 C. for 20 min
  • [0553]
    The results of this experiment are given in Table 9 below and illustrated in FIG. 15
    TABLE 9
    Transformants obtained per 1/50th volume of transposition
    reaction, three stop treatments.
    TnsB
    Volume 75C 10 min EtOH pptd 65C 20 min.
    Aliquot (μl) #1 #2 #1 #2 #1 #2
    1 1 158 8 13 3 15 10
    1 1.5 186 0 16 0 3 0
    1 2 178 170 13 13 30 16
    1 3 454 366 47 21 11 8
    2 1 324 140 21 3 9 2
    2 1.5 506 462 58 44 25 25
    2 2 1220 1102 88 37 54 18
    2 3 1802 1690 129 126 37 14
  • [0554]
    These two experiments demonstrate that heat treatment at 75 C. for 10 min is an adequate method of stopping the transposition reaction and gives as many transformants as treatment with phenol, chloroform and ethanol precipitation; whereas no treatment, ethanol precipitation alone, and heat treatment at 65 C. for 20 min is inadequate, giving no transformants or a greatly reduced number of transformants.
  • EXAMPLE 6
  • [0555]
    Storing Three Components of Tn7 Transposase Together
  • [0556]
    Convenient routine use of in vitro transposition as a method in molecular biology would be facilitated if the protein components of the reaction could be stored in a single tube. In this way, variability in volume measurement from one experiment to another would be minimized, time and labor would be saved, and reproducibility enhanced. The TnsABC127 transposition reaction described in the foregoing examples involves the addition of three different protein components.
  • [0557]
    This example demonstrates that these three protein components of the reaction can be mixed and stored together without interfering with the efficiency of the transposition reaction.
  • [0558]
    Section A. MATERIALS
  • [0559]
    A1) INDIVIDUAL PROTEINS
  • [0560]
    TnsA 30 μg/ml in 10% glycerol
  • [0561]
    TnsB 20 μg/ml in 50% glycerol
  • [0562]
    TnsC127 100 μg/ml in 50% glycerol
  • [0563]
    Keep stored at −70 C.
  • [0564]
    A2) MIXED PROTEINS, COMPRISING
  • [0565]
    TnsA 7.36 μg/ml
  • [0566]
    TnsB 11.3 μg/ml
  • [0567]
    TnsC127 18.9 μg/ml
  • [0568]
    in 40% glycerol
  • [0569]
    A2a) Keep stored at −70□ C., or
  • [0570]
    A2b) Keep stored at −20□ C.
  • [0571]
    A3) OTHER COMPONENTS
  • [0572]
    These are as in example 1, parts A and B; including chemically competent ER2502 (6106 transformants/μg of LITMUS) prepared as in example 1.
  • [0573]
    Section B. Tn7 IN VITRO TRANSPOSITION REACTION PROTOCOL
  • [0574]
    B1. Reaction volume=100 μl
  • [0575]
    B2. Experimental variations (2 experiments are shown, reactions were carried out in quadruplicate).
  • [0576]
    Tube 1 Proteins of Al added individually at step 6 below in a total volume of 5.3 μl
  • [0577]
    Tube 2 Mixture of A2a added together at step 6 below in a total volume of 5.3 μl
  • [0578]
    Tube 3 Mixture of A2b added together at step 6 below in a total volume of 5.3 μl (Experiment 2 only)
  • [0579]
    B3. Make up a mix as in Example 1, section C
  • [0580]
    B4. Dispense mix of step 3 as in Example 1, section C
  • [0581]
    B5. Add target DNA as in Example 1, section C. In this example, this is pLITMUS28, 1 μl
  • [0582]
    B6. Add to each tube
    Tube 1 Tube 2 Tube 3
    TnsA 1.3 μl (40 ng)
    TnsB 3 μl (20 ng)
    TnsC127 1 μl (100 ng)
    TnsABC127 0 5.3 μl (39 ng A, 5.3 μl (39 ng A,
    59.9 ng B 59.9 ng B
    100.2 ng C127) 100.2 ng C127)
  • [0583]
    B7. Add 1 μl donor DNA (0.1 μg pMCB40) as in example 1C
  • [0584]
    B8. Incubate 10 minutes at 30 C. (assembly reaction) as in example 1C
  • [0585]
    B9. Add 4 μl MgAc (375 mM) to each tube as in example 1C
  • [0586]
    B10. Incubate 1 hour 30 C. (transposition reaction) as in example 1C
  • [0587]
    B11. Heat Inactivate 75 C. 10 minutes
  • [0588]
    B12. Transform using chemically competent cells, as in example 1.
  • [0589]
    In this example, selective medium was RB Kan (20 μg/ml) Amp (100 μg/ml). Competent cells were ER2502, chemically competent (Example 1, Section D1).
  • [0590]
    C. Transformation result:
  • [0591]
    Experiment 1: Proteins were stored individually at −70 C. or as a mixture at −70 C. (A2a). In this experiment, the proteins in both treatments had suffered the same number of freeze-thaw cycles. 10 μl of each 100 μl reaction was transformed, and 100 μl of the 500 μl outgrowth culture was plated.
    TABLE 10
    Transformants obtained per 1/50th volume of transposition
    reaction, transposition proteins added as a mixture
    or individually. Result is displayed in Figure 16.
    Replicate avg per
    Storage #1 #2 #3 #4 Average reaction
    Individually 27 62 59 41 47 2350
    As a mixture 47 68 60 23 49 2450
  • [0592]
    Experiment 2: Proteins were stored individually at −70 C., as a mixture at −70 C. (A2a material) or as a mixture at −20 C. (A2b material). In this experiment, the proteins stored individually had suffered more freeze-thaw cycles than those stored together. 10 μl of each 100 μl reaction was transformed, and 100 μl of the 500 μl outgrowth culture was plated.
    TABLE 11
    Transformants obtained per 1/50th volume of transposition
    reaction, transposition proteins added as a mixture
    or individually following storage at −20 C. or
    −70 C. Result is displayed in Figure 17.
    Replicate avg per
    Storage #1 #2 #3 #4 Average reaction
    Individually 13 38 17 22 22 1100
    As a mixture, 167 173 117 218 168 8400
    −70 C.,
    (A2a)
    As a mixture, 179 125 219 199 180 9000
    −20 C.,
    (A2b)
  • [0593]
    These two experiments demonstrate that the three Tns proteins can be stored together. The difference in experiment 2 between individual storage and storage together may be attributed to the number of freeze-thaw cycles.
  • BIBLIOGRAPHY
  • [0594]
    1. Craig N L. 1997. In Ann Rev Biochem. ed. pp. 437-74. Palo Alto: Annual Reviews Inc.
  • [0595]
    2. Kleckner N. 1989. In Mobile DNA. ed. Berg D and Howe M, pp. 227-68. Washington, D.C.: American Society for Microbiology.
  • [0596]
    3. van Luenen HGAM, et al. 1994. Nucleic Acids Res. 22:262-94. Rosenzweig B, et al. 1983. Nucleic Acids Res. 11:4201-10
  • [0597]
    5. Mori I, et al. 1988. Proc Natl Acad Sci USA. 85:861-4
  • [0598]
    6. Eide D, et al. 1988. Mol Cell Biol. 8:737-46
  • [0599]
    7. Mizuuchi M, et al. 1993. Cold Spring Harbor Symp. Quant. Biol. 58:515-23
  • [0600]
    8. Berg D E. 1989. In Mobile DNA. ed. Berg D and Howe M, pp. 185-210. Washington, D.C.: American Society for Microbiology.
  • [0601]
    9. Kirchner J, et al. 1995. Science. 267:1443-4
  • [0602]
    10. Rogers M, et al. 1986. Mol. Gen. Genet. 205:550-6
  • [0603]
    11. Waddell C S, et al. 1988. Genes Dev. 2:137-49
  • [0604]
    12. Samovsky R, et al. 1996. EMBO J. 15:6348-61
  • [0605]
    13. Kubo K M, et al. 1990. J. Bacteriol. 172:2774-8
  • [0606]
    14. Wolkow C A, et al. 1996. Genes Dev. 10:2145-57
  • [0607]
    15. Hauer B, et al. 1984Mol Gen Genet. 194:149-58
  • [0608]
    16. Arciszewska L K, et al. 1989. J. Mol. Biol. 207:35-52
  • [0609]
    17. Lee C-H, et al. 1983. Proc Natl Acad Sci USA. 80:6765-9
  • [0610]
    18. Reyes I, et al. 1987. Plasmid. 18:183-92
  • [0611]
    19. Adzuma K, et al. 1988. Cell. 53:257-66
  • [0612]
    20. Sakai J, et al. 1995. EMBO J. 14:4374-83
  • [0613]
    21. Kleckner N, et al. 1996. Curr Top Microbiol Immunol. 204:49-82
  • [0614]
    22. Bainton R, et al. 1991. Cell. 65:805-16
  • [0615]
    23. Bainton R J, et al. 1993. Cell. 72:931-43
  • [0616]
    24. Gamas P, et al. 1992. Nucl. Acids Res. 20:2525-32
  • [0617]
    25. Stellwagen A, et al. 1997. Genetics. 145:573-85
  • [0618]
    26. Stellwagen A, et al. 1997. EMBO J. (in press):
  • [0619]
    27. Sankar P, et al. 1993. J.Bacteriol. 175:5145-52
  • [0620]
    28. Devine S E, et al. 1994. Nucleic Acids Res. 22:3765-72
  • [0621]
    29. Pryciak P M, et al. 1992. Proc Natl Acad Sci USA. 89:9237-41
  • [0622]
    30. Pryciak P M, et al. 1992. Cell. 69:769-80
  • [0623]
    31. Pryciak P M, et al. 1992. Embo J. 11:291-303
  • [0624]
    32. Singh I R, et al. 1997. Proc Natl Acad Sci USA. 94:1304-09
  • [0625]
    33. Kholodii G, et al. 1995. Mol. Microbiol. 17:1189-200
  • [0626]
    34. Radstrom P, et al. 1994. J. Bacteriol. 176:3257-68
  • [0627]
    35. Reimmann C, et al. 1989. Mol Gen Genet. 215:416-24
  • [0628]
    36. Rowland S-J, et al. 1990. Mol. Microbiol. 4:961-75
  • [0629]
    37. Walker, et al., eds. 1983. Techniques in Molecular Biology. New York: MacMillan Publishing Company
  • [0630]
    38. Kunkel. 1985. Proc Natl Acad Sci USA. 82:488-92
  • [0631]
    39. Kunkel, et al. 1987. Methods Enzymol. 154:367-82
  • [0632]
    40. Sambrook J, et al., eds. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, N.Y.: Cold Spring Harbor Press
  • [0633]
    41. Dayhoff, et al., eds. 1978. Washington, D.C.: Natl. Biomed Res. Found.
  • [0634]
    42. Miller J H. 1972. In Experiments in Molecular Genetics. ed. pp. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory.
  • [0635]
    43. Elespuru R K, et al. 1979. Environ Mutagen. 1:65-78
  • [0636]
    44. Yarmolinsky M B, et al. 1983. Mol Gen Genet. 192:140-8
  • [0637]
    45. Haniford D B, et al. 1989. Cell. 59:385-94
  • [0638]
    46. McKown R L, et al. 1987. Proc.Natl.Acad.Sci. USA. 84:7807-11
  • [0639]
    47. McKown R L, et al. 1988. J. Bacteriol. 170:352-8
  • [0640]
    48. Johnson R C, et al. 1984. Genetics. 9-18
  • [0641]
    49. Rose M D, et al., eds. 1990. Methods in Yeast Genetics: A Laboratory Course Manual Cold Spring Harbor: Cold Spring Harbor Laboratory
  • [0642]
    50. Hughes O. 1993. Host Components of Tn7 Transposition.
  • [0643]
    51. Huisman O, et al. 1987. Genetics. 116:185-9
  • [0644]
    52. DeBoy R, et al. 1996. J. Bacteriol. 178:6184-91
  • [0645]
    53. Flores C, et al. 1990. Nucl. Acids Res. 18:901-11
  • [0646]
    54. Walker J E, et al. 1984. Biochem J. 224:799-815
  • [0647]
    55. Saraste M, et al. 1990. Trends Biochem Sci. 15:430-4
  • [0648]
    56. Sancar A, et al. 1993. Science. 259:1415-20
  • [0649]
    57. Chaconas G, et al. 1985. J Biol Chem. 260:2662-9
  • [0650]
    58. Faelen M, et al. 1978. Nature. 271:580-2
  • [0651]
    59. O'Day K J, et al. 1978. In Microbiology. ed. Schlessinger D, pp. 48-51. Washington, D.C.: American Society of Microbiology.
  • [0652]
    60. Surette M G, et al. 1987. Cell. 49:254-62
  • [0653]
    61. Craigie R, et al. 1987. Cell. 51:493-501
  • [0654]
    62. Koonin E V. 1992. Nucleic Acids Res. 20:1997
  • [0655]
    63. Gary P A, et al. 1996. J. Mol Biol. 257:301-16
  • [0656]
    64. Gwinn M L, et al. 1997. J. Bacteriology. 179:7315-20
  • [0657]
    65. Bender J, et al. 1992. EMBO J. 11:741-50
  • [0658]
    66. Lichtenstein C, et al. 1982. Unique insertion site of Tn7 in E coli chromosome. 297:601-3#001#
  • 1 15 1670 base pairs nucleic acid single linear DNA (genomic) CDS 1..1668 1 ATG AGT GCT ACC CGG ATT CAA GCA GTT TAT CGT GAT ACG GGG GTA GAG 48 Met Ser Ala Thr Arg Ile Gln Ala Val Tyr Arg Asp Thr Gly Val Glu 1 5 10 15 GCT TAT CGT GAT AAT CCT TTT ATC GAG GCC TTA CCA CCA TTA CAA GAG 96 Ala Tyr Arg Asp Asn Pro Phe Ile Glu Ala Leu Pro Pro Leu Gln Glu 20 25 30 TCA GTG AAT AGT GCT GCA TCA CTG AAA TCC TCT TTA CAG CTT ACT TCC 144 Ser Val Asn Ser Ala Ala Ser Leu Lys Ser Ser Leu Gln Leu Thr Ser 35 40 45 TCT GAC TTG CAA AAG TCC CGT GTT ATC AGA GCT CAT ACC ATT TGT CGT 192 Ser Asp Leu Gln Lys Ser Arg Val Ile Arg Ala His Thr Ile Cys Arg 50 55 60 ATT CCA GAT GAC TAT TTT CAG CCA TTA GGT ACG CAT TTG CTA CTA AGT 240 Ile Pro Asp Asp Tyr Phe Gln Pro Leu Gly Thr His Leu Leu Leu Ser 65 70 75 80 GAG CGT ATT TCG GTC ATG ATT CGA GGT GGC TAC GTA GGC AGA AAT CCT 288 Glu Arg Ile Ser Val Met Ile Arg Gly Gly Tyr Val Gly Arg Asn Pro 85 90 95 AAA ACA GGA GAT TTA CAA AAG CAT TTA CAA AAT GGT TAT GAG CGT GTT 336 Lys Thr Gly Asp Leu Gln Lys His Leu Gln Asn Gly Tyr Glu Arg Val 100 105 110 CAA ACG GGA GAG TTG GAG ACA TTT CGC TTT GAG GAG GCA CGA TCT ACG 384 Gln Thr Gly Glu Leu Glu Thr Phe Arg Phe Glu Glu Ala Arg Ser Thr 115 120 125 GCA CAA AGC TTA TTG TTA ATT GGT TGT TCT GGT AGT GGG AAG ACG ACC 432 Ala Gln Ser Leu Leu Leu Ile Gly Cys Ser Gly Ser Gly Lys Thr Thr 130 135 140 TCT CTT CAT CGT ATT CTA GCC ACG TAT CCT CAG GTG ATT TAC CAT CGT 480 Ser Leu His Arg Ile Leu Ala Thr Tyr Pro Gln Val Ile Tyr His Arg 145 150 155 160 GAA CTC AAT GTA GAG CAG GTG GTG TAT TTG AAA ATA GAC TGC TCG CAT 528 Glu Leu Asn Val Glu Gln Val Val Tyr Leu Lys Ile Asp Cys Ser His 165 170 175 AAT GGT TCG CTA AAA GAA ATC TGC TTG AAT TTT TTC AGA GCG TTG GAT 576 Asn Gly Ser Leu Lys Glu Ile Cys Leu Asn Phe Phe Arg Ala Leu Asp 180 185 190 CGA GCC TTG GGC TCG AAC TAT GAG CGT CGT TAT GGC TTA AAA CGT CAT 624 Arg Ala Leu Gly Ser Asn Tyr Glu Arg Arg Tyr Gly Leu Lys Arg His 195 200 205 GGT ATA GAA ACC ATG TTG GCT TTG ATG TCG CAA ATA GCC AAT GCA CAT 672 Gly Ile Glu Thr Met Leu Ala Leu Met Ser Gln Ile Ala Asn Ala His 210 215 220 GCT TTA GGG TTG TTG GTT ATT GAT GAA ATT CAG CAT TTA AGC CGC TCT 720 Ala Leu Gly Leu Leu Val Ile Asp Glu Ile Gln His Leu Ser Arg Ser 225 230 235 240 CGT TCG GGT GGA TCT CAA GAG ATG CTG AAC TTT TTT GTG ACG ATG GTG 768 Arg Ser Gly Gly Ser Gln Glu Met Leu Asn Phe Phe Val Thr Met Val 245 250 255 AAT ATT ATT GGC GTA CCA GTG ATG TTG ATT GGT ACC CCT AAA GCA CGA 816 Asn Ile Ile Gly Val Pro Val Met Leu Ile Gly Thr Pro Lys Ala Arg 260 265 270 GAG ATT TTT GAG GCT GAT TTG CGG TCT GCA CGT AGA GGG GCA GGG TTT 864 Glu Ile Phe Glu Ala Asp Leu Arg Ser Ala Arg Arg Gly Ala Gly Phe 275 280 285 GGA GCT ATA TTC TGG GAT CCT ATA CAA CAA ACG CAA CGT GGA AAG CCC 912 Gly Ala Ile Phe Trp Asp Pro Ile Gln Gln Thr Gln Arg Gly Lys Pro 290 295 300 AAT CAA GAG TGG ATC GCT TTT ACG GAT AAT CTT TGG CAA TTA CAG CTT 960 Asn Gln Glu Trp Ile Ala Phe Thr Asp Asn Leu Trp Gln Leu Gln Leu 305 310 315 320 TTA CAA CGC AAA GAT GCG CTG TTA TCG GAT GAG GTC CGT GAT GTG TGG 1008 Leu Gln Arg Lys Asp Ala Leu Leu Ser Asp Glu Val Arg Asp Val Trp 325 330 335 TAT GAG CTA AGC CAA GGA GTG ATG GAC ATT GTA GTA AAA CTT TTT GTA 1056 Tyr Glu Leu Ser Gln Gly Val Met Asp Ile Val Val Lys Leu Phe Val 340 345 350 CTC GCT CAG CTC CGT GCG CTA GCT TTA GGC AAT GAG CGT ATT ACC GCT 1104 Leu Ala Gln Leu Arg Ala Leu Ala Leu Gly Asn Glu Arg Ile Thr Ala 355 360 365 GGT TTA TTG CGG CAA GTG TAT CAA GAT GAG TTA AAG CCT GTG CAC CCC 1152 Gly Leu Leu Arg Gln Val Tyr Gln Asp Glu Leu Lys Pro Val His Pro 370 375 380 ATG CTA GAG GCA TTA CGC TCG GGT ATC CCA GAA CGC ATT GCT CGT TAT 1200 Met Leu Glu Ala Leu Arg Ser Gly Ile Pro Glu Arg Ile Ala Arg Tyr 385 390 395 400 TCT GAT CTA GTC GTT CCC GAG ATT GAT AAA CGG TTA ATC CAA CTT CAG 1248 Ser Asp Leu Val Val Pro Glu Ile Asp Lys Arg Leu Ile Gln Leu Gln 405 410 415 CTA GAT ATC GCA GCG ATA CAA GAA CAA ACA CCA GAA GAA AAA GCC CTT 1296 Leu Asp Ile Ala Ala Ile Gln Glu Gln Thr Pro Glu Glu Lys Ala Leu 420 425 430 CAA GAG TTA GAT ACC GAA GAT CAG CGT CAT TTA TAT CTG ATG CTG AAA 1344 Gln Glu Leu Asp Thr Glu Asp Gln Arg His Leu Tyr Leu Met Leu Lys 435 440 445 GAG GAT TAC GAT TCA AGC CTG TTA ATT CCC ACT ATT AAA AAA GCG TTT 1392 Glu Asp Tyr Asp Ser Ser Leu Leu Ile Pro Thr Ile Lys Lys Ala Phe 450 455 460 AGC CAG AAT CCA ACG ATG ACA AGA CAA AAG TTA CTG CCT CTT GTT TTG 1440 Ser Gln Asn Pro Thr Met Thr Arg Gln Lys Leu Leu Pro Leu Val Leu 465 470 475 480 CAG TGG TTG ATG GAA GGC GAA ACG GTA GTG TCA GAA CTA GAA AAG CCC 1488 Gln Trp Leu Met Glu Gly Glu Thr Val Val Ser Glu Leu Glu Lys Pro 485 490 495 TCC AAG AGT AAA AAG GTT TCG GCT ATA AAG GTA GTC AAG CCC AGC GAC 1536 Ser Lys Ser Lys Lys Val Ser Ala Ile Lys Val Val Lys Pro Ser Asp 500 505 510 TGG GAT AGC TTG CCT GAT ACG GAT TTA CGT TAT ATC TAT TCA CAA CGC 1584 Trp Asp Ser Leu Pro Asp Thr Asp Leu Arg Tyr Ile Tyr Ser Gln Arg 515 520 525 CAA CCT GAA AAA ACC ATG CAT GAA CGG TTA AAA GGG AAA GGG GTA ATA 1632 Gln Pro Glu Lys Thr Met His Glu Arg Leu Lys Gly Lys Gly Val Ile 530 535 540 GTG GAT ATG GCG AGC TTA TTT AAA CAA GCA GGT TAG CC 1670 Val Asp Met Ala Ser Leu Phe Lys Gln Ala Gly * 545 550 555 555 amino acids amino acid linear protein 2 Met Ser Ala Thr Arg Ile Gln Ala Val Tyr Arg Asp Thr Gly Val Glu 1 5 10 15 Ala Tyr Arg Asp Asn Pro Phe Ile Glu Ala Leu Pro Pro Leu Gln Glu 20 25 30 Ser Val Asn Ser Ala Ala Ser Leu Lys Ser Ser Leu Gln Leu Thr Ser 35 40 45 Ser Asp Leu Gln Lys Ser Arg Val Ile Arg Ala His Thr Ile Cys Arg 50 55 60 Ile Pro Asp Asp Tyr Phe Gln Pro Leu Gly Thr His Leu Leu Leu Ser 65 70 75 80 Glu Arg Ile Ser Val Met Ile Arg Gly Gly Tyr Val Gly Arg Asn Pro 85 90 95 Lys Thr Gly Asp Leu Gln Lys His Leu Gln Asn Gly Tyr Glu Arg Val 100 105 110 Gln Thr Gly Glu Leu Glu Thr Phe Arg Phe Glu Glu Ala Arg Ser Thr 115 120 125 Ala Gln Ser Leu Leu Leu Ile Gly Cys Ser Gly Ser Gly Lys Thr Thr 130 135 140 Ser Leu His Arg Ile Leu Ala Thr Tyr Pro Gln Val Ile Tyr His Arg 145 150 155 160 Glu Leu Asn Val Glu Gln Val Val Tyr Leu Lys Ile Asp Cys Ser His 165 170 175 Asn Gly Ser Leu Lys Glu Ile Cys Leu Asn Phe Phe Arg Ala Leu Asp 180 185 190 Arg Ala Leu Gly Ser Asn Tyr Glu Arg Arg Tyr Gly Leu Lys Arg His 195 200 205 Gly Ile Glu Thr Met Leu Ala Leu Met Ser Gln Ile Ala Asn Ala His 210 215 220 Ala Leu Gly Leu Leu Val Ile Asp Glu Ile Gln His Leu Ser Arg Ser 225 230 235 240 Arg Ser Gly Gly Ser Gln Glu Met Leu Asn Phe Phe Val Thr Met Val 245 250 255 Asn Ile Ile Gly Val Pro Val Met Leu Ile Gly Thr Pro Lys Ala Arg 260 265 270 Glu Ile Phe Glu Ala Asp Leu Arg Ser Ala Arg Arg Gly Ala Gly Phe 275 280 285 Gly Ala Ile Phe Trp Asp Pro Ile Gln Gln Thr Gln Arg Gly Lys Pro 290 295 300 Asn Gln Glu Trp Ile Ala Phe Thr Asp Asn Leu Trp Gln Leu Gln Leu 305 310 315 320 Leu Gln Arg Lys Asp Ala Leu Leu Ser Asp Glu Val Arg Asp Val Trp 325 330 335 Tyr Glu Leu Ser Gln Gly Val Met Asp Ile Val Val Lys Leu Phe Val 340 345 350 Leu Ala Gln Leu Arg Ala Leu Ala Leu Gly Asn Glu Arg Ile Thr Ala 355 360 365 Gly Leu Leu Arg Gln Val Tyr Gln Asp Glu Leu Lys Pro Val His Pro 370 375 380 Met Leu Glu Ala Leu Arg Ser Gly Ile Pro Glu Arg Ile Ala Arg Tyr 385 390 395 400 Ser Asp Leu Val Val Pro Glu Ile Asp Lys Arg Leu Ile Gln Leu Gln 405 410 415 Leu Asp Ile Ala Ala Ile Gln Glu Gln Thr Pro Glu Glu Lys Ala Leu 420 425 430 Gln Glu Leu Asp Thr Glu Asp Gln Arg His Leu Tyr Leu Met Leu Lys 435 440 445 Glu Asp Tyr Asp Ser Ser Leu Leu Ile Pro Thr Ile Lys Lys Ala Phe 450 455 460 Ser Gln Asn Pro Thr Met Thr Arg Gln Lys Leu Leu Pro Leu Val Leu 465 470 475 480 Gln Trp Leu Met Glu Gly Glu Thr Val Val Ser Glu Leu Glu Lys Pro 485 490 495 Ser Lys Ser Lys Lys Val Ser Ala Ile Lys Val Val Lys Pro Ser Asp 500 505 510 Trp Asp Ser Leu Pro Asp Thr Asp Leu Arg Tyr Ile Tyr Ser Gln Arg 515 520 525 Gln Pro Glu Lys Thr Met His Glu Arg Leu Lys Gly Lys Gly Val Ile 530 535 540 Val Asp Met Ala Ser Leu Phe Lys Gln Ala Gly 545 550 555 5926 base pairs nucleic acid single circular other nucleic acid /desc = “pEM delta R.adj to 1” 3 TTTAGAGCAA TTCGGTGTTA GTTTCAGCAA GCAAACATTA ACCATAGCTA ATGATTTATA 60 GCCATATTAA CCATTGGGGT ACCGAGCTCG AATTCCATGG TCTGTTTCCT GTGTGAAATT 120 GTTATCCGCT CACAATTCCA CACATTATAC GAGCCGGATG ATTAATTGTC AACAGCTCAT 180 TTCAGAATAT TTGCCAGAAC CGTTATGATG TCGGCGCAAA AAACATTATC CAGAACGGGA 240 GTGCGCCTTG AGCGACACGA ATTATGCAGT GATTTACGAC CTGCACAGCC ATACCACAGC 300 TTCCGATGGC TGCCTGACGC CAGAAGCATT GGTGCACCGT GCAGTCGATG ATAAGCTGTC 360 AAACCAGATC AATTCGCGCT AACTCACATT AATTGCGTTG CGCTCACTGC CCGCTTTCCA 420 GTCGGGAAAC CTGTCGTGCC AGCTGCATTA ATGAATCGGC CAACGCGCGG GGAGAGGCGG 480 TTTGCGTATT GGGCGCCAGG GTGGTTTTTC TTTTCACCAG TGAGACGGGC AACAGCTGAT 540 TGCCCTTCAC CGCCTGGCCC TGAGAGAGTT GCAGCAAGCG GTCCACGCTG GTTTGCCCCA 600 GCAGGCGAAA ATCCTGTTTG ATGGTGGTTG ACGGCGGGAT ATAACATGAG CTGTCTTCGG 660 TATCGTCGTA TCCCACTACC GAGATATCCG CACCAACGCG CAGCCCGGAC TCGGTAATGG 720 CGCGCATTGC GCCCAGCGCC ATCTGATCGT TGGCAACCAG CATCGCAGTG GGAACGATGC 780 CCTCATTCAG CATTTGCATG GTTTGTTGAA AACCGGACAT GGCACTCCAG TCGCCTTCCC 840 GTTCCGCTAT CGGCTGAATT TGATTGCGAG TGAGATATTT ATGCCAGCCA GCCAGACGCA 900 GACGCGCCGA GACAGAACTT AATGGGCCCG CTAACAGCGC GATTTGCTGG TGACCCAATG 960 CGACCAGATG CTCCACGCCC AGTCGCGTAC CGTCTTCATG GGAGAAAATA ATACTGTTGA 1020 TGGGTGTCTG GTCAGAGACA TCAAGAAATA ACGCCGGAAC ATTAGTGCAG GCAGCTTCCA 1080 CAGCAATGGC ATCCTGGTCA TCCAGCGGAT AGTTAATGAT CAGCCCACTG ACGCGTTGCG 1140 CGAGAAGATT GTGCACCGCC GCTTTACAGG CTTCGACGCC GCTTCGTTCT ACCATCGACA 1200 CCACCACGCT GGCACCCAGT TGATCGGCGC GAGATTTAAT CGCCGCGACA ATTTGCGACG 1260 GCGCGTGCAG GGCCAGACTG GAGGTGGCAA CGCCAATCAG CAACGACTGT TTGCCCGCCA 1320 GTTGTTGTGC CACGCGGTTG GGAATGTAAT TCAGCTCCGC CATCGCCGCT TCCACTTTTT 1380 CCCGCGTTTT CGCAGAAACG TGGCTGGCCT GGTTCACCAC GCGGGAAACG GTCTGATAAG 1440 AGACACCGGC ATACTCTGCG ACATCGTATA ACGTTACTGG TTTCACATTC ACCACCCTGA 1500 ATTGACTCTC TTCCGGGCGC TATCATGCCA TACCGCGAAA GGTTTTGCAC CATTCGATGG 1560 TGTCAACGTA AATGCATGCC GCTTCGCCTT CGCGCGCGAA TTGATCTGCT GCCTCGCGCG 1620 TTTCGGTGAT GACGGTGAAA ACCTCTGACA CATGCAGCTC CCGGAGACGG TCACAGCTTG 1680 TCTGTAAGCG GATGCCGGGA GCAGACAAGC CCGTCAGGGC GCGTCAGCGG GTGTTGGCGG 1740 GTGTCGGGGC GCAGCCATGA CCCAGTCACG TAGCGATAGC GGAGTGTATA CTGGCTTAAC 1800 TATGCGGCAT CAGAGCAGAT TGTACTGAGA GTGCACCATA TGCGGTGTGA AATACCGCAC 1860 AGATGCGTAA GGAGAAAATA CCGCATCAGG CGCTCTTCCG CTTCCTCGCT CACTGACTCG 1920 CTGCGCTCGG TCGTTCGGCT GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG 1980 TTATCCACAG AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG 2040 GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC 2100 GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA 2160 TACCAGGCGT TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT 2220 ACCGGATACC TGTCCGCCTT TCTCCCTTCG GGAAGCGTGG CGCTTTCTCA TAGCTCACGC 2280 TGTAGGTATC TCAGTTCGGT GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC 2340 CCCGTTCAGC CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGGTA 2400 AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT 2460 GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCCTAACT ACGGCTACAC TAGAAGGACA 2520 GTATTTGGTA TCTGCGCTCT GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT 2580 TGATCCGGCA AACAAACCAC CGCTGGTAGC GGTGGTTTTT TTGTTTGCAA GCAGCAGATT 2640 ACGCGCAGAA AAAAAGGATC TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT 2700 CAGTGGAACG AAAACTCACG TTAAGGGATT TTGGTCATGA GATTATCAAA AAGGATCTTC 2760 ACCTAGATCC TTTTAAATTA AAAATGAAGT TTTAAATCAA TCTAAAGTAT ATATGAGTAA 2820 ACTTGGTCTG ACAGTTACCA ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA 2880 TTTCGTTCAT CCATAGTTGC CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC 2940 TTACCATCTG GCCCCAGTGC TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT 3000 TTATCAGCAA TAAACCAGCC AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTTA 3060 TCCGCCTCCA TCCAGTCTAT TAATTGTTGC CGGGAAGCTA GAGTAAGTAG TTCGCCAGTT 3120 AATAGTTTGC GCAACGTTGT TGCCATTGCT GTAGGCATCG TGGTGTCACG CTCGTCGTTT 3180 GGTATGGCTT CATTCAGCTC CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCCATG 3240 TTGTGCAAAA AAGCGGTTAG CTCCTTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC 3300 GCAGTGTTAT CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC 3360 GTAAGATGCT TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA ATAGTGTATG 3420 CGGCGACCGA GTTGCTCTTG CCCGGCGTCA ACACGGGATA ATACCGCGCC ACATAGCAGA 3480 ACTTTAAAAG TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAAACTCTC AAGGATCTTA 3540 CCGCTGTTGA GATCCAGTTC GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT 3600 TTTACTTTCA CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAAG 3660 GGAATAAGGG CGACACGGAA ATGTTGAATA CTCATACTCT TCCTTTTTCA ATATTATTGA 3720 AGCATTTATC AGGGTTATTG TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT 3780 AAACAAAAAG AGTTTGTAGA AACGCAAAAA GGCCATCCGT CAGGATGGCC TTCTGCTTAA 3840 TTTGATGCCT GGCAGTTTAT GGCGGGCGTC CTGCCCGCCA CCCTCCGGGC CGTTGCTTCG 3900 CAACGTTCAA ATCCGCTCCC GGCGGATTTG TCCTACTCAG GAGAGCGTTC ACCGACAAAC 3960 AACAGATAAA ACGAAAGGCC CAGTCTTTCG ACTGAGCCTT TCGTTTTATT TGATGCCTGG 4020 CAGTTCCCTA CTCTCGCATG GGGAGACCCC ACACTACCAT CGGCGCTACG GCGTTTCACT 4080 TCTGAGTTCG GCATGGGGTC AGGTGGGACC ACCGCGCTAC TGCCGCCAGG CAAATTCTGT 4140 TTTATCAGAC CGCTTCTGCG TTCTGATTTA ATCTGTATCA GGCTGAAAAT CTTCTCTCAT 4200 CCGCCAAAAC AGCCAAGCTT GCATGCCTGC AGGTCGACTC TAGAGGATCC CCAAGAAAGT 4260 CCGTCGGACA GCTTTAATAA ACCCTGCACT TATCTGTTTA GTGTGGGCGG ACAAAATAGT 4320 TGGGAACTGG GAGGGGTGGA AATGGAGTTT TTAAGGATTA TTTAGGGAAG AGTGACAAAA 4380 TAGATGGGAA CTGGGTGTAG CGTCGTAAGC TAATACGAAA ATTAAAAATG ACAAAATAGT 4440 TTGGAACTAG ATTTCACTTA TCTGGTTGGT CGACCTGCAG GGGGGGGGGG GAAAGCCACG 4500 TTGTGTCTCA AAATCTCTGA TGTTACATTG CACAAGATAA AAATATATCA TCATGAACAA 4560 TAAAACTGTC TGCTTACATA AACAGTAATA CAAGGGGTGT TATGAGCCAT ATTCAACGGG 4620 AAACGTCTTG CTCGAGGCCG CGATTAAATT CCAACATGGA TGCTGATTTA TATGGGTATA 4680 AATGGGCTCG CGATAATGTC GGGCAATCAG GTGCGACAAT CTATCGATTG TATGGGAAGC 4740 CCGATGCGCC AGAGTTGTTT CTGAAACATG GCAAAGGTAG CGTTGCCAAT GATGTTACAG 4800 ATGAGATGGT CAGACTAAAC TGGCTGACGG AATTTATGCC TCTTCCGACC ATCAAGCATT 4860 TTATCCGTAC TCCTGATGAT GCATGGTTAC TCACCACTGC GATCCCCGGG AAAACAGCAT 4920 TCCAGGTATT AGAAGAATAT CCTGATTCAG GTGAAAATAT TGTTGATGCG CTGGCAGTGT 4980 TCCTGCGCCG GTTGCATTCG ATTCCTGTTT GTAATTGTCC TTTTAACAGC GATCGCGTAT 5040 TTCGTCTCGC TCAGGCGCAA TCACGAATGA ATAACGGTTT GGTTGATGCG AGTGATTTTG 5100 ATGACGAGCG TAATGGCTGG CCTGTTGAAC AAGTCTGGAA AGAAATGCAT AAGCTTTTGC 5160 CATTCTCACC GGATTCAGTC GTCACTCATG GTGATTTCTC ACTTGATAAC CTTATTTTTG 5220 ACGAGGGGAA ATTAATAGGT TGTATTGATG TTGGACGAGT CGGAATCGCA GACCGATACC 5280 AGGATCTTGC CATCCTATGG AACTGCCTCG GTGAGTTTTC TCCTTCATTA CAGAAACGGC 5340 TTTTTCAAAA ATATGGTATT GATAATCCTG ATATGAATAA ATTGCAGTTT CATTTGATGC 5400 TCGATGAGTT TTTCTAATCA GAATTGGTTA ATTGGTTGTA ACACTGGCAG AGCATTACGC 5460 TGACTTGACG GGACGGCGGC TTTGTTGAAT AAATCGAACT TTTGCTGAGT TGAAGGATCA 5520 GATCACGCAT CTTCCCGACA ACGCAGACCG TTCCGTGGCA AAGCAAAAGT TCAAAATCAC 5580 CAACTGGTCC ACCTACAACA AAGCTCTCAT CAACCGTGGC TCCCTCACTT TCTGGCTGGA 5640 TGATGGGGCG ATTCAGGCCT GGTATGAGTC AGCAACACCT TCTTCACGAG GCAGACCTCA 5700 GCGCCCCCCC CCCCCTGCAG GTCGACCCCA CGCCCCTCTT TAATACGACG GGCAATTTGC 5760 ACTTCAGAAA ATGAAGAGTT TGCTTTAGCC ATAACAAAAG TCCAGTATGC TTTTTCACAG 5820 CATAACTGGA CTGATTTCAG TTTACAACTA TTCTGTCTAG TTTAAGACTT TATTGTCATA 5880 GTTTAGATCT ATTTTGTTCA GTTTAAGACT TTATTGTCCG CCCACA 5926 5926 base pairs nucleic acid single circular other nucleic acid /desc = “pEM-delta” 4 CAGATCAATT CGCGCTAACT CACATTAATT GCGTTGCGCT CACTGCCCGC TTTCCAGTCG 60 GGAAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG 120 CGTATTGGGC GCCAGGGTGG TTTTTCTTTT CACCAGTGAG ACGGGCAACA GCTGATTGCC 180 CTTCACCGCC TGGCCCTGAG AGAGTTGCAG CAAGCGGTCC ACGCTGGTTT GCCCCAGCAG 240 GCGAAAATCC TGTTTGATGG TGGTTGACGG CGGGATATAA CATGAGCTGT CTTCGGTATC 300 GTCGTATCCC ACTACCGAGA TATCCGCACC AACGCGCAGC CCGGACTCGG TAATGGCGCG 360 CATTGCGCCC AGCGCCATCT GATCGTTGGC AACCAGCATC GCAGTGGGAA CGATGCCCTC 420 ATTCAGCATT TGCATGGTTT GTTGAAAACC GGACATGGCA CTCCAGTCGC CTTCCCGTTC 480 CGCTATCGGC TGAATTTGAT TGCGAGTGAG ATATTTATGC CAGCCAGCCA GACGCAGACG 540 CGCCGAGACA GAACTTAATG GGCCCGCTAA CAGCGCGATT TGCTGGTGAC CCAATGCGAC 600 CAGATGCTCC ACGCCCAGTC GCGTACCGTC TTCATGGGAG AAAATAATAC TGTTGATGGG 660 TGTCTGGTCA GAGACATCAA GAAATAACGC CGGAACATTA GTGCAGGCAG CTTCCACAGC 720 AATGGCATCC TGGTCATCCA GCGGATAGTT AATGATCAGC CCACTGACGC GTTGCGCGAG 780 AAGATTGTGC ACCGCCGCTT TACAGGCTTC GACGCCGCTT CGTTCTACCA TCGACACCAC 840 CACGCTGGCA CCCAGTTGAT CGGCGCGAGA TTTAATCGCC GCGACAATTT GCGACGGCGC 900 GTGCAGGGCC AGACTGGAGG TGGCAACGCC AATCAGCAAC GACTGTTTGC CCGCCAGTTG 960 TTGTGCCACG CGGTTGGGAA TGTAATTCAG CTCCGCCATC GCCGCTTCCA CTTTTTCCCG 1020 CGTTTTCGCA GAAACGTGGC TGGCCTGGTT CACCACGCGG GAAACGGTCT GATAAGAGAC 1080 ACCGGCATAC TCTGCGACAT CGTATAACGT TACTGGTTTC ACATTCACCA CCCTGAATTG 1140 ACTCTCTTCC GGGCGCTATC ATGCCATACC GCGAAAGGTT TTGCACCATT CGATGGTGTG 1200 AACGTAAATG CATGCCGCTT CGCCTTCGCG CGCGAATTGA TCTGCTGCCT CGCGCGTTTC 1260 GGTGATGACG GTGAAAACCT CTGACACATG CAGCTCCCGG AGACGGTCAC AGCTTGTCTG 1320 TAAGCGGATG CCGGGAGCAG ACAAGCCCGT CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT 1380 CGGGGCGCAG CCATGACCCA GTCACGTAGC GATAGCGGAG TGTATACTGG CTTAACTATG 1440 CGGCATCAGA GCAGATTGTA CTGAGAGTGC ACCATATGCG GTGTGAAATA CCGCACAGAT 1500 GCGTAAGGAG AAAATACCGC ATCAGGCGCT CTTCCGCTTC CTCGCTCACT GACTCGCTGC 1560 GCTCGGTCGT TCGGCTGCGG CGAGCGGTAT CAGCTCACTC AAAGGCGGTA ATACGGTTAT 1620 CCACAGAATC AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG CAAAAGGCCA 1680 GGAACCGTAA AAAGGCCGCG TTGCTGGCGT TTTTCCATAG GCTCCGCCCC CCTGACGAGC 1740 ATCACAAAAA TCGACGCTCA AGTCAGAGGT GGCGAAACCC GACAGGACTA TAAAGATACC 1800 AGGCGTTTCC CCCTGGAAGC TCCCTCGTGC GCTCTCCTGT TCCGACCCTG CCGCTTACCG 1860 GATACCTGTC CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA 1920 GGTATCTCAG TTCGGTGTAG GTCGTTCGCT CCAAGCTGGG CTGTGTGCAC GAACCCCCCG 1980 TTCAGCCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT TGAGTCCAAC CCGGTAAGAC 2040 ACGACTTATC GCCACTGGCA GCAGCCACTG GTAACAGGAT TAGCAGAGCG AGGTATGTAG 2100 GCGGTGCTAC AGAGTTCTTG AAGTGGTGGC CTAACTACGG CTACACTAGA AGGACAGTAT 2160 TTGGTATCTG CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT 2220 CCGGCAAACA AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG CAGATTACGC 2280 GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC TACGGGGTCT GACGCTCAGT 2340 GGAACGAAAA CTCACGTTAA GGGATTTTGG TCATGAGATT ATCAAAAAGG ATCTTCACCT 2400 AGATCCTTTT AAATTAAAAA TGAAGTTTTA AATCAATCTA AAGTATATAT GAGTAAACTT 2460 GGTCTGACAG TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC TGTCTATTTC 2520 GTTCATCCAT AGTTGCCTGA CTCCCCGTCG TGTAGATAAC TACGATACGG GAGGGCTTAC 2580 CATCTGGCCC CAGTGCTGCA ATGATACCGC GAGACCCACG CTCACCGGCT CCAGATTTAT 2640 CAGCAATAAA CCAGCCAGCC GGAAGGGCCG AGCGCAGAAG TGGTCCTGCA ACTTTATCCG 2700 CCTCCATCCA GTCTATTAAT TGTTGCCGGG AAGCTAGAGT AAGTAGTTCG CCAGTTAATA 2760 GTTTGCGCAA CGTTGTTGCC ATTGCTGTAG GCATCGTGGT GTCACGCTCG TCGTTTGGTA 2820 TGGCTTCATT CAGCTCCGGT TCCCAACGAT CAAGGCGAGT TACATGATCC CCCATGTTGT 2880 GCAAAAAAGC GGTTAGCTCC TTCGGTCCTC CGATCGTTGT CAGAAGTAAG TTGGCCGCAG 2940 TGTTATCACT CATGGTTATG GCAGCACTGC ATAATTCTCT TACTGTCATG CCATCCGTAA 3000 GATGCTTTTC TGTGACTGGT GAGTACTCAA CCAAGTCATT CTGAGAATAG TGTATGCGGC 3060 GACCGAGTTG CTCTTGCCCG GCGTCAACAC GGGATAATAC CGCGCCACAT AGCAGAACTT 3120 TAAAAGTGCT CATCATTGGA AAACGTTCTT CGGGGCGAAA ACTCTCAAGG ATCTTACCGC 3180 TGTTGAGATC CAGTTCGATG TAACCCACTC GTGCACCCAA CTGATCTTCA GCATCTTTTA 3240 CTTTCACCAG CGTTTCTGGG TGAGCAAAAA CAGGAAGGCA AAATGCCGCA AAAAAGGGAA 3300 TAAGGGCGAC ACGGAAATGT TGAATACTCA TACTCTTCCT TTTTCAATAT TATTGAAGCA 3360 TTTATCAGGG TTATTGTCTC ATGAGCGGAT ACATATTTGA ATGTATTTAG AAAAATAAAC 3420 AAAAAGAGTT TGTAGAAACG CAAAAAGGCC ATCCGTCAGG ATGGCCTTCT GCTTAATTTG 3480 ATGCCTGGCA GTTTATGGCG GGCGTCCTGC CCGCCACCCT CCGGGCCGTT GCTTCGCAAC 3540 GTTCAAATCC GCTCCCGGCG GATTTGTCCT ACTCAGGAGA GCGTTCACCG ACAAACAACA 3600 GATAAAACGA AAGGCCCAGT CTTTCGACTG AGCCTTTCGT TTTATTTGAT GCCTGGCAGT 3660 TCCCTACTCT CGCATGGGGA GACCCCACAC TACCATCGGC GCTACGGCGT TTCACTTCTG 3720 AGTTCGGCAT GGGGTCAGGT GGGACCACCG CGCTACTGCC GCCAGGCAAA TTCTGTTTTA 3780 TCAGACCGCT TCTGCGTTCT GATTTAATCT GTATCAGGCT GAAAATCTTC TCTCATCCGC 3840 CAAAACAGCC AAGCTTGCAT GCCTGCAGGT CGACTCTAGA GGATCCCCAA GAAAGTCCGT 3900 CGGACAGCTT TAATAAACCC TGCACTTATC TGTTTAGTGT GGGCGGACAA AATAGTTGGG 3960 AACTGGGAGG GGTGGAAATG GAGTTTTTAA GGATTATTTA GGGAAGAGTG ACAAAATAGA 4020 TGGGAACTGG GTGTAGCGTC GTAAGCTAAT ACGAAAATTA AAAATGACAA AATAGTTTGG 4080 AACTAGATTT CACTTATCTG GTTGGTCGAC CTGCAGGGGG GGGGGGGAAA GCCACGTTGT 4140 GTCTCAAAAT CTCTGATGTT ACATTGCACA AGATAAAAAT ATATCATCAT GAACAATAAA 4200 ACTGTCTGCT TACATAAACA GTAATACAAG GGGTGTTATG AGCCATATTC AACGGGAAAC 4260 GTCTTGCTCG AGGCCGCGAT TAAATTCCAA CATGGATGCT GATTTATATG GGTATAAATG 4320 GGCTCGCGAT AATGTCGGGC AATCAGGTGC GACAATCTAT CGATTGTATG GGAAGCCCGA 4380 TGCGCCAGAG TTGTTTCTGA AACATGGCAA AGGTAGCGTT GCCAATGATG TTACAGATGA 4440 GATGGTCAGA CTAAACTGGC TGACGGAATT TATGCCTCTT CCGACCATCA AGCATTTTAT 4500 CCGTACTCCT GATGATGCAT GGTTACTCAC CACTGCGATC CCCGGGAAAA CAGCATTCCA 4560 GGTATTAGAA GAATATCCTG ATTCAGGTGA AAATATTGTT GATGCGCTGG CAGTGTTCCT 4620 GCGCCGGTTG CATTCGATTC CTGTTTGTAA TTGTCCTTTT AACAGCGATC GCGTATTTCG 4680 TCTCGCTCAG GCGCAATCAC GAATGAATAA CGGTTTGGTT GATGCGAGTG ATTTTGATGA 4740 CGAGCGTAAT GGCTGGCCTG TTGAACAAGT CTGGAAAGAA ATGCATAAGC TTTTGCCATT 4800 CTCACCGGAT TCAGTCGTCA CTCATGGTGA TTTCTCACTT GATAACCTTA TTTTTGACGA 4860 GGGGAAATTA ATAGGTTGTA TTGATGTTGG ACGAGTCGGA ATCGCAGACC GATACCAGGA 4920 TCTTGCCATC CTATGGAACT GCCTCGGTGA GTTTTCTCCT TCATTACAGA AACGGCTTTT 4980 TCAAAAATAT GGTATTGATA ATCCTGATAT GAATAAATTG CAGTTTCATT TGATGCTCGA 5040 TGAGTTTTTC TAATCAGAAT TGGTTAATTG GTTGTAACAC TGGCAGAGCA TTACGCTGAC 5100 TTGACGGGAC GGCGGCTTTG TTGAATAAAT CGAACTTTTG CTGAGTTGAA GGATCAGATC 5160 ACGCATCTTC CCGACAACGC AGACCGTTCC GTGGCAAAGC AAAAGTTCAA AATCACCATT 5220 TGGTCCACCT ACAACAAAGC TCTCATCAAC CGTGGCTCCC TCACTTTCTG GCTGGATGAT 5280 GGGGCGATTC AGGCCTGGTA TGAGTCAGCA ACACCTTCTT CACGAGGCAG ACCTCAGCGC 5340 CCCCCCCCCC CTGCAGGTCG ACCCCACGCC CCTCTTTAAT ACGACGGGCA ATTTGCACTT 5400 CAGAAAATGA AGAGTTTGCT TTAGCCATAA CAAAAGTCCA GTATGCTTTT TCACAGCATA 5460 ACTGGACTGA TTTCAGTTTA CAACTATTCT GTCTAGTTTA AGACTTTATT GTCATAGTTT 5520 AGATCTATTT TGTTCAGTTT AAGACTTTAT TGTCCGCCCA CATTTAGAGC AATTCGGTGT 5580 TAGTTTCAGC AAGCAAACAT TAACCATAGC TAATGATTTA TAGCCATATT AACCATTGGG 5640 GTACCGAGCT CGAATTCCAT GGTCTGTTTC CTGTGTGAAA TTGTTATCCG CTCACAATTC 5700 CACACATTAT ACGAGCCGGA TGATTAATTG TCAACAGCTC ATTTCAGAAT ATTTGCCAGA 5760 ACCGTTATGA TGTCGGCGCA AAAAACATTA TCCAGAACGG GAGTGCGCCT TGAGCGACAC 5820 GAATTATGCA GTGATTTACG ACCTGCACAG CCATACCACA GCTTCCGATG GCTGCCTGAC 5880 GCCAGAAGCA TTGGTGCACC GTGCAGTCGA TGATAAGCTG TCAAAC 5926 8906 base pairs nucleic acid single circular other nucleic acid /desc = “pER183 (target plasmid)” 5 GAATTCCGGA TGAGCATTCA TCAGGCGGGC AAGAATGTGA ATAAAGGCCG GATAAAACTT 60 GTGCTTATTT TTCTTTACGG TCTTTAAAAA GGCCGTAATA TCCAGCTGAA CGGTCTGGTT 120 ATAGGTACAT TGAGCAACTG ACTGAAATGC CTCAAAATGT TCTTTACGAT GCCATTGGGA 180 TATATCAACG GTGGTATATC CAGTGATTTT TTTCTCCATT TTAGCTTCCT TAGCTCCTGA 240 AAATCTCGAT AACTCAAAAA ATACGCCCGG TAGTGATCTT ATTTCATTAT GGTGAAAGTT 300 GGAACCTCTT ACGTGCCGAT CAACGTCTCA TTTTCGCCAA AAGTTGGCCC AGGGCTTCCC 360 GGTATCAACA GGGACACCAG GATTTATTTA TTCTGCGAAG TGATCTTCCG TCACAGGTAT 420 TTATTCGGCG CAAAGTGCGT CGGGTGATGC TGCCAACTTA CTGATTTAGT GTATGATGGT 480 GTTTTTGAGG TGCTCCAGTG GCTTCTGTTT CTATCAGCTG TCCCTCCTGT TCAGCTACTG 540 ACGGGGTGGT GCGTAACGGC AAAAGCACCG CCGGACATCA GCGCTAGCGG AGTGTATACT 600 GGCTTACTAT GTTGGCACTG ATGAGGGTGT CAGTGAAGTG CTTCATGTGG CAGGAGAAAA 660 AAGGCTGCAC CGGTGCGTCA GCAGAATATG TGATACAGGA TATATTCCGC TTCCTCGCTC 720 ACTGACTCGC TACGCTCGGT CGTTCGACTG CGGCGAGCGG AAATGGCTTA CGAACGGGGC 780 GGAGATTTCC TGGAAGATGC CAGGAAGATA CTTAACAGGG AAGTGAGAGG GCCGCGGCAA 840 AGCCGTTTTT CCATAGGCTC CGCCCCCCTG ACAAGCATCA CGAAATCTGA CGCTCAAATC 900 AGTGGTGGCG AAACCCGACA GGACTATAAA GATACCAGGC GTTTCCCCTG GCGGCTCCCT 960 CGTGCGCTCT CCTGTTCCTG CCTTTCGGTT TACCGGTGTC ATTCCGCTGT TATGGCCGCG 1020 TTTGTCTCAT TCCACGCCTG ACACTCAGTT CCGGGTAGGC AGTTCGCTCC AAGCTGGACT 1080 GTATGCACGA ACCCCCCGTT CAGTCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG 1140 AGTCCAACCC GGAAAGACAT GCAAAAGCAC CACTGGCAGC AGCCACTGGT AATTGATTTA 1200 GAGGAGTTAG TCTTGAAGTC ATGCGCCGGT TAAGGCTAAA CTGAAAGGAC AAGTTTTGGT 1260 GACTGCGCTC CTCCAAGCCA GTTACCTCGG TTCAAAGAGT TGGTAGCTCA GAGAACCTTC 1320 GAAAAACCGC CCTGCAAGGC GGTTTTTTCG TTTTCAGAGC AAGAGATTAC GCGCAGACCA 1380 AAACGATCTC AAGAAGATCA TCTTATTAAT CAGATAAAAT ATTTCTAGAT TTCAGTGCAA 1440 TTTATCTCTT CAAATGTAGC ACCTGAAGTC AGCCCCATAC GATATAAGTT GTAATTCTCA 1500 TGTTTGACAG CTTATCATCG GATGGATCTG AAATTGTAAA CGTTAATATT TTGTTAAATT 1560 CGCGTTAAAT TTTTGTTAAA TCAGCTCATT TTTTAACCAA TAGGCCGAAA TCGGCAAAAT 1620 CCCTTATAAA TCAAAAGAAT AGACCGAGAT AGGGTTGAGT GTTGTTCCAG TTTGGAACAA 1680 GAGTCCACTA TTAAAGAACG TGGACTCCAA CGTCAAAGGG CGAAAAACCG TCTATCAGGG 1740 CGATGGCCCA CTACGTGAAC CATCACCCTA ATCAAGTTTT TTGGGGTCGA GGTGCCGTAA 1800 AGCACTAAAT CGGAACCCTA AAGGGAGCCC CCGATTTAGA GCTTGACGGG GAAAGCCGGC 1860 GAACGTGGCG AGAAAGGAAG GGAAGAAAGC GAAAGGAGCG GGCGCTAGGG CGCTGGCAAG 1920 TGTAGCGGTC ACGCTGCGCG TAACCACCAC ACCCGCCGCG CTTAATGCGC CGCTACAGGG 1980 CGCGTCAGAT CCCATCGATA AGCTTTAATG CGGTAGTTTA TCACAGTTAA ATTGCTAACG 2040 CAGTCAGGCA CCGTGTATGA AATCTAACAA TGCGCTCATC GTCATCCTCG GCACCGTCAC 2100 CCTGGATGCT GTAGGCATAG GCTTGGTTAT GCCGGTACTG CCGGGCCTCT TGCGGGATAT 2160 CGTCCATTCC GACAGCATCG CCAGTCACTA TGGCGTGCTG CTAGCGCTAT ATGCGTTGAT 2220 GCAATTTCTA TGCGCACCCG TTCTCGGAGC ACTGTCCGAC CGCTTTGGCC GCCGCCCAGT 2280 CCTGCTCGCT TCGCTACTTG GAGCCACTAT CGACTACGCG ATCATGGCGA CCACACCCGT 2340 CCTGTGGATC CGCTGGCGAA AGGGGGATGT GCTGCAAGGC GATTAAGTTG GGTAACGCCA 2400 GGGTTTTCCC AGTCACGACG TTGTAAAACG ACGGCCAGTG AATTGCGGCC GCCCTGCAAG 2460 GAAGGGAATG TCGCCAACAG CGAAGAGAGT TGGGCAACGG ATGTGCTGGT GGAGGTGATC 2520 GCCTCCTGAT GATGAGCCGC TCCCGATGTG GTGTCGGGAG CGGTATTTTC TATAAAACTT 2580 ACCGCTTATT TGAGATATTC ATCGAAAATG TCGAGTAATT CTTGATGTAT ACACGGCCAT 2640 TCCTGACCTA AATTGACGGT ACACAAGCCA ATATCGAAGC CATTAATTTT ATAACGATGT 2700 TTCACTGCGG TATCTACGTG GGGATATATT AATAACCCCC CTATGTTTTC GCCATTTTCA 2760 GGCTTTAACG ACCATAAGTA ATTCATCAGT TGATAAAGAT TTTGCGAATG AAATTTTTCT 2820 GTTCCCATTC GTCGTGAAAA AATGCTCTTA TAGTATTTGG CGTCAACGAT AAGTATTTTT 2880 TCTGATGAGC GAATGGTGAT GTCAGTTTCC ATTCGAGGTA ACAAATTAAG TGACTGATCC 2940 GATATACTCG ATGCATCCCA TTTTAAATAA GAGCGGGTTG TGTTTGCAGA CGTTAATTCA 3000 CGACGGCAAA ATTCATAAAG AAACTTTTGA TAAAGTAATG ACATCTCTTT TTCGTTTCTT 3060 TCAAAATCAT AGAAACGGTA GTGTCCTTTG TTTTGACCTG GAATAGAATT ATTGACGATG 3120 AATTTGCAGA CACTGATAAC GAATTTATAA TAACGCGTAT TTTTTCCGCC ATTCAGATAG 3180 CTGAAATGCT GCGGAGTTAA ATGAAGAGTG CTAATGCCCG GTAATTTTCT ATAAAGTGAA 3240 CGAGCTTCAT CTCTGATAGT TGAATTTAAC TTTTCATGCT TAATTAATAT GGCTAATGTG 3300 CTTTTTATAA TTCGGTTAGC CAGCGTGTCT TCATTAAGCA TATCAAAAGT ACTGACGGTT 3360 TTCCCATGAT TAAGATGGAA GCCGCGTATT GTTTTAGCAA ACTCTATTCG CCCTTTGATG 3420 CCAGGAATGA TCTCGGTGTT AGGATTGTAA TCAAGCTCAA GCCCTCGGCG TGAAAGCTGT 3480 AAAACCCCTT TATTTAATAC ATACCCCAGG ATATCAAGAA GATTGTTACC GGGTATGGCT 3540 TCAAGGTTTG CCTGCTTAAT TTCCTGTAAA TAACCCCATG CATAGGTAAG CATGTAATAG 3600 ATATTACGGA CAGGTATCAC GGGCTGTTCC ACTATGAGTC CCCTAATAAT TTGTTGGTCC 3660 ATTTCTGTTG TTTATAGGGG TCATCAAAGA AATATTCTTC GAGTAAAGGG GCGATATCCG 3720 TCATCACAAT TTCATTAAGC CATTGCGTAT CCGGAGAGGT GCCATCTTCC AACCCACGCA 3780 AGAAGTAACT ATGCCCAATG CGGAATCCTT TCCCAAGGAT AGTGGCCTCT TTGCTGATTT 3840 CCTGGTTCAA CTCGTTCATT TTTTGGCATA AAGACTCAAC AAATGAAGGT TCTGCTTTTT 3900 TATTCAGTAA AAAATTCCGG AACTGTGGTG TATCAAAACC TGGCTCAATA TCTATGAAAG 3960 AAAATCGTCT GCGTAGGGCA TAGTCAACAA CGGCCAGAGA GCGATCGGCA GTATTCATTA 4020 AACCGATGAT ATAAACATTC TCCGGGACAT AGAATCGTTC TTCATCGTTT TCGGAGTAGG 4080 TTAGGGGAAC AGACCAGTTT TCACCTCGTT TATCATGTTC CATTAACATC ATCACTTCGC 4140 CAAATACTTT ACTGAGATTG GCACGATTGA TTTCATCTAT AATAAAAATA TACTTTTTCT 4200 CTGGCTGCTC TTTAGCTTGC TGACAAAAAT TGTAAAATAT GCCGTCTTTA CGTCGGAAGC 4260 CGACGCCATT CGGACGATAG CCCTGTATAA AATCCTCATA GCTATAAGAT TGATGGAACT 4320 GAACCATATT GACGCGTTGC GGAGCCTTTT CTCCTGTCAG CAAGTAAGCC AGACGGCGTG 4380 CAACAAAGGT TTTTCCAACG CCGGGCGGCC CCTGGAGGAT AATATTTTTT TTGATGGTTA 4440 ATCGTTTGAG TATCGTCTCT ATTGTGGTTT CAGGGATAAA CAAATCATTT AACGCATCTT 4500 CCAGACAGTA TGATTCAGTT TTTGACATAG GTGGAATAAC ACTCTTGCCA GAATTAAATA 4560 TTAATTTATA GTCGTTGATT ATGTTGTCCA GCATAGAGGC AAATCGGGTG TAATCAATAC 4620 CCTGTGAGAC TTTTTGGGAA CAGGCGTAAT AGGACTGTCC GTATTTTTTA GGATATACAC 4680 CCGAAGTTGC CTGAAAATAC TCTGCGATTG TTTTAGGTAT GTCTGAAGAG AACTGCCATT 4740 GGGCATGTGG TTCATTCGTG TCGCTTATAC CATAAGCCAA AACCAACTCA TCAAAATCTT 4800 TATAATAGAG AATAACGGGA TATATACCGT TAGAAGCTTC CTGACCTTCT CCAAGAAATG 4860 CAAACCAGGG AATAGACGTA AAATTACCAT AACCGAAACT CAATTTTACT CGCAGGTTAC 4920 GGTAAGACGT TGGATAATCT TTAGTGGATT GCGAACGTTG TTGCTGTGCT TGCTTAATAA 4980 ATTTTTCAAT CCAGGGTTGA ATAGATTCCA TAAGATATGC CTTCCTCATT GCTAAGCCTC 5040 TATTATCGCT TTCGCAACGT ACTGAAACAA TAGATTTTTA CTGCAAAATC AGACTGGTAA 5100 ATATTTACTG AGGGGGAAAG TTTCTATTGA GTCAGTGGAA GGCTCCCGGT GGTTAACCGG 5160 GAGTAAACGC TGTTACGCGA CTTTCTGTTT ACCGGCAATC ACTCCAATAA ACGCCTGCAC 5220 CTGCTTTTGT TTACGCGCCG ACAGTTTGCA CACCTGGCGT AGCGACTGCA TCAGTTCGCT 5280 CTCCTCGGCG GCGGGTGGTT GGGCGGTGAG GACAATACAG CCTTCCATCA CTTTGACATC 5340 TACCGCCGTG CCAGTGGCAA AACCGGCGGC TTCCAGCCAC TGACCTTTCA GGGTGATGGC 5400 GGGAATACGG CTGTAATCCG GGTAGCGACT CGCATAACCG ACGGTGACAT GACGGTTATT 5460 TGCCGGGGAG ACTTCTGCTT CGAACGGTTG TGCAATAGAA TGCGTGTCAG TCATAACTGC 5520 TATTCTCCAG GAATAGTGAT TGTGATTAGC GATGCGGGTG TGTTGGCGCA CATCCGCACC 5580 GCGCTAAATA CCTGTATATA TCATCAGTAA ATATGGGGAA AGTCCAGCTA AAAATAGAAT 5640 AAAATGGGCA ATTTCTGGAA TGATTTAAAT ATATTTATGT GGGTTATGAT TGGCGTGAAA 5700 TAATAAAAAG CGCACCGGAA AGGTGCGCCA GAAAATAATG TTCAGGATTT TTTACGTGAG 5760 GCTTTTTTAC CCCCGCTAGC TGCGCGTTCA GCTTTGATTT TTTCCAGCAA CGCGGCGGCG 5820 CTGTTTTCTC CGCTGATCAA ATCCGGGTTT TCGGCCCGCC ACTGGGCGGT AAGTTCACCA 5880 CGGAACGCTT TTGCCAGGAT GGATTGCGTC AGGTTGTTGA CGCGGGCTAA GGCGTTGTTG 5940 ACCTGTTTTT CTATGGTGTC GGCGTAGGCG AAGAGTTGCT CGACGCGGCG AACGATTTCG 6000 GCTTGTTCTT TTACTGGAGG TAATAAAACA ACTTGGGATT TGATATCTTT TCCTGAAATA 6060 CCTTTTTGAC CAGAAGTTGT TTTCACGCAG TTCATCATTG CATTTCGTGC TGAGGGGGAT 6120 GAAAAAAATA TTTCGATATA TTCTGGTAAA GCATCTTTGG TTAATCGAGC TCGAATAAGT 6180 TTATCAGGAT ATAGCAAATT TTGATGTTGT AATTTTTTCA ATAACCCACA AACACCAACA 6240 AATTCTAAAC TTCCGTTATA GCGAGTAAAT AAAAGATCTC CATCTTGTAA TTTGTGGCGG 6300 TTTAGTTCAC TTTCTGAACA TTCTAGAGTC GACCTGCAGG CATGCAAGCT TGGCGTAATC 6360 ATGGTCATAG CTGTTTCCTG TGTGAAATTG TTATCCGCTC ACAATTCCAC ACAACATACG 6420 AGCCGGAAGC ATAAAGTGTA AAGCCTGGGG TGCCTAATGA GTGAGCTAAC TCACATTAAT 6480 TGCGTTGCGC TCACTGCCCG CTTTCCAGTC GGGAAACCTG TCGTGCCAGC GGATCCTCTA 6540 CGCCGGACGC ATCGTGGCCG GCATCACCGG CGCCACAGGT GCGGTTGCTG GCGCCTATAT 6600 CGCCGACATC ACCGATGGGG AAGATCGGGC TCGCCACTTC GGGCTCATGA GCGCTTGTTT 6660 CGGCGTGGGT ATGGTGGCAG GCCCCGTGGC CGGGGGACTG TTGGGCGCCA TCTCCTTGCA 6720 TGCACCATTC CTTGCGGCGG CGGTGCTCAA CGGCCTCAAC CTACTACTGG GCTGCTTCCT 6780 AATGCAGGAG TCGCATAAGG GAGAGCGTCG ACCGATGCCC TTGAGAGCCT TCAACCCAGT 6840 CAGCTCCTTC CGGTGGGCGC GGGGCATGAC TATCGTCGCC GCACTTATGA CTGTCTTCTT 6900 TATCATGCAA CTCGTAGGAC AGGTGCCGGC AGCGCTCTGG GTCATTTTCG GCGAGGACCG 6960 CTTTCGCTGG AGCGCGACGA TGATCGGCCT GTCGCTTGCG GTATTCGGAA TCTTGCACGC 7020 CCTCGCTCAA GCCTTCGTCA CTGGTCCCGC CACCAAACGT TTCGGCGAGA AGCAGGCCAT 7080 TATCGCCGGC ATGGCGGCCG ACGCGCTGGG CTACGTCTTG CTGGCGTTCG CGACGCGAGG 7140 CTGGATGGCC TTCCCCATTA TGATTCTTCT CGCTTCCGGC GGCATCGGGA TGCCCGCGTT 7200 GCAGGCCATG CTGTCCAGGC AGGTAGATGA CGACCATCAG GGACAGCTTC AAGGATCGCT 7260 CGCGGCTCTT ACCAGCCTAA CTTCGATCAT TGGACCGCTG ATCGTCACGG CGATTTATGC 7320 CGCCTCGGCG AGCACATGGA ACGGGTTGGC ATGGATTGTA GGCGCCGCCC TATACCTTGT 7380 CTGCCTCCCC GCGTTGCGTC GCGGTGCATG GAGCCGGGCC ACCTCGACCT GAATGGAAGC 7440 CGGCGGCACC TCGCTAACGG ATTCACCACT CCAAGAATTG GAGCCAATCA ATTCTTGCGG 7500 AGAACTGTGA ATGCGCAAAC CAACCCTTGG CAGAACATAT CCATCGCGTC CGCCATCTCC 7560 AGCAGCCGCA CGCGGCGCAT CTCGGGCAGC GTTGGGTCCT GGCCACGGGT GCGCATGATC 7620 GTGCTCCTGT CGTTGAGGAC CCGGCTAGGC TGGCGGGGTT GCCTTACTGG TTAGCAGAAT 7680 GAATCACCGA TACGCGAGCG AACGTGAAGC GACTGCTGCT GCAAAACGTC TGCGACCTGA 7740 GCAACAACAT GAATGGTCTT CGGTTTCCGT GTTTCGTAAA GTCTGGAAAC GCGGAAGTCC 7800 CCTACGTGCT GCTGAAGTTG CCCGCAACAG AGAGTGGAAC CAACCGGTGA TACCACGATA 7860 CTATGACTGA GAGTCAACGC CATGAGCGGC CTCATTTCTT ATTCTGAGTT ACAACAGTCC 7920 GCACCGCTGC CGGTAGCTCC TTCCGGTGGG CGCGGGGCAT GACTATCGTC GCCGCACTTA 7980 TGACTGTCTT CTTTATCATG CAACTCGTAG GACAGGTGCC GGCAGCGCCC AACAGTCCCC 8040 CGGCCACGGG GCCTGCCACC ATACCCACGC CGAAACAAGC GCCCTGCACC ATTATGTTCC 8100 GGATCTGCAT CGCAGGATGC TGCTGGCTAC CCTGTGGAAC ACCTACATCT GTATTAACGA 8160 AGCGCTAACC GTTTTTATCA GGCTCTGGGA GGCAGAATAA ATGATCATAT CGTCAATTAT 8220 TACCTCCACG GGGAGAGCCT GAGCAAACTG GCCTCAGGCA TTTGAGAAGC ACACGGTCAT 8280 ACTGCTTCCG GTAGTCAATA AACCGGTAAA CCAGCAATAG ACATAAGCGG CTATTTAACG 8340 ACCCTGCCCT GAACCGACGA CCGGGTCGAA TTTGCTTTCG AATTTCTGCC ATTCATCCGC 8400 TTATTATCAC TTATTCAGGC GTAGCAACCA GGCGTTTAAG GGCACCAATA ACTGCCTTAA 8460 AAAAATTACG CCCCGCCCTG CCACTCATCG CAGTACTGTT GTAATTCATT AAGCATTCTG 8520 CCGACATGGA AGCCATCACA GACGGCATGA TGAACCTGAA TCGCCAGCGG CATCAGCACC 8580 TTGTCGCCTT GCGTATAATA TTTGCCCATG GTGAAAACGG GGGCGAAGAA GTTGTCCATA 8640 TTGGCCACGT TTAAATCAAA ACTGGTGAAA CTCACCCAGG GATTGGCTGA GACGAAAAAC 8700 ATATTCTCAA TAAACCCTTT AGGGAAATAG GCCAGGTTTT CACCGTAACA CGCCACATCT 8760 TGCGAATATA TGTGTAGAAA CTGCCGGAAA TCGTCGTGGT ATTCACTCCA GAGCGATGAA 8820 AACGTTTCAG TTTGCTCATG GAAAACGGTG TAACAAGGGT GAACACTATC CCATATCACC 8880 AGCTCACCGT CTTTCATTGC CATACG 8906 3190 base pairs nucleic acid single circular other nucleic acid /desc = “pRM2 (target plasmid)” 6 GCGCCCAATA CGCAAACCGC CTCTCCCCGC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA 60 CGACAGGTTT CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG TGAGTTAGCT 120 CACTCATTAG GCACCCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT TGTGTGGAAT 180 TGTGAGCGGA TAACAATTTC ACACAGGAAA CAGCTATGAC CATGATTACG AATTCGAGCT 240 CGGTACCCGG GGATCCTCTA GAGTCGAGAT GCCGCATGTG GAAGAGGTGA TTGCACCGAT 300 CTTCTACACC GTTCCGCTGC AGCTGCTGGC TTACCATGTC GCGCTGATCA AAGGCACCGA 360 CGTTGACCAG CCGCGTAACC TGGCAAAATC GGTTACGGTT GAGTAATAAA TGGATGCCCT 420 GCGTAAGCGG GGCATTTTTC TTCCTGTTAT GTTTTTAATC AAACATCCTG CCAACTCCAT 480 GTGACAAACC GTCATCTTCG GCTACTTTTT CTCTGTCACA GAATGAAAAT TTTCTGTCAT 540 CTCTTCGTTA TTAATGTTTG TAATTGACTG AATATCAACG CTTATTTAAA TCAGACTGAA 600 GACTTATCTC TCTCTGTCAT AAAACTGTCA TATTCCTTAC ATATAACTGT CACCTGTTTG 660 TCCTATTTTG CTTGTCGTAG CCAACAAACA ATGCTTTATG AATCCTCCCA GGAGACATTA 720 TGAAAGTTAT GCGTACCACC GTCGCAACTG TTGTCGCCGC GACCTTATCG ACCTGCAGGC 780 ATGCAAGCTT GGCACTGGCC GTCGTTTTAC AACGTCGTGA CTGGGAAAAC CCTGGCGTTA 840 CCCAACTTAA TCGCCTTGCA GCACATCCCC CTTTCGCCAG CTGGCGTAAT AGCGAAGAGG 900 CCCGCACCGA TCGCCCTTCC CAACAGTTGC GCAGCCTGAA TGGCGAATGG CGCCTGATGC 960 GGTATTTTCT CCTTACGCAT CTGTGCGGTA TTTCACACCG CATATGGTGC ACTCTCAGTA 1020 CAATCTGCTC TGATGCCGCA TAGTTAAGCC AGCCCCGACA CCCGCCAACA CCCGCTGACG 1080 CGCCCTGACG GGCTTGTCTG CTCCCGGCAT CCGCTTACAG ACAAGCTGTG ACCGTCTCCG 1140 GGAGCTGCAT GTGTCAGAGG TTTTCACCGT CATCACCGAA ACGCGCGAGA CGAAAGGGCC 1200 TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT AATGGTTTCT TAGACGTCAG 1260 GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC TAAATACATT 1320 CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA 1380 GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT 1440 GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCT GAAGATCAGT 1500 TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT 1560 TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG 1620 TATTATCCCG TATTGACGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC TATTCTCAGA 1680 ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA 1740 GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC TTACTTCTGA 1800 CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA 1860 CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA 1920 CCACGATGCC TGTAGCAATG GCAACAACGT TGCGCAAACT ATTAACTGGC GAACTACTTA 1980 CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC 2040 TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA TAAATCTGGA GCCGGTGAGC 2100 GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG TAAGCCCTCC CGTATCGTAG 2160 TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA 2220 TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTCAGACCA AGTTTACTCA TATATACTTT 2280 AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA GGTGAAGATC CTTTTTGATA 2340 ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA CTGAGCGTCA GACCCCGTAG 2400 AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTTCTGCG CGTAATCTGC TGCTTGCAAA 2460 CAAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA CCAACTCTTT 2520 TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA TACTGTCCTT CTAGTGTAGC 2580 CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC TACATACCTC GCTCTGCTAA 2640 TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG TCTTACCGGG TTGGACTCAA 2700 GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC GGGGGGTTCG TGCACACAGC 2760 CCAGCTTGGA GCGAACGACC TACACCGAAC TGAGATACCT ACAGCGTGAG CTATGAGAAA 2820 GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC GGTAAGCGGC AGGGTCGGAA 2880 CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG GTATCTTTAT AGTCCTGTCG 2940 GGTTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG CTCGTCAGGG GGGCGGAGCC 3000 TATGGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT GGCCTTTTGC TGGCCTTTTG 3060 CTCACATGTT CTTTCCTGCG TTATCCCCTG ATTCTGTGGA TAACCGTATT ACCGCCTTTG 3120 AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG CAGCGAGTCA GTGAGCGAGG 3180 AAGCGGAAGA 3190 30 base pairs nucleic acid single linear other nucleic acid /desc = “Oligonucleotide (NLC95) 7 ATAATCCTTA AAAACTCCAT TTCCACCCCT 30 29 base pairs nucleic acid single linear other nucleic acid /desc = ”Oligonucleotide (NLC209) 8 GTGATTGCAC CGATCTTCTA CACCGTTCC 29 30 base pairs nucleic acid single linear other nucleic acid /desc = “Oligonucleotide (NLC429) 9 TTTCACCGTC ATCACCGAAA CGCGCGAGAC 30 30 base pairs nucleic acid single linear other nucleic acid /desc = ”Oligonucleotide (NLC430) 10 AATGACTTGG TTGAGTACTC ACCAGTCACA 30 30 base pairs nucleic acid single linear other nucleic acid /desc = “Oligonucleotide (NLC431) 11 ATGAACGAAA TAGACAGATC GCTGAGATAG 30 30 base pairs nucleic acid single linear other nucleic acid /desc = ”Oligonucleotide (NLC432) 12 CAAGACGATA GTTACCGGAT AAGGCGCAGC 30 30 base pairs nucleic acid single linear other nucleic acid /desc = “Oligonucleotide (NLC94) 13 AAAGTCCAGT ATGCTTTTTC ACAGCATAAC 30 5 amino acids amino acid single linear peptide 14 Asn Tyr Asn Arg Asn 1 5 5 amino acids amino acid single linear peptide 15 Asn Tyr Thr Arg Asn 1 5
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7527966Jun 26, 2003May 5, 2009Transgenrx, Inc.Gene regulation in transgenic animals using a transposon-based vector
US7608451Oct 31, 2007Oct 27, 2009Transgen Rx, Inc.Gene regulation in transgenic animals using a transposon-based vector
US8071364Dec 24, 2004Dec 6, 2011Transgenrx, Inc.Gene therapy using transposon-based vectors
US8236294Nov 8, 2010Aug 7, 2012The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical CollegeGene therapy using transposon-based vectors
US8283518Oct 31, 2007Oct 9, 2012Transgenrx, Inc.Administration of transposon-based vectors to reproductive organs
US9150880Sep 25, 2009Oct 6, 2015Proteovec Holding, L.L.C.Vectors for production of antibodies
US9150881Apr 9, 2010Oct 6, 2015Proteovec Holding, L.L.C.Production of proteins using transposon-based vectors
US9157097Sep 25, 2009Oct 13, 2015Proteovec Holding, L.L.C.Vectors for production of growth hormone
US20110162096 *Nov 8, 2010Jun 30, 2011The Board of Supervisors of Louisiana State University and Agricultural and MechanicalGene Therapy Using Transposon-Based Vectors
Classifications
U.S. Classification530/350, 435/473, 435/196, 435/320.1, 435/69.1
International ClassificationC12N1/21, C12N15/55, C12N9/14, C12N15/70, C12N15/90
Cooperative ClassificationC12N15/90, C12N9/14, C12N15/70
European ClassificationC12N9/14, C12N15/70, C12N15/90
Legal Events
DateCodeEventDescription
Apr 23, 2004ASAssignment
Owner name: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, MARYL
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRAIG, NANCY;REEL/FRAME:015257/0845
Effective date: 20030829
Owner name: NEW ENGLAND BIOLABS, INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RALEIGH, ELISABETH;STEWART, FIONA;REEL/FRAME:015254/0810;SIGNING DATES FROM 20030915 TO 20030916